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Summary
The general objective of my research project was to study in vitro neurotransmitter release from 
different brain areas, as a consequence of presynaptic nicotinic acetylcholine receptor (nAChR) 
activation. Chapter I in this thesis presents a general introduction to ligand gated 
ion channels and modulation of neurotransmitter release by presynaptic nAChR in the 
vertebrate Central Nervous System. The experimental core of this work (chapters 2 - 6 ) is 
divided into two main sections: section I (chapters 2 & 3) and
section II (chapters 4 - 6 )  relate to the rat hippocampal and striatal brain areas, respectively. 
Finally, chapter 7 summarises the main achievements of the project and suggests possible 
research directions derived from the results presented.
In particular, section I of this thesis describes initial experimental attempts aimed to examine 
the involvement of rat a7 nAChR in nicotinic agonist-evoked glutamate release from 
hippocampus. Electrophysiological evidence relating presynaptic a-bungarotoxin-sensitive 
nAChR to glutamatergic transmission (McGehee et al., 1995; Gray et al., 1996) together with 
previous pharmacological / neurochemical studies carried out in rat hippocampal preparations in 
Dr. Wonnacotts' lab (Barrantes et al., 1995a; 1995b; Wilkie et al., 1996) supported the plan. 
The project initially involved the development of two topics:
1 ) the biochemical, pharmacological and functional characterisation of native and 
heterologously expressed rat a7 nAChR (this thesis chapter 2); and
2) the study of nicotinic-evoked glutamate release in rat hippocampus (this thesis chapter 3).
As a source of "wild type" hippocampal a7 nAChR, E18 neuronal cultures from foetal rat 
hippocampi (Barrantes et al., 1995a) were established and assayed for surface expression of 
[125l]-a-bungarotoxin binding sites (Bmax = 97.0±14.0 fmol / mg protein). To heterologously 
express the rat a7 nAChR subunit, its cDNA was subcloned into the commercial vector 
pCDNA3, a plasmid previously used in studies involving protein expression in either Xenopus 
oocytes or mammalian cell lines. To test if pCDNA3a7 was capable of generating functional 
surface homomeric a7 nAChR, it was transiently expressed in Xenopus oocytes and assayed 
using the Two-electrode Voltage Clamp technique. The a-Bgt-sensitivity, fast desensitisation 
and inward rectifying properties of (-)-nicotine-evoked currents observed in Xenopus oocytes 
injected with pCDNA3 a7, demonstrated its viability as an expression vector. When the same 
plasmid was lipotransfected into a7-non-expressing- (HEK-293) and a7-expressing- 
(SH-SY5Y - Bmax = 26.8±5.9 fmol [125l]-a-bungarotoxin binding sites / mg protein) 
mammalian cell lines, it failed to increase basal levels of surface [125l]-a-bungarotoxin binding 
sites, although rat a7 mRNA was detected. The discussion in chapter 2 reviews the scarcity of 
successful studies and possible explanations for the difficulties reported worldwide in 
heterologously expressing the a7 nAChR subunit in mammalian cell lines.
In chapter 3, two different experimental approaches were utilised to explore possible functional 
responses elicited in rat hippocampal synaptosomes when challenged with nicotinic agonists. 
[3H]-glutamate release evoked by (-)-nicotine was studied using the superfusion technique, and 
(-)-nicotine-evoked Ca2+-influx was examined by fluorimetry in rat hippocampal synaptosomes 
preloaded with fura-2/AM. Stimulation with the general depolarising agent KCI resulted in 
detectable responses, whereas (-)-nicotine failed to produce detectable signals. 
The discussion in chapter 3 analyses the negative results in terms of the functional 
properties/density of the putative nAChR proposed to be present and the limitations of the 
techniques applied in their study.
The facilitation of catecholamine release, particularly dopamine release, by nAChR is well 
documented, especially at the level of the terminal projections in vitro (Wonnacott, 1997). 
In section II, the superfusion technique was used to explore the following aspects of the 
nicotinic modulation of dopamine release in rat striatum:
1) identification of presynaptic and/or preterminal nAChR subtypes modulating striatal 
dopamine release (this thesis chapters 4 & 5)
2) functional crosstalk between striatal nerve terminals as a consequence of nAChR 
stimulation (this thesis chapter 5), and
3) second messenger mechanisms underlying nicotinic agonist-evoked striatal dopamine 
release (this thesis chapter 6 )
In chapter 4, the novel Conus toxin a-conotoxin-MII, a potent and selective antagonist of 
a3p2-containing nAChR (Cartier et al., 1996; Harvey ef al., 1997), was exploited to evaluate the 
contribution of the a3p2 subunit combination to the presynaptic modulation of 
striatal DA release. Moreover, the nicotinic agonist UB-165, a novel anatoxin-a/epibatidine 
hybrid (Wright et al., 1997), was also assayed to evoke dopamine release from 
rat striatal synaptosomes. These studies primarily showed that:
1) a maximally effective concentration of a-conotoxin-MII (112 nM) inhibited 
mecamylamine-sensitive 1pM (±)-anatoxin-a-evoked [3H]-dopamine release from striatal 
synaptosomes and slices by 56.0±5.5% (IC5o=24.3±2.9nM) and 28.4±4.1% (IC5o=17.3±0.1nM), 
respectively; and
2) UB-165 potently stimulated [3H]-dopamine release from rat striatal synaptosomes 
(EC5o=88±18nM) but only elicited ~40% of the maximum release evoked by 
1 pM (±)-anatoxin-a (EC5o=134±26nM). Moreover, this partial agonism of UB-165 was almost 
completely abolished by a-conotoxin-MII (112nM) but unaffected by MI_A (50nM).
From these results it was concluded: 1) at least two populations of presynaptic nAChR 
(a-CTx-MII sensitive and a-CTx-MII insensitive) are involved in the direct modulation of 
dopamine release from rat striatal dopaminergic terminals; 2) the presynaptic a-CTx-MII 
sensitive nAChR comprises a3 and p2 nAChR subunits but additional subunits cannot be 
excluded; 3) nAChR on non-dopaminergic terminals may enhance DA release by releasing 
other neurotransmitters that in turn act on dopamine terminals; 4) a-CTx-MII sensitive nAChR
iii
are not involved or play a minimum role in this indirect effect; and 5) UB-165 may selectively 
activate a3p2 type nAChR on dopamine terminals.
The results in chapter 4 demonstrated that nAChR on dopaminergic nerve terminals are 
heterogeneous and those containing a3p2 subunits have been identified. The aims of the 
studies performed in chapter 5 were: 1) to investigate in the striatum a possible indirect 
enhancement of nicotinic agonist-evoked dopamine release, via activation of nAChR on 
glutamatergic nerve terminals, and 2) to pharmacologically characterise the nAChR subtype/s 
involved.
In rat striatal slices, (±)-anatoxin-a-evoked [3H]-dopamine release was biphasic with apparent 
EC50S of 241.8±36.1nM and 5.1±0.3pM. Moreover, the second phase of the dose-response 
curve was almost completely suppressed in the presence of ionotropic glutamate receptor 
antagonists (kynurenic acid, DNQX) or a7-containing nAChR antagonists 
(a-bungarotoxin, a-conotoxin-lml, methyllycaconitine). The observations presented in this 
chapter suggest for the very first time, and using a neurochemical approach, the involvement of 
presynaptic a-bungarotoxin-sensitive nAChR in striatal glutamate release that in turn enhances 
(±)-anatoxin-a-evoked DA release by acting on dopamine nerve terminal ionotropic glutamate 
receptors.
Finally, chapter 6  explores the involvement of second messenger cascades in the response 
evoked by nicotinic agonists acting on dopaminergic nerve terminal nAChR. 
This study presents preliminary functional (from superfusion experiments) and biochemical 
evidence (from immunoblot assays) for the involvement of Ca2+/calmodulin kinase II and 
protein kinase C in (±)-AnTx-a-evoked DA release from rat striatal synaptosomes.
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The work carried out during the course of this project has been aimed at understanding some of 
the effects that chemical species capable of interacting with nicotinic acetylcholine receptors 
(nAChR) have on brain preparations, in particular on evoked-neurotransmitter release with 
relevance to brain function. In order to set this work in context, the General Introduction covers 
two areas:
1. The ionotropic acetylcholine receptor a fast transducer of chemical signals with specificity 
for the alkaloid (-)-nicotine.
2. nAChR as presynaptic modulators of neurotransmitter release in Central Nervous System
1.1 Ligand Gated Ion Channels: 
the nicotinic acetylcholine receptor
1.1.1 “Receptive substances”
The existence of synaptic transmission and, indirectly, the presence of 
ligand-gated ion channels were first adequately reported by Claude Bernard in the 1850s on the 
basis of the blockage of the neuromuscular junction by curare (Bernard, 1857). 
In 1862, Kolliker (Kolliker, 1862) and Kuhne (Kuhne, 1862) first described it using oblique 
illumination at the microscope.
At the end of the nineteenth century, Paul Ehriich (Ehriich, 1865) from the field of the 
Immunology and John Langley (Langley, 1905; 1907; 1914) from that of Pharmacology, 
proposed that hormones and neurotransmitters are recognised by “receptive substances", 
now more commonly known as receptors. They introduced, for the very first time, the concept 
that these “receptive substances" combine with pharmacologically active compounds, 
drugs or toxins, and behave as their specific physiological targets. Langley went further and 
specified that “the muscle substance which combines with nicotine and curare is not identical to 
the substance that contracts" and that such a “receptive substance” or receptor is capable of 
“receiving the stimulus" and “transmitting" it, thus formulating the concepts of receptor and 
signal transduction in his present day terms. For many years Langleys' receptive substance was 
considered “mythical".
In 1914 Sir Henry Dale first differentiated receptor subtypes when he noted that the action of 
acetylcholine (ACh) at the neuromuscular junction could be selectively mimicked by nicotine but 
that its action in the autonomic nervous system was mimicked by another alkaloid: muscarine. 
He postulated that the different actions of muscarine and nicotine were caused by two distinct 
cholinergic receptors with different specificities. The observation that each receptor also 
responded selectively to different competitive antagonists supported this distinction: 
curare selectively blocked nicotinic receptors and atropine blocked muscarinic receptors. 
But, despite of all these observations, he was reticent to use the term receptor.
1
Chapter 1
Present in very small quantities, this protein seemed to defy chemical identification. 
Two convergent strategies led to success.
First, one had to find an organ containing much greater quantities of receptor than 
the striated muscle. The electric organ of the teleost fish Torpedo or the elasmobranch 
Electrophorus (electric eel) satisfied this condition (Nachmanson, 1959). The other point was to 
specifically isolate this protein from the other components of the electroplax to identify its 
chemical structure. Once again, the answer came from the animal world. 
Certain cobra (i.e. Naja Naja) or krait (i.e. Bungarus multicinctus) venoms cause death by 
paralysing the respiratory muscles when injected into the bloodstream. The paralysing 
substance in the venoms of these snakes are small proteins (MW 7000-8000) called 
alpha-toxins (Lee and Chang, 1966). These a-toxins, notably a-bungarotoxin (a-Bgt), bind 
pseudo-irreversibly and very selectively to the synaptic site where acetylcholine binds. 
Even if the Torpedo fish and the Bungarus snake have little chance of meeting naturally, 
their encounter in the test tube finally resulted in the isolation of the muscle embryonic 
nicotinic acetylcholine receptor (Changeux et al., 1970). These natural advantages, 
as well as advances in experimental techniques applicable to studying the end-plate region of 
the neuromuscular junction have secured the nAChR its position as one as the most studied of 
all receptors.
1.1.2 nAChR as members of a superfamily of ligand gated ion channels
The nicotinic acetylcholine receptors are members of a gene superfamily of 
ligand-gated ion channels (LGIC) which includes the inhibitory receptors gated by glycine 
(Betz, 1992) and y-amino butyric acid (GABAa receptors; review: McKeman and Whiting, 1996) 
which contain a chloride selective ion channel; and the excitatory receptors gated by 
acetylcholine (nAChR), serotonin (5-HT3 type) and glutamate (forming a related group; 
review: Seeburg, 1993; Galzi and Changeux, 1995). These LGIC are involved in fast 
transmission of “information" between nerve cells and sensory or effector cells, where they
transduce a chemical signal released by the nerve into an electrical one. Moreover, all these
membrane intrinsic proteins share the common function of regulated opening
(upon ligand binding to a specific binding site) and closing of an ion channel (Figure 1.1).
Hydropathy analysis of doned and sequenced LGIC subunits have revealed the presence of a 
common four hydrophobic segment motif (designated M1-M4 - Figure 1.2), first interpreted for 
Torpedo nAChR subunits to be membrane spanning regions (Popot and Changeux, 1984). 
Although the subunits of nAChR, 5HT3, GABAa and glydne receptors are homologous, 
particularly in their predicted transmembrane segments, this subfamily shares no overall 
homology with the glutamate-gated family which consists of AMPA-
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Figure 1.1 The ligand gated ion channel (LGIC). Stylised representation of a receptor 
inserted in the membrane of an excitable cell. Upon the binding of an agonist molecule, 
conformational changes in the protein structure occur, the channel opens and ions flow through 
the pore following their electrochemical driving forces (adapted from Thomas, 1995).
nACHR a1 p j_______________ m+m____________ _ C
nACHR a2 _______________ _____________________
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Figure 1.2 Subunits of the LGIC superfamily members. Represented are the "nAChR-type" 
(first 5 subunits) and the "Glutamate-type" (remainder) LGIC families, aligned at the predicted 
pore forming M2 region. Lengths correspond directly to amino acid numbers. 
Predicted membrane-spanning regions common to all subunits are shown (M1-M4). 
These similarities may be misleading as several lines of evidence show that the structure and 
topology of ionotropic glutamate LGIC receptor subunits differ from the others 
("nAChR-type" family, see text below) (adapted from Thomas, 1995).
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Homology between the subunits of different members of the LGIC superfamily is between 
20% and 40% whereas in the different subunits which create the individual receptors of 
each family, homology is generally at least 40%. In addition all members of the "nAChR-like" 
family share certain motifs which are absent or substantially different in ionotropic glutamate 
receptor subunits:
1. An extracellular N-terminal domain of approximately 200 amino acids containing the agonist 
binding site. The corresponding domain in glutamatergic LGIC receptor subunits is typically 
at least twice as long (Unwin, 1993). In addition, sequence comparisons with metabotropic 
glutamate receptors and bacterial periplasmic amino-acid binding proteins suggest that the 
portion of sequence between M3 and M4 contributes to binding in this receptors 
(O'Hara et al., 1993). This has been confirmed by the creation of chimeric constructs 
(Stem-Bach etai, 1994).
2. A 15 residue cys-loop in the N-terminal domain (Ortells and Lunt, 1995) which is absent in 
glutamatergic subunits (Hollman etai, 1994).
3. Conserved residues in the M2 transmembrane segment, proposed to form a primarily 
a-helical structure lining the ion channel and gating ion-flow (Akabas et at, 1994; 
Ortells and Lunt, 1995; Unwin et at, 1995). Evidence gained using N-glycosilation site 
tagging (Hollman et at, 1994) and prolactin reporter epitopes 
(Bennett and Dingledine, 1995) suggests that the "M2” sequence identified in glutamatergic 
subunits does not traverse the cell membrane at all, instead forming a re-entrant loop 
similar to that seen in, e.g. K* channels. As a consequence the large M3-M4 loop is 
extracellular and appears to form part of the ligand binding site. In these receptors, 
the C-terminus is cytoplasmic.
This evidence suggests that LGIC receptor subunits may be divided into two-families 
("nAChR-type" and "glutamate-type"), with different binding site structures, transmembrane 
topologies and channel lining structures.
1.1.3 nAChR classification and general structural architecture
A rational description of this receptor family can be based on sequence comparisons, but this 
lacks the functional significance, as knowledge of the contribution of particular subunits to 
specific nAChR is lacking. Alternatively, an anatomical-pharmacological approach can be 
adopted (Lindstrom, 1996), which serves as a useful, but not totally adequate, classification. 
The latter approach, adopted here, divides the nAChR family into three main branches: 
(1) peripheral, muscle or end-plate nAChR, (2) central and autonomic nAChR that, unlike those 
of muscle, do not bind a-Bgt, and (3) central an autonomic nAChR that do bind a-Bgt. 
All are presumed to be pentameric ACh-gated cation channels (Cooper et at, 1991; 
Anand et at, 1991; Unwin, 1993; Palma et at, 1996) formed by one to four homologous 
subunit types. These are thought to be organised like barrel staves around a central cation 
channel (Figure 1.3). As mentioned in 1.1.2, the nAChR subunit genes encode proteins that
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have a relatively hydrophilic amino terminal portion, constituting a major extracellular domain of 
the receptor protein where ACh binds, followed by putative three hydrophobic transmembrane 
domains (M1-M3), a large intracellular loop, and a fourth hydrophobic transmembrane domain 
(M4). The hydrophobic segments are thought to stack in the membrane with the amphiphilic M2 
helix orientated towards the channel lumen to form an ion permeant pathway (Karlin,1993). 
At least in the nAChR, a kink in this helix projects a hydrophobic leucine residue into the pore in 
the closed configuration (Unwin, 1993). The predicted M2 region forms a rather non-selective 
channel, largely by virtue of hydroxylated serine and threonine residues which line the internal 
face and is identical or highly homologous in excitatory (cation channels) and inhibitory 
(anion channels) receptors (Imoto et al., 1991; Konno et al., 1991; 
Villarroel and Sakmann, 1992; Bertrand et al., 1993). Ionic selectivity appears to be conferred 
by rings of fully charged amino acids just outside the bilayer plane which may attract permeant 
counterions to each end of the pore (Imoto etai., 1988).
(a) (b)
Synaptic





Figure 1.3 Model of transmembrane topology and organisation of the nAChR subunits.
Possible arrangement of the five subunits about the axis of pseudosymmetry of the receptor (a) 
in the creation of the ion pore (b). Models of the subunit topology, largely based on 
hydrophobicity profiles of the amino acid sequence and antibodies studies, reveal the presence 
of four transmembrane regions (M1-M4) per subunit which associate non-covalently as they 
cross the membrane with the M2 portion (dark gray) facing the channel lumen (b). Each subunit 
(c) and (d) is characterised by a large extracellulary located N-terminal domain bearing 
glycosilation sites (N) and, in a subunits, a pair of conserved cysteines (CC - Karlin, 1993). 
Between M3 and M4 is an intracellular loop containing potential phosphorylation sites through 
which receptor function can be modulated (from Thomas, 1995).
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Nicotinic acetylcholine receptors are the predominant excitatory receptors in the mammalian 
peripheral nervous system (PNS), whereas glutamate receptors are the predominant excitatory 
receptors in central nervous system (CNS). In the peripheral nervous system nAChR are critical 
for controlling skeletal muscles and consequently, as mentioned above, are the target of toxins 
such as snake venom toxins like a-Bgt, and muscle nAChR are the target of an antibody- 
mediated autoimmune response in myasthenia gravis. Although outnumbered by glutamate 
receptors in the vertebrate central nervous system, neuronal nAChR are widespread.
1.1.4 Neuronal nAChR
The synthesis, structure, and function of muscle-type nAChR are known in relatively great 
detail, whereas the more diverse structures, functional properties, and functional roles of 
neuronal nAChR are much less well characterised. The functional properties of various 
combinations of neuronal nAChR subunits expressed in Xenopus oocytes have been better 
characterised than have the functional properties of diverse neuronal nAChR subtypes in vivo. 
("native" nAChR). However, the actual functional roles in the nervous system of many of the real 
and potential subtypes of neuronal nAChR still remain to be determined. Despite this, they have 
been implicated in learning and memory, and it has been observed that their number is 
decreased in Parkinsons' syndrome and Alzheimer’s disease. One measure of their scientific 
and commercial significance is that through nicotine they mediate the addiction to tobacco 
(Dani and Heinemann, 1996). The idea that neuronal nAChR have the same direct arid linking 
role that has the muscle endplate type receptor in neurotransmission, is changing. Now, these 
receptors are viewed like putative modulators / regulators of conventional mechanisms of 
neurotransmission (Role and Berg, 1996; Wonnacott, 1997).
During the past decade, diverse nAChR subunits have been identified in the central nervous 
system. To date, 11 gene products (a2-a9; p2-p4 in rat or na1-na3 in chick) have been isolated 
from avian, rodent or human tissues (reviewed in: Role and Berg, 1996; Lindstrom, 1996). 
Unlike the a2-a6 subunits that require the presence of at least a p subunit to form a functional 
receptor (Luetje and Patrick, 1991; Role, 1992; Conroy and Berg, 1995; 
McGehee and Role, 1995; Lindstrom 1996; Forsayeth and Kobrin, 1997), the a7-a9 subunits 
are capable of forming functional ion channels when expressed as 
homo-oligomers in Xenopus oocytes (Couturier et al., 1990; Bertrand et al., 1992; 
S6gu6la et al., 1993; Elgoyhen et al., 1994; this study chapter 2). As mentioned before, 
the receptor macromolecules are composed most likely of five subunits. With the presence of 
such variety of nAChR gene products, there is much scope for diversity of nAChR, through the 
formation of hetero-oligomeric assemblies. Expression of brain nAChR subunits in Xenopus 
oocytes have shown that only one or two different subunits are needed to form functional 
channels (a or ACh binding subunit and p or structural subunit) 
(e.g. Deneris etai., 1991). One of the key questions in the field involves the determination of all 
the possible neuronal nAChR subunit combinations actually present in the brain and their 
distribution. Based on autoradiography / radiolabelled ligand binding (e.g. Clarke et al., 1985;
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Wonnacott, 1990), lesion studies (e.g. Schwartz et al., 1984; Clarke and Pert, 1985), 
immunohistochemistry (e.g. Dominguez del Toro; 1994), in situ hybridisation (Wada et al., 1989; 
S6gu6la et al., 1993) and knock-out suppression of particular neuronal nAChR subunits 
((32 - Zoli et al., 1998; a7 - Orr-Urtreger et al., 1997), evidence for discrete anatomical and 
cellular expression of subunits is beginning to emerge.
Three pharmacological classes of native neuronal nAChR have been identified
By definition, al! nAChR bind (-)-nicotine. However in order for binding by a tritiated ligand to be 
detectable in binding assays, it must be of relatively high affinity (Kq measurable in nM or lower; 
see Wonnacott, 1987). As early as 1985 (Clarke et al., 1985), autoradiographic analysis of rat 
brain sections labelled with [3H]-(-)-nicotine and [3H]-ACh revealed an identical pattern of 
distribution of these ligands. The strongest presence was revealed in the interpeduncular 
nucleus, superior colliculus, medial habenula, some thalamic nuclei, layers I and lll/IV of the 
cerebral cortex, substantia nigra pars compacta and ventral tegmental area. 
[3H]-Cytisine and [3H]-methylcartamylcholine also bound to the same site with high affinity 
(Anderson and Americ, 1994). a-Bgt (see below) interacts with the high affinity [3H]-(-)-nicotine 
binding site very weakly if at all (no displacement of binding is seen even at high micromolar 
concentrations). Immunoprecipitation studies have uncovered the composition of the main 
high affinity [3H]-(-)-nicotine binding sites in mammalian and avian brain. In rodent brain, 
experiments with mAb270 (an antibody raised against the chick (32 nAChR subunit) have shown 
the mammalian high affinity [3H]-(-)-nicotine binding site to be composed of a4 and p2 subunits 
alone (Whiting and Lindstrom, 1986). In chick brain, more than 90% of high affinity 
[3H]-(-)-nicotine binding immunoprecipitated using mAb270, appeared to be composed of a4(32 
and a2|32 receptors with trace contributions by a3. In the light of the finding that a5 can 
coassemble with a4 subunits in chicken brain (Conroy et al., 1992), it is possible that some 
a4a5p2 sites may also be present. Flores et al. (1992) used antisera to a4 and p2 fusion 
proteins to show that immunoprecipitation of either subunit from rat brain also removes virtually 
all of the other, and that this results in the removal of >90% of high affinity [3H]-cytisine binding 
sites from rat brain extracts. Moreover, loss of high affinity-agonist binding sites in p2 null mice 
has been recently reported by Picciotto et al. (1995). Thus, in mammalian brain, 
the great majority of high affinity [3H]-(-)-nicotine binding sites are a4p2 receptors.
As mentioned before, a-Bgt displaces high affinity [3H]-(-)-nicotine binding weakly (if at all), 
despite [125l]-a-Bgts' ability to bind with extremely high affinity (Ko in the pM-nM range) to many 
neuronal preparations (Wonnacott, 1990). Clarke et al. (1985) showed in rat brain that the 
distribution of [3H]-(-)-nicotine binding was significantly different from that observed for 
[125l]-a-Bgt which was high in distinct layers of cerebral and cerebelar cortices, hypothalamus, 
hippocampus, inferior and superior colliculus and some regions of the brain stem. 
The only brain regions showing significant overlap between tritiated agonist and iodinated 
antagonist binding were the superior colliculus and layer I of the cortex. This indicated that this 
two labelled ligands could not be labelling the same receptor. nAChR immunoprecipitated using
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a7 and a8 antisera have been characterised pharmacologically and biophysically 
(Anand et al., 1993; Gotti et al., 1994; Gerzanich et al., 1994). These investigations have 
confirmed that these receptors have high affinities for [125l]-a-Bgt (higher for a7-containing 
receptors) and generally low affinities for nicotinic agonists (although a8-containing receptors 
generally have higher affinities for this type of ligand than those containing a7 alone). 
Extensive immunocytochemical studies have shown that the distribution of a7 subunits in rat 
brain (a8 has not been found in rat) is well correlated with that of a-Bgt binding 
(Dominguez del Toro et al., 1994). Moreover, the distribution of the a7 gene transcript in 
rat brain (S6gu6la et al., 1993) and loss of [125l]-a-Bgt binding sites in a7 null mouse brain 
(Orr-Urtreger et al., 1997) overlapped the pattern of [125l]-a-Bgt binding sites 
(Clarke et al., 1985). The recently cloned a9 subunit (Elgoyhen et al., 1994) has also been 
found to interact with a-Bgt with high affinity, and preliminary in situ hybridisation studies in rat 
and chicken have shown it to have an unsually restricted pattern of expression (consistent with 
a role in the auditory system where a-Bgt is known to block auditory gating in rat and chicken).
The venom of Bungarus multicinctus contains a mixture of related a-toxins 
(Ravdin and Berg, 1979), including a-Bgt and a minor component which has by consensus 
been named neuronal bungarotoxin (n-Bgt; other names previously used include toxin F, x-Bgt 
and toxin 3.1). It is capable of blocking the ACh-induced currents in the Xenopus oocyte 
expressed rat a3p2 subtype and partially blocking the a4p2 subtype, but is incapable of 
blocking the a2p2 and a3p4 subtypes (Luetje et al., 1990; 1993; Luetje and Patrick, 1991). 
More recent studies have shown the interaction of n-Bgt with nAChR subtypes to be more 
complex, with the p-subunit dictating the kinetics of binding (Papke et al., 1993). 
Hence interpretation of results with this toxin may be difficult. a-Bgt insensitive binding of this 
toxin has been reported in the rat CNS (reviewed by Sargent, 1993) and it has been reported to 
partially (Wonnacott and Drasdo, 1991) or completely (Schulz and Zigmond, 1989; 
Grady et al., 1992) block nAChR-mediated [3H]-dopamine release from striatal preparations. 
A partial decrease of striatal [3H]-dopamine release would be consistent with the evidence for 
heterogeneity of nAChR, including a3p2-containing nAChR (see chapter 4; Kulak et al., 1997; 
Kaiser etai., 1998).
In summary, the mammalian brain expresses three predominant and pharmacologically 
distinguishable classes of nAChR: those labelled with high affinity by [3H]-(-)-nicotine and 
[3H]-ACh (~90% a4p2 nAChR - Whiting and Lindstrom, 1986), those labelled with high affinity 
by [125l]-a-Bgt (a7-containing nAChR - Clarke et al., 1985; 
Dominguez del Toro, 1994) and those labelled with high affinity by [125l]-n-Bgt 
(a3-containing nAChR - Schulz et al., 1991). Recently, Zoli et al. (1998) used [3H]-epibatidine 
for nAChR autoradiography studies, and demonstrated that this tritiated ligand labels more than 
one nAChR subtype (type 2 (a4£2-containing receptor in most brain regions), type 3 
(a3p4-containing receptor) and type 4 (a2p4- and/or a4p4-containing receptor) nAChR).
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nAChR subunit mRNA expression
The distribution of nAChR subunit mRNAs within the rat CNS has been characterised using 
in situ hybridisation techniques (Wada et al., 1989; S6gu6la et al., 1993). These studies have 
shown that expression of nAChR subunit mRNAs within the brain is widespread, with most 
regions of the brain expressing significant quantities of at least one example. However, 
the pattern of expression differ between subunits, and some subunits are much less common 
than others. For example, high concentrations of a2 transcripts were only found in the 
interpeduncular area of the rat, with small amounts detected at a limited number of other sites, 
while a4 mRNAs were strongly expressed in a large number of locations. The extent of a3 gene 
expression was shown to be intermediate between those of the a2 and a4 subunits 
(Wada et al., 1989). Extensive expression of a6 mRNA was found in catecholaminergic nuclei 
of the brain: i.e. locus coeruleus, ventral tegmental area and substantia nigra 
(LeNovere etal., 1996). Similarly, among the 0-subunits, (32 mRNA was almost found in all parts 
of the brain (Wada et al., 1989), while 04 mRNA was initially found only in 
the medial habenula (Duvoisin etal., 1989) with low levels of expression at other loci identified 
later by Dineley-Miller and Patrick (1992). 03 has been shown to colocalise with a6 in 
catecholaminergic nuclei (LeNovere et al., 1996). However, 03 is less commonly expressed 
than 02, but is more widely expressed than the 04 subunit (Deneris et al., 1989). 
a7 mRNA is found in most regions of the brain, but particularly high levels are found in the 
amygdala, olfactory regions, and distinct layers of the hippocampus and cerebral cortex 
(S6gu6la et al., 1993). In some (but not most) weakly expressing regions, a small subset of cells 
may be strongly labelled. For example, a small percentage of Purkinje cells in the cerebellum 
transcribe large amounts of a2 mRNA, but overall a2 expression in this region is rather weak 
(Wada etal., 1989).
From the brief account above, it can be concluded that every brain region expresses mRNAs for 
a plethora of nAChR subunits (Wada et al., 1989, see Wonnacott 1997). Although this approach 
cannot provide definitive answers, it can exclude the presence of certain subunits and can 
provide supporting evidence for subunit combinations suggested on the basis of other 
techniques.
Summary
It is evident that a variety of nAChR subtypes are present in different neuronal tissues, and even 
within individual neurones (e.g. Alkondon et al., 1993). As a consequence of this diversity, 
particular nAChR subunit combinations exhibit distinct 1) pharmacological and 
biophysical properties (e.g. Alkondon et al., 1993), 2) Ca2+ conductances (e.g. reviewed in 
Lindstrom, 1996), 3) expression patterns during development (e.g. Blumenthal et al., 1999),
4) regulatory mechanisms e.g. through nAChR phosphorylation 
(e.g. Gopalakrishnan et al., 1997) and 5) subcellular targeting (e.g. Shoop et al., 1999).
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The next section will primarily discuss how neuronal nAChR activation contributes to 
neurotransmitter release at the level of the nerve terminal. The local integration of neuronal 
elements and the contribution of presynaptic nAChR to synaptic transmission in a broader 
physiological context will also be discussed.
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1.2 Presynaptic Neuronal Nicotinic Receptors: Pharmacology, 
Heterogeneity and Cellular Mechanisms
1.2.1 Presynaptic receptors
Despite the widespread distribution and extensive heterogeneity of nAChR subunits in the CNS 
(see 1.1.4), the physiological significance of nAChR remains more or less obscure. The paucity 
of evidence of nicotinic synaptic transmission in the CNS prompted speculation that the purpose 
of nAChR is to modulate, rather than mediate, neurotransmission (Role and Berg, 1996). 
The presynaptic localisation of nAChR is compatible with such a role (Wonnacott, 1997).
In 1961, Koelle proposed that ACh can facilitate its own release from preganglionic sympathetic 
neurones, in addition to its postsynaptic action. Subsequently, receptors that could modulate the 
release of other neurotransmitters from their respective nerve endings were demonstrated, 
and the term “presynaptic receptor" was coined (see Langer, 1997). The initial reports described 
autoreceptors, where the presynaptic receptor was stimulated by the endogenous transmitter of 
that neurone, presumably serving a feedback loop through which the transmitter could regulate 
its own release. In addition to the case described by Koelle (1961), there are a number of 
examples of nicotinic autoreceptors modulating ACh release (see 1.2.2.1). Presynaptic nAChR 
also reside on terminals releasing transmitters) other than ACh. Such heteroreceptors are 
assumed to reflect an opportunity for crosstalk between different nerve terminals. 
A further distinction is sometimes made between presynaptic and preterminal receptors 
(see Wonnacott, 1997). The latter are considered to reside on axons, rather than terminal 
boutons, and to elicit neurotransmitter release via a tetrodotoxin (TTX)-sensitive mechanism 
(Wessler, 1992; see 1.2.3.2). Thus, TTX-sensitivity has been taken to define a preterminal 
localisation. While this may be a reasonable assumption for the motor nerve tenminals 
originally studied (Wessler, 1992), it may not be valid to extend this distinction to the CNS 
where the configuration of synaptic specialisations can vary enormously, from small synaptic 
boutons to glomerular terminals and varicosities (Walmsley etal., 1998). TTX-sensitivity is likely 
to reflect the relative proximities of nAChR to voltage dependent Na+ channels, voltage operated 
Ca2+ channels (VOCC) and the active zone for release, as well as factors such as the local 
membrane potential etc. which may be perturbed by the experimental conditions.
The occurrence of heteroreceptors raises a fundamental (and largely unanswered) question 
about the endogenous source of agonist. Not only is the precise location of nAChR on the nerve 
terminal unknown but there is little knowledge about the precise topographical relationship 
between nicotinic heteroreceptors and cholinergic terminals. For example, in the rat striatum 
where the association of nAChR with dopamine terminals is well documented (see 1.2.2.2), 
cholinergic interneurones form symmetrical synapses with shafts and spines of the medium 
spiny projection neurones that are GABAergic (Smith and Bolam, 1990). Rather than a brief 
pulse of a high concentration (mM) of ACh delivered across the synaptic cleft, ACh may be 
required to diffuse to adjacent terminals, achieving a lower concentration (pM-nM) but for a
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longer duration. This assumes that sufficient ACh will escape hydrolysis by 
acetylcholinesterase: the sensitivity of particular nAChR subtypes to ACh, and their propensity 
to desensitise may become important factors in shaping their responsiveness. 
The recent demonstration that choline is an agonist at a7-type nAChR (Alkondon et al., 1997) 
offers an alternative candidate for activation (and / or desensitisation) of nAChR. 
Ultrastructural and / or electrophysiological approaches will be necessary to determine the 
relationship between nAChR and the source of endogenous agonist, before we can appreciate 
the physiological potential of presynaptic nAChR. Despite this caution, presynaptic nAChR are 
valid therapeutic targets for pharmaceutical products, and have been employed as screens for 
the evaluation of novel drugs (see Holladay et al., 1997).
1.2.2 Pharmacology and heterogeneity of presynaptic nAChR
There is considerable evidence for presynaptic nAChR, but in no case has the complete subunit 
composition of any presynaptic nAChR been unequivocally assigned. The ability to define their 
subunit composition is constrained not only by methodological limitations 
(see Kaiser and Wonnacott, 1999), but also by a lack of definitive subtype-selective antagonists 
or agonists. The following review of the literature, grouped by neurotransmitter released, 
attempts to summarise the current knowledge of some of the better characterised examples.
1.2.2.1 Acetylcholine (ACh)
Nicotinic autoreceptors on cholinergic terminals represent the most straightforward example of 
presynaptic nAChR and, as already noted, were the first to be recognised (Koelle, 1961). 
More recently, the pharmacology of the positive feedback modulation via nAChR of [3H]-ACh 
release from acutely isolated rat superior cervical ganglia was studied (Liang and Vizi, 1997). 
Inhibition by a-Bgt suggests an involvement of the a7 subunit. 
This corroborates the findings of McGehee et al. (1995) who used an antisense approach to 
implicate a7-containing nAChR (a-Bgt-sensitive) in the release of ACh from chick sympathetic 
neurones in culture. Both electrophysiological and neurochemical techniques have 
demonstrated that nAChR have a modulatory role at motor nerve terminals 
(Bowman et al. 1990; see Wonnacott, 1997). These presynaptic nAChR may be 
heterogeneous, with co-expression of both positive and negative feedback mechanisms 
requiring different stimulation frequencies and having different drug specificities 
(Bowman et al. 1990; Tian et al. 1994). The facilitatory nicotinic effect is blocked by 
hexamethonium and d-tubocurarine (dTC) but is insensitive to a-Bgt and n-Bgt (Wessler, 1989; 
Vizi and Somogyi, 1989; Bowman et al. 1990). An inhibitory nicotinic action, observed at low 
frequency stimulation, has been attributed to prejunctional (preterminal) nAChR 
(Tian et al., 1994). The relative insensitivity to methyllycaconitine (MLA) would seem to exclude 
the a7 subunit (Tian et al. 1997), although a-Bgt has been claimed to block this negative 
feedback (Domet etal. 1995). A a7-type presynaptic nAChR has recently been implicated in the 
development of neuromuscular synapses, studied in cocultures of Xenopus laevis embryos
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(Fu and Liu, 1997). Cholinergic autoreceptors also serve a feedback role in the regulation of 
ACh release from cholinergic fibres innervating the guinea pig ileum. Pharmacological evidence 
for both inhibitory muscarinic receptors and facilitatory nAChR was derived using synaptosomes 
from the myenteric plexus (Briggs and Cooper, 1982), and DMPP was shown to stimulate 
[3H]-ACh release from perfused myenteric plexus (Takahashi etal., 1992).
In the CNS, the superfusion technique has been used to demonstrate the nicotinic stimulation of 
ACh release from rat hippocampal synaptosomes and slices (Araujo et al., 1988; 
Wilkie et al., 1996) and cortical synaptosomes and slices (Rowell and Winkler, 1984; 
Ochoa and O'Shea, 1994; Marchi and Raiteri, 1996). nAChR comprised of a4 and (32 subunits 
are a candidate for the autoreceptors in hippocampus (Wilkie et al., 1996), based on 
pharmacology (sensitivity to mecamylamine, dTC and dihydro(3erythroidine (DH(3E), but not to 
methyllycaconitine (MLA) or a-Bgt) and agonist dose-response profiles, compared with rat a4p2 
nAChR expressed in Xenopus oocytes, although cytisine appeared to be a full agonist in 
evoking ACh release. a4p2 nAChR are consistent with the loss of 
[3H]-nicotine binding sites in the hippocampus, following degeneration of the septo-hippocampal 
projection in Alzheimer's disease. In contrast to these examples, attempts to demonstrate the 
nicotinic stimulation of ACh release in rat striatum have proved negative (Lapchak et al., 1989; 
Rao etal., 1997).
1.2.2.2 Dopamine
The nicotinic stimulation of dopamine (DA) release has been the most documented example of 
presynaptic nicotinic modulation in the CNS and its pharmacological profile has been examined 
with respect to both conventional and novel ligands (see Holladay et al., 1997). 
The superfusion technique has been widely used in this respect, to characterise the nicotinic 
stimulation of DA release from striatal synaptosomes (e.g. Rapier et al, 1990; 
Grady et al, 1992; El-Bizri and Clarke, 1994, Kulak et al., 1997) and slices
(e.g. Giorguieff-Chesselet et al., 1979; Sacaan et al., 1995; Kaiser et al. 1998), as well as from 
nucleus accumbens minces (Rowell et al., 1987) and frontal cortex synaptosomes 
(Whiteaker et al., 1995). In striatal synaptosomes, the nicotinic stimulation of DA release is 
blocked by mecamylamine, DHpE and n-Bgt but is insensitive to a-Bgt,
a-conotoxin-lml (a-CTx-lml) and low concentrations of MLA. The sensitivity of 
(-)-nicotine-evoked [3H]-DA release to n-Bgt has been interpreted in favour of a3-type nAChR 
(Schulz and Zigmond, 1989; Grady et al., 1992). However, loss of [3H]-(-)-nicotine binding sites 
following lesion of the nigrostriatal tract (Clarke and Pert, 1985) favours presynaptic nAChR 
composed of a4 and (32 subunits on dopamine terminals in the striatum. This paradox can be 
explained in the light of recent reports that used the a3|32-selective antagonist a-conotoxin-MII 
(a-CTx-MII - Kulak etal., 1997; Kaiser et al., 1998 - chapter 4). Low nanomolar concentrations 
of a-CTx-MII dose-dependently inhibited [3H]-DA release from striatal synaptosomes, elicited by 
(-)-nicotine (Kulak et al., 1997) or (±)-anatoxin-a ((±)-AnTx-a; Kaiser et al., 1998 - chapter4).
The IC50 value for this inhibition is close to that for blockade of a3J32 nAChR in
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Xenopus oocytes. However, the maximum inhibition achieved was only 40-60% of the evoked 
release, compared with antagonism by the non-selective nicotinic antagonist, mecamylamine, 
of greater than 80%. This suggests the presence of a heterogeneous population of presynaptic 
nAChR, with a proportion containing a3 and p2 subunits (possibly in association with other, 
additional subunits) having sensitivity to nanomolar concentrations of a-CTx-MII, 
and a proportion lacking one or both of these subunits and insensitive to a-CTx-MII (chapter 4).
Nicotinic agonists evoke dopamine release with different potencies and efficacies 
(see chapter 4 and Holladay et al., 1997). For example, the novel agonist UB-165 that is a 
hybrid of (+)-AnTx-a and (-)-epibatidine (Wright et al., 1997) elicits only ~40% of the maximum 
[3H]-DA release evoked by (±)-AnTx-a from striatal synaptosomes (chapter 4). This partial effect 
of UB-165 is totally blocked by a-CTx-MII, suggesting that UB-165 only activates 
the a3p2-containing nAChR on striatal dopamine terminals (chapter 4).
1.2.2.3 Noradrenaline
Presynaptic nAChR on noradrenergic afferents were postulated to be responsible for 
(-)-nicotine-evoked noradrenaline release in hypothalamus, cortex and cerebellum 
(Westfall, 1974). Subsequently, presynaptic nAChR modulating noradrenaline release from 
hippocampal slices (Sacaan et al., 1995, 1996; Sershen et al., 1997) and synaptosomes 
(Clarke and Reuben, 1996), and in the dorsal raphe nucleus (Li et al., 1998) have been 
characterised. In the peripheral nervous system, presynaptic nAChR can induce the release of 
noradrenaline from sympathetic neurones (Dolezal et al., 1996). nAChR in vas deferens are 
located on noradrenaline terminals. Stimulation of these nAChR induces the release of 
noradrenaline and ATP, which in turn induce contraction of the smooth muscle cells 
(Cameiro and Markus, 1990; Todorov et al., 1991). ACh has no direct effect on the muscle cells 
in this preparation, and it is interesting to consider that the sole purpose of the cholinergic 
innervation of the tissue may be to exert this presynaptic modulation. 
The nicotinic enhancement exhibits a diurnal variation (Markus et al., 1996), attributed to the 
appearance of a second population of low affinity nicotinic binding sites in response to 
melatonin.
To gain an insight into the subtypes of nAChR that modulate noradrenaline release, 
the pharmacological profile of the presynaptic response can be compared with that of 
heterologously expressed nAChR (although in most cases the latter comprise pairwise 
combinations of subunits, whereas evidence is accumulating that native nAChR may be more 
complex, Ramirez-Latorre et al., 1996). Such a comparison led Clarke and Reuben (1996) 
to propose that the presynaptic nAChR mediating noradrenaline release from hippocampal 
synaptosomes most closely resembles a3p4 nAChR. The lower potency of nicotinic agonists in 
eliciting noradrenaline release, and the lower sensitivity of (-)-nicotine-evoked noradrenaline 
release to DHpE and MLA was distinctly different from striatal dopamine release measured in 
parallel. Noradrenaline release from hippocampal and thalamic slices (Sacaan et al., 1995;
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1996) has been described with similar properties to those seen in synaptosome preparations. 
Sensitivity to n-Bgt, together with insensitivity to the a7-selective antagonists a-Bgt and 
a-CTx-lml (Sershen et al., 1997), reinforces the idea of a nAChR containing the a3 subunit. 
Furthermore, a nAChR with an a3p2 interface can be excluded, since Kulak et al. (1997) 
showed that (-)-nicotine-evoked noradrenaline release from hippocampal synaptosomes is not 
blocked by a-CTx-MII. A novel Conus toxin, a-conotoxin-AulB (a-CTx-AulB), with specificity for 
a3p4 subunit combinations, has just been used to confirm that these subunits contribute to the 
presynaptic nAChR that modulates noradrenaline release from hippocampal synaptosomes 
(Luo et al., 1998). This finding validates the conclusion arrived at by Clarke and Reuben (1996) 
that presynaptic nAChR mediating noradrenaline release are pharmacologically and structurally 
distinct from those involved in the regulation of dopamine release in striatum.
In contrast, the DMPP-evoked depolarisation of dorsal raphe neurones, attributed to the 
nicotinic stimulation of noradrenaline release, was selectively blocked by MLA (0.1 and 1 pM), 
and a a7-containing nAChR has been invoked (Li et al., 1998). This result suggests that 
different subtypes of presynaptic nAChR may regulate noradrenaline release in different 
brain regions, although more data are required to confirm or refute this assertion.
1.2.2.4 5-Hydroxytryptamine (5-HT)
Nicotine is reported to increase arousal and attention and to elevate mood, effects that are 
associated with monoaminergic systems. It is perhaps surprising that there are few reports of a 
direct presynaptic nicotinic modulation of 5HT release. (-)-Nicotine can release [3H]-5-HT from 
striatal slices (Westfall et al., 1982; Yu and Wecker, 1994). Moreover, a recent in vivo study 
(Takahashi etal., 1998) demonstrated that (-)-nicotine induces striatal 5-HT release upon stress 
application by stimulating presynaptic nAChR. DMPP (but not (-)-nicotine or cytisine) is reported 
to stimulate [3H]-5-HT release from hippocampal slices and this response was blocked by 
mecamylamine (but not by DHpE) but was Ca2+-independent (Lendvai et al., 1996). 
This differs from the Ca2+-dependent nicotinic modulation of other transmitters. 
A recent report (Li et al., 1998) documents the nicotinic facilitation of 5-HT release in 
the dorsal raphe via a MLA-insensitive mechanism, in contrast to the nicotinic stimulation of 
noradrenaline release from the same preparation (see 1.2.2.3). The nicotinic modulation of 
5-HT release deserves more attention, especially in the light of increasing evidence that 
5-HT can modulate the activity of neural reward pathways (Parsons etal., 1996).
1.2.2.5 Y-Aminobutyric acid (GABA)
Neurochemical and electrophysiological studies have provided evidence for presynaptic nAChR 
modulating GABA release in both avian and mammalian brain. Chiappinelli and colleagues 
have used whole cell patch clamp recording in the chick lateral spiriform 
(McMahon et al., 1994a) and ventral lateral geniculate nuclei (McMahon et al., 1994b; 
Guo et al., 1998) to disclose a nicotinic facilitation of GABA release. 
Responses were insensitive to a-Bgt and MLA, disqualifying a7-type nAChR as likely
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contenders. Responses from the lateral spiriform nucleus were also insensitive to n-Bgt, 
making the a302 subunit combination unlikely.
(-)-Nicotine-induced inhibition in rat medial septum, studied using extracellular, single unit 
recording in vivo, was attributed to presynaptic nAChR on GABA terminals (Yang et al, 1996). 
This response was blocked by DHpE but subtypes were not characterised further. 
Presynaptic ("preterminal") nAChR are present on GABAergic terminals in the rat 
interpeduncular nucleus and facilitate GABA release in a TTX- and DHpE-sensitive manner 
(Lena et al, 1993). In the mouse thalamus, nicotinic agonists increased the frequency of 
miniature GABAergic synaptic currents in the presence of TTX, consistent with presynaptic 
nAChR on the GABA terminals (Lena and Changeux, 1997). The absence of this facilitation in 
transgenic mice lacking the p2 subunit provides compelling evidence for the participation of this 
subunit in the presynaptic nAChR in question. This view is supported and extended in a 
comprehensive neurochemical study of the stimulation by nicotinic agonists of [3H]-GABA 
release from mouse synaptosomes (Lu et al, 1998). Nicotine stimulated [3 H]-GABA release in 
all crudely dissected brain regions examined, and was highest in striatum and thalamus. 
The magnitude of nicotine-evoked [3H]-GABA release was highly correlated with the level of 
[3H]-nicotine binding sites and with the magnitude of nicotine-evoked Rb+ flux in each region, 
measures which are proposed to reflect a4p2 nAChR. Nicotine-stimulated release was absent 
in tissues prepared from p2 knockout mice, with an intermediate level of responsiveness in 
heterozygotes. Thus there is a consistent picture from these mammalian studies of presynaptic 
nAChR containing the (32 subunit (possibly in combination with a4).
1.2.2.6 Glutamate
Sensitive electrophysiological recording has disclosed a a-Bgt- and MLA-sensitive modulation 
of glutamate transmission in rat hippocampus (Gray etal, 1996; Radcliffe and Dani, 1998) and 
olfactory bulb (Alkondon et al, 1996). In cocultures of chick interpeduncular nucleus and medial 
habenula, antisense ablation of the a7 subunit abolished the a-Bgt-sensitivity of the 
enhancement by nicotine of EPSC frequency (McGehee et al, 1996). Interestingly, (-)-nicotine 
continued to modulate glutamate transmission after antisense treatment, suggesting plasticity in 
the assembly of subunits to create nAChR. Recently, Guo and colleagues (1998) reported that 
carbachol and other nicotinic agonists produced marked increases in the frequency of 
glutamatergic spontaneous postsynaptic currents in chick ventral lateral geniculate nucleus. 
While sensitivity to a-Bgt implies the involvement of a a7-type nAChR, the pharmacology is 
unusual in the lack of sensitivity to MLA and strychnine (other antagonists of 
a7-containing nAChR).
Attempts to directly demonstrate the nicotinic modulation of glutamate release using 
neurochemical approaches have been negative (e.g. Wonnacott et al, 1995 - chapter 3). 
This may reflect the rapid desensitisation of a7-type nAChR which will require more sensitive 
methods with better time resolution in order to detect their direct effects. However, our lab has
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recently acquired indirect evidence for the nicotinic modulation of glutamate release from 
rat striatal slices; again this effect appears to mediated by a a7-type nAChR 
(Kaiser et al, 1998 - chapter 5). In this preparation, [3H]-DA release elicited by nicotinic agonists 
includes a component that is blocked by a-Bgt, a-CTx-IMI, MLA and ionotropic glutamate 
receptor antagonists. It has been hypothesised that this derives from the nicotinic stimulation of 
glutamate release via a a7-type nAChR on cortico-striatal afferents; the glutamate released in 
turn promotes [3H]-DA release which is measured (chapter 5).
1.2.2.7 ATP
ATP is co-released with classical transmitters with which it is co-stored in synaptic vesicles. 
Therefore, presynaptic nAChR that modulate the release of such classical transmitters 
(e.g. ACh, noradrenaline) will be expected to also elevate extracellular levels of ATP. 
There is direct evidence for (-)-nicotine-stimulated ATP release from myenteric plexus 
synaptosomes (White and Al-Hummayyd, 1983).
1.2.2.8 Summary
It is evident that presynaptic nAChR are widespread, and are associated with many different 
transmitters. The pharmacological characteristics of nAChR in different preparations vary, 
consistent with various nAChR subtypes fulfilling a presynaptic role. While the evidence to date 
associates the a7 subtype with glutamate terminals and the a4|32 subtype with GABA terminals, 
nAChR found on dopamine terminals are heterogeneous. There are insufficient data to draw 
any firm conclusions about the patterns of distribution. Moreover, despite the wealth of 
information, we are still far from understanding the contribution of presynaptic nAChR to 
synaptic transmission and brain function.
1.2.3 Molecular and cellular mechanisms underlying the nicotinic 
modulation of transmitter release
1.2.3.1 Current views of exocytosis
The coupling between presynaptic nerve terminal depolarisation (e.g. by an incoming 
action potential) and transmitter release has been the subject of a large number of studies over 
several decades (e.g. Katz, 1969; Sudhof, 1995). In the nerve terminal, different compartments 
are assumed for storage (reserve pool of vesicles or vesicles tethered to the cytoskeleton) and 
for docking and release (readily releasable vesicle pool). It is clear that nerve terminal 
depolarisation causes the opening of voltage-operated calcium channels (VOCC), entry of Ca2+ 
into the nerve terminal, and Ca2+-dependent release of neurotransmitters. Moreover, Ca2+ influx 
following nerve terminal depolarisation has also been shown to increase the phosphorylation 
state of a number of proteins, including synapsin I. This protein binds synaptic vesicles to 
cytoskeletal elements and after phosphorylation by CaM kinase II (Ca2+-dependent) liberates 
vesicles from these attachments (Llin£s et al, 1991).
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The docking of vesicles at specialised areas of the presynaptic plasma membrane called active 
zones, fusion and release of transmitter involve interactions between vesicle (VSNARES) 
proteins and proteins of the nerve terminal plasma membrane (TSNARES): the VAMPs 
(synaptobrevins) and synaptotagmin (P65) on the vesicle membrane and syntaxins and 
neurexins on the nerve teiminal membrane (reviewed by Sudhof, 1995). It is interesting to 
highlight the close topological association that exists between nerve terminal VOCC and the 
exocytotic machinery. The colocalisation of N-type VOCC and syntaxin have been reported 
(Sheng et al., 1994). After docking, synaptic vesicles go through a maturation or "priming" 
process that makes them competent for Ca2+-triggered membrane fusion. Then, primed 
synaptic vesicles are stimulated for rapid fusion / exocytosis by a transient and local increase in 
the intraterminal Ca2+ concentration, e.g. during an action potential. The identity of the vesicle 
and plasma membrane proteins that constitute the fusion pore remains unclear, but 
synaptophysin is thought to form the vesicle contribution to the fusion pore while physophilin 
may constitute the plasma membrane contribution to the pore protein.
1.2.3.2 Na* dependence and TTX sensitivity
In the few instances where it has been examined, the nicotinic stimulation of transmitter release 
is Na+-dependent: replacement of extracellular Na+ with N-methyl-D-glucamine abolished 
(±)-antx-a-evoked dopamine release from striatal synaptosomes 
(Soliakov and Wonnacott, 1996). This is in agreement with the earlier demonstration that 
the (-)-nicotine-induced depolarisation of cortical synaptosomes is Na+-dependent 
(Hillard, 1992). More controversial is whether the Na+ current through nicotinic channels alone 
accounts for the nerve terminal depolarisation and is sufficient for stimulating transmitter 
release, or if it is augmented by the opening of voltage gated Na+ channels. Sensitivity to TTX 
has been used to assess the contribution of voltage gated Na+ channels, and various degrees of 
inhibition of nAChR-evoked transmitter release have been reported. For example, 
in striatal synaptosome preparations [3H]-DA release elicited by nicotinic agonists has been 
found to be insensitive to TTX (Rapier et al., 1988; Prince et al., 1996) or 
partially blocked by TTX (Soliakov and Wonnacott, 1996 - chapter 4), whereas [3H]-DA release 
from striatal slices may be partially (Sacaan et al., 1995) or totally blocked by TTX 
(Marshall et al., 1996). Examination of (-)-nicotine-stimulated efflux of 86Rb+ from 
mouse brain synaptosomes, a direct measure of ion flux arising from nAChR activation, 
found a partial (40%) inhibition by TTX (Marks et al., 1995). TTX was shown to decrease 
the rate of 86Rb+ flux without affecting the EC50 for (-)-nicotine, consistent with a block of voltage 
gated Na+ channels that augment the response to (-)-nicotine. This conclusion, together with the 
varying degrees of TTX sensitivity reported in the literature, makes the use of TTX-msensitivity 
to define functional presynaptic nAChR problematic. Rather, the failure of TTX to inhibit a 
nAChR-mediated enhancement of transmitter release is likely to reflect the location of receptors 
close to the release sites (Guo etal., 1998).
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1.2.3.3 Ca2+ dependence and involvement of VOCC
The high relative permeability to Ca2+ of neuronal nAChR raises the possibility that they might 
interface directly with the exocytotic machinery to promote transmitter release. Alternatively, 
the Na+ current and ensuing depolarisation might activate VOCC (Figure 1.4). In most cases 
examined, a partial (Lena and Changeux, 1997) or total (Soliakov and Wonnacott, 1996; 
Sershen et al., 1997) inhibition of nicotinic responses by non-selective blockers of VOCC such 
as Cd2+ has been observed, consistent with the participation of such channels. 
Selective inhibitors of subtypes of VOCC have implicated N-type channels as the principle 
mediator of the nicotinic stimulation of neurotransmitter release (Harsing et al., 1992; 
Soliakov and Wonnacott, 1996; Sershen et al., 1997). Then, it could be suggested that in the 
case of TTX-insensitive nicotinic stimulation of transmitter release, Na+ influx though the 
nicotinic channel produces sufficient local depolarisation to activate e.g. N-type VOCC. 
As these channels colocalise with syntaxin (Sheng et al., 1994), presynaptic nAChR may reside 
in close proximity at the active zone. A similar situation is observed in the presynaptic nAChR 
modulation of transmitter release in the peripheral nervous system: DMPP-evoked release of 
[3H]-ACh from guinea pig myenteric plexus is coupled to Ca2+ influx via N-type channels 
(Takahashi et al., 1992). In CNS preparations, co-Agatoxin IVA, a blocker of P-type VOCC, 
has a small (Prince et al., 1996) or negligible effect (Soliakov and Wonnacott, 1996) on release 
evoked by nicotinic agonists, and inhibitors of T-type channels have no effect 
(Harsing et al., 1992). L-type channel blockers (e.g dihydropyridines such as nifedipine) 
exert nonspecific actions on the nicotinic stimulation of transmitter release, attributed to a 
direct interaction with nAChR (Prince et al., 1996; Soliakov and Wonnacott, 1996).
Evidence that in some cases the Ca2+ flux through the nicotinic channel itself is sufficient for 
transmitter release comes from electrophysiological studies, coupled with the use of fluorescent 
indicators to demonstrate an increase in presynaptic intracellular Ca2+ in the presence of TTX 
and Cd2+ (Gray et al., 1996). The fact that the a7-type nAChR is responsible in this case may be 
relevant as it has the highest Ca2+ permeability of any neuronal nAChR: indeed the Ca2+ signal 
attributed to influx via the a7 nAChR is equivalent to that generated by an action potential. As 
experiments were not carried out in the absence of Cd2+ it is not certain that VOCC would not 
enhance the response. At GABAergic terminals in the medial habenula, presynaptic nicotinic 
enhancement of postsynaptic currents was insensitive to Cd2+ at some synapses but not others 
(Lena and Changeux, 1997); the a7 subunit has not been implicated in this response 
(see 1.2.2.5). In the presence of TTX, DMPP-evoked [3H]-noradrenaline release from chick 
sympathetic neurones in culture was not blocked by inhibitors of VOCC (Dolezal et al., 1996). 
The relative proximity of presynaptic nAChR to the exocytotic machinery and/or VOCC is likely 









Figure 1.4 Proposed model for the nAChR-mediated facilitation of neurotransmitter 
release from nerve terminals. Stimulation of nAChR with agonist initiates Na+ and Ca2+ influx 
through the receptor channel. The increase in intracellular Na+ results in depolarisation of the 
synaptic membrane and, depending on their relative proximities, may lead to opening of 
Na+ channels and / or voltage operated Ca2+ channels (VOCC). Alternatively, Ca2+ entering via 
the nicotinic channel may itself be sufficient to provoke neurotransmitter (NT) release. 
In parallel, activation of nAChR may lead to a number of intracellular events, 
(i) Phospholipase C (PLC) localised close to the nAChR may be activated (possibly by a 
Ca2+-dependent mechanism), leading to the generation of inositol triphosphate (IP3) and 
diacylglycerol (DAG). The latter, in concert with Ca2\  can lead to concomitant activation of 
protein kinase C (PKC). In turn, PKC could modulate the efficacy of neurotransmitter release by 
regulating ion-channel function or by enhancement of the readily releasable pool of synaptic 
vesicles, or both, (ii) The increase in intracellular Ca2+ may activate the synaptic vesicle- 
associated Ca2+ / calmodulin-dependent protein kinase II (CaM-KII), resulting in the 
phosphorylation of synapsin I. In its unphosphorylated state, synapsin I anchors synaptic 
vesicles to the actin cytoskeleton, whereas phosphorylation releases them from this reserve 
position, increasing the readily releasable pool of synaptic vesicles near the active zone, 
(iii) Further regulation of presynaptic mechanisms may be achieved through tyrosine kinase 
(TK) pathways that may be linked to nAChR activation by a route that is presently unknown.
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1.2.3.4 The involvement of second messengers in the nicotinic modulation of 
neurotransmission
Presynaptic nAChR may have more subtle modulatory functions than simply provoking 
transmitter release: they are proposed to increase the probability of release (Gray et al., 1996) 
or to sustain release through mobilisation of a reserve pool of transmitter (Bowman et al., 1990). 
Such actions are likely to be mediated by second messengers, and 
phosphorylation / dephosphorylation events offer a plausible regulatory mechanism. 
The high relative permeability to Ca2+ of neuronal nAChR advocates the potential involvement 
of Ca2+-dependent kinases (such as protein kinase C (PKC) and calcium-calmodulin dependent 
kinase II (CaM kinase II)) and Ca2+-activatable phosphatases (see Figure 1.4).
1.2.3.4.1 PKC
PKC is implicated in the modulation of exocytosis and PKC activators such as phorbol esters 
enhance neurotransmitter release evoked by electrical stimulation or KCI depolarisation 
(Dekker et al., 1991). Evidence for a PKC enhancement of the nicotinic stimulation of 
transmitter release comes from chromaffin cells (Terbush etal., 1988; Cox and Parsons, 1997). 
Here the (-)-nicotine-induced secretion of catecholamines is associated with entry of 
extracellular Ca2+ (Wakade et al., 1986), rapid translocation of PKC from cytosol to membrane 
(Terbush et al., 1988) and concomitant activation of PKC (Brocklehurst et al., 1985). 
There has been little work published on any interaction between nAChR and PKC in neurones. 
Cheramy and colleagues (1996) reported that the synergism between (-)-nicotine and NMDA in 
stimulating [3H]-dopamine release from striatal synaptosomes (attributed to the nicotinic 
depolarisation relieving the Mg2+ block of NMDA receptors) was sensitive to blockade by the 
PKC inhibitors staurosporine and chelerythrine.
Dr Wonnacott's lab has examined the potential interaction between presynaptic nAChR and 
PKC in striatal terminals in more detail (Soliakov and Wonnacott, 1998). They observed that two 
potent and specific PKC inhibitors, Ro 31-8220 and D-e/yfhro-sphingosine 
(but not the inactive analogue bisindolylmaleimide V) significantly inhibited the release of 
[3H]-dopamine evoked by the nicotinic agonist anatoxin-a. Moreover, two phorbol esters that 
activate PKC, phorbol-12,13-dibutyrate and phorbol-12-myristate-13-acetate 
(but not the inactive phorbol ester 4a-phorbol-12,13-didecanoate) potentiated 
anatoxin-a-evoked [3H]-dopamine release. This potentiation was Ca2+-dependent and blocked 
by PKC inhibitors. Identification of particular PKC subtypes involved has proved to be less 
tractable, not least because a large proportion of the majority of subtypes is already membrane 
bound in the brain under resting conditions, so that translocation to the membrane fraction is not 
an absolute prerequisite for activation if other necessary conditions (e.g. Ca2+ and 
diacylglycerol) prevail (Chakracarthy etal., 1994). The source of diacylglycerol following nAChR 
stimulation is not clear. There is considerable documentation that depolarising conditions elicit 
the generation of inositol phosphates (presumably in concert with the formation of 
diacylglycerol; see Dekker et al., 1991), and nicotinic stimulation may fall into this category.
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Indeed, In chromaffin cells KCI depolarisation or nAChR stimulation by DMPP increased the 
accumulation of inositol phosphates (Eberhard and Holz, 1987), and a mechanism based on the 
activation of PLCT by the increase in intracellular Ca2+ was advocated. There is also scope for 
interplay between nicotinic and muscarinic receptors (or with other metabotropic receptors 
coupled to phosphoinositide turnover). Both nicotinic and muscarinic stimulation of PC12 cells 
results in the translocation of PKC to the plasma membrane (Messing et al., 1989).
PKC can influence transmitter release by phosphorylating ion channels (Smart, 1997) or acting 
on proteins that participate in vesicle docking and fusion events (Gillis et al., 1996). 
The presynaptic nAChR may itself be a target for PKC: phosphorylation of the a4 subunit by 
PKC has been hypothesised to be necessary for maintaining the a4p2 nAChR in an activatable 
state (Eilers et al., 1997), although phosphorylation of muscle and ganglionic nAChR has been 
found to enhance desensitisation (Downing and Role, 1987; Hoffman et al., 1994). Transmitter 
release or ^Rb* efflux stimulated by presynaptic nAChR is subject to short term 
(desensitisation) and long term (functional inactivation) reduction, in response to sub-stimulating 
and stimulatory agonist concentrations, respectively (Marks et al., 1996; 
Rowell and Hillebrand, 1994). Any contribution of kinase or phosphatase activities in mediating 
these responses is not known, but such mechanisms are very plausible.
1.2.3.4.2 CaM kinase II
Another link between presynaptic nAChR stimulation, protein kinase activation and transmitter 
release, relevant to the mobilisation of a reserve pool of transmitter, comes from the study of 
Ochoa and O'Shea (1994). These authors reported that the nicotinic stimulation of ACh release 
from cortical synaptosomes was accompanied by a Ca2+-dependent increase in the 
phosphorylation of an 80 KDa band, proposed to correspond to synapsin I. This synaptic 
vesicle-associated protein regulates the availability of vesicles for release via its phosphorylated 
status (Greengard et al., 1993). Further analysis indicated that nicotine (50 pM) results in 
phosphorylation of site 3 on the synapsin I molecule (Ochoa an O'Shea, 1994). This site is 
known to be phosphorylated by vesicle-associated CaM kinase II (Benfenati et al., 1992), and 
Ca2+ entry accompanying nAChR activation might provide the stimulus.
Recently, an increase in the level of site 3-phospho-synapsin I, together with an increase in 
CaM kinase II activity, has been proposed to play a role in the enhancement of dopamine 
release from striatal synaptosomes provoked by amphetamine (Iwata et al., 1997). 
Our preliminary data (Soliakov and Kaiser, unpublished data - see chapter 6 ) also support 
synapsin I phosphorylation in response to the stimulation of nAChR in striatal nerve terminals: 
this response shows a critical, biphasic time dependence similar to that observed in response to 
KCI depolarisation (Sihra etal., 1989).
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1.2.3.4.3 Tyrosine kinase signalling pathways
Tyrosine kinases are increasingly recognised as important mediators and regulators of 
intracellular events, as well as intercellular communication. Although there is no evidence for 
the participation of tyrosine kinases in the nicotinic modulation of transmitter release in the 
brain, some support for such a link comes from chromaffin cells (Ely et al., 1990). Stimulation 
with either nicotine or KCI resulted in rapid tyrosine phosphorylation of the 
extracellular signal-related kinase (ERK2), and this was correlated with the Ca2+-dependent 
release of catecholamines provoked by the same depolarising agents. An involvement of 
tyrosine kinase is supported by the blockade of both nicotine-induced protein tyrosine 
phosphorylation and noradrenaline exocytosis in chromaffin cells by two different tyrosine 
kinase inhibitors, genistein and tyrphostin 23 (Cox etal., 1996).
In chromaffin cells, the tyrosine kinase Fyn, a member of the Src family, resides predominantly 
in the plasma membrane fraction and undergoes nicotine-induced activation in 
a Ca2+-dependent manner; this activation is abolished by mecamylamine (Allen et al., 1996). 
In the brain, Fyn is widely expressed and involved in a variety of neuronal events 
(Umemori et al., 1992). Consensus sequences for tyrosine kinases have been identified in the 
intracellular loops of several subunits of neuronal nAChR (Gurd, 1997) so modulation of the 
receptor via such pathways is also plausible.
1.2.4 Concluding remarks
This section has attempted to summarise the evidence for presynaptic nAChR on central and 
peripheral nerve terminals. It is evident that presynaptic nAChR are widespread, they are 
associated with all of the classical transmitters. However, presynaptic nAChR are not ubiquitous 
with respect to all nerve terminals and the release of some neurotransmitters in certain brain 
areas does not appear to be modulated by nicotinic agonists. In addition to this gross 
anatomical heterogeneity in their distribution, differences in the susceptibility to TTX and VOCC 
blockers suggests that there is local heterogeneity with respect to the localisation of presynaptic 
nAChR on nerve terminals, in relation to release sites. The subunit composition of presynaptic 
nAChR is also heterogeneous. So far, a7-type nAChR appear to modulate glutamate release, 
the p2 subunit is associated with GABA release, and multiple subtypes may influence dopamine 
release. More extensive information is required before generalisations can be made with any 
confidence. For the widespread occurrence of presynaptic nAChR to have physiological 
relevance, a similarly widely distributed source of ACh is required. Although cholinergic 
innervation is extensive in the brain, lack of evidence for axo-axonic synapses may favour a 
diffuse action of ACh (Descarries etal., 1997).
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In this section, several ways in which presynaptic nAChR might interface with signalling 
pathways to modulate transmitter availability and its release, were also briefly considered. 
Such studies are in their infancy but can be predicted to constitute a major research initiative in 
the near future. Signalling cascades provide a route for receptor crosstalk, well documented for 
metabotropic receptors but applicable also to ligand gated ion channels. Knowledge of this 
interface will illuminate the mechanisms of local regulation of nerve terminal functioning, 
that will extend beyond the simple enhancement of transmitter release.
1.3 Project aims
The general aim of this work was to study in vitro the modulation of neurotransmitter release by 
presynaptic nAChR in the vertebrate CNS. In this respect, two rat brain areas were examined: 
the hippocampus (section I) and the striatum (section II).
Section I of this thesis presents initial experimental attempts aimed at examining the 
involvement of presynaptic a7 nAChR in nicotinic agonist-evoked glutamate release from 
hippocampal preparations. The project initially involved the development of two topics:
1 ) the biochemical, pharmacological and functional characterisation of native and 
heterologously expressed rat a7 nAChR (this thesis next chapter), and the application of 
the potential results to
2 ) the study of nicotinic agonist-evoked glutamate release in rat hippocampus 
(this thesis chapter 3).
These studies were largely unsuccessful. Consequently, the modulation of striatal dopamine 
release as a consequence of presynaptic nAChR activation became the main focus of 
this thesis. In section II, the superfusion technique was used to explore the following aspects of 
the nicotinic modulation of dopamine release in striatum:
1) identification of presynaptic and/or preterminal nAChR modulating striatal dopamine release 
(this thesis chapters 4 & 5)
2) functional crosstalk between striatal nerve terminals as a consequence of nAChR 
stimulation (this thesis chapter 5), and
3) second messenger mechanisms underlying nicotinic agonist-evoked striatal dopamine 
release (this thesis chapter 6 )
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Section I: The hippocampus
The hippocampus
Learning and memory have since long been considered to be related to changes in 
synaptic efficacy, and long-term potentiation is a major candidate for such a role. 
In the last few years there has been a rapid advance in the understanding of long-term 
potentiation, especially with regard to its induction mechanisms. This advance has been based 
mainly on work performed on pathways in the hippocampal formation but similar induction 
mechanisms for long-term synaptic potentiation might operate for neocortical synapses as well.
The hippocampus is necessary for earty stages of memory formation
Enduring memories are stored in a stable form that survives seizures, most injuries to the brain 
and coma. Such memories appear to be stored, at least in part, as structural changes at specific 
synapses within neuronal networks that encode and connect the sensory impressions 
associated with each memory. These structural changes are thought to occur in the neocortex. 
Loss of neurones in a particular area of cortex never erases one particular set of memories but 
can degrade specific aspects of many memories. Thus, memories seem to be stored in a highly 
distributed fashion throughout many neocortical areas.
Some of the processes underlying the early stages if memory formation are more localised. 
For example a set of cortical structures including the entorhinal cortex, the subicullum, and the 
hippocampus are necessary to transform short-term declarative memories 
(e.g. memories of persons, places, things) into a more permanent form. The role of the 
hippocampus, a brain structure that lies beneath the caudal edge of the neocortex, has been 
thoroughly examined. Clinical studies have demonstrated that destruction of parts of the 
hippocampus, e.g. by ischemia, is sufficient to cause severe anterograde amnesia, 
an inability to form new memories.
Neuroanatomy of the hippocampus
The hippocampal formation is composed of two sheets of neurones that are highly 
interconnected with each other. The first sheet consists of three contiguous areas of cortex 
called CA fields (cornu Ammonis or Ammons' horn), the subicular complex, and 
the entorhinal cortex, which is continuous with the neocortex (see Figure la). The CA fields are 
often referred to as the hippocampus proper. They form a large flap of tightly packed pyramid- 
shaped neurones that is folded and tucked under the edge of the neocortex. The second sheet 
of neurones in the hippocampal formation is the dentate gyrus, which contains round, tightly 
packed neurones called granule cells.
In primates, the axons of pyramidal neurones from many neocortical association areas project 
into the entorhinal cortex. Information from these areas is relayed via a fan of axons called the 
perforant pathway through the subicullum and into the dentate gyrus. This cortical information is 
processed in the hippocampus through a network of synaptic connections that is not yet 
completely understood. One major part of the network, called the trisynaptic loop, has been
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extensively studied in vitro because it is preserved in coronal thin slices of hippocampus 
(Figure la). The first segment of this loop is formed by the synapses from perforant path axons 
onto dentate granule cells. Axons of the granule cells, called mossy fibres, leave the dentate 
gyrus and make the second set of synapses on dendrites of pyramidal cells in area CA3 in the 
hippocampus proper. The pyramidal cells of area CA3 produce branched axons. One branch 
leaves the hippocampus; the other makes a loop to form synapses with dendrites of pyramidal 
cells in area CA1. This third projection in the trisynaptic loop is called the Schaeffer collateral 
pathway. Axons of the CA1 neurones project to dendrites of neurones in the subicullar complex 
and, to complete the circuit, these neurones send axons to the entorhinal cortex. All areas of the 
hippocampal formation except the dentate gyrus contain neurones that project to various other 
parts of the brain. The apparent flow of information from neocortical association areas, through 
the hippocampal formation, and back out to the rest of the brain suggests that a function of the 
hippocampus may be to act "linking" activity from areas of the brain encoding information from 
many different sensory modalities into a record of a specific object or event. Such widespread 
temporary associations may constitute a short-term memory, which can be slowly transformed 
into a permanent memory encoded in the neocortex.
Figure la The hippocampal formation and the trisynaptic loop in the rat.
(A) Schematic diagram of the rat brain showing the position of the hippocampal formation. The 
dashed line shows the position of the horizontal section shown in (B). (B) Schematic diagram of 
a horizontal section through the hippocampal formation and overlying neocortex. Dashed lines 
and shaded areas represent layers of neuronal cell bodies. In the CA fields and dentate gyrus, 
cell bodies are packed into narrow layers. CA1 and CA3 are areas of the hippocampus. 
(C) Schematic diagram of the trisynaptic circuit in a hippocampal slice. Dashed lines represent 
outlines of tightly packed layers of neuronal cell bodies. Areas outside the dashed lines contain 
axons, dendrites, and numerous synaptic contacts. Additional axons enter the hippocampus 
through the fimbria or through the subicular complex and entorhinal cortex (A & B from 
Kennedy, 1989; C from Amaral, 1987).
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Afferent projections to the hippocampus include those containing acetylcholine 
(from the medial septum nucleus and diagonal band of Broca), noradrenaline 
(from nuclei in brain areas: A6  (locus coeruleus), A1, A5 & A7) 5-hydroxytryptamine 
(from dorsal (B7) and medial (B8 ) raphe nuclei), glutamate 
(perforant pathways, mossy fibre input, Schaffer collateral), aspartate (commisural pathway 
i.e. from contralateral entorhinal cortex), dopamine (from midbrain) and histamine 
(mainly from hypothalamus). Inhibitory GABA-containing innervation is also present 
(e.g. basket cells and GABAergic interneurones in CA1).
Synapses in the trisynaptic loop display LTP
A brief high-frequency train of stimuli to one of the segments of the trisynaptic loop, increases 
the excitatory postsynaptic potentials in the target hippocampal neurones, an increase that can 
last for hours in vitro, and in vivo for days and even weeks. This facilitation is called 
long-term potentiation (LTP). However, LTP is not produced in the same way in all three of 
these pathways. At glutamatergic synapses from the mossy fibres onto pyramidal neurones in 
area CA3, LTP can be induced only by high-frequency stimulation of presynaptic terminals. 
The strength of stimulation is not influenced by depolarisation of the postsynaptic membrane. 
This type of LTP is called homosynaptic or nonassociative, because is independent of events 
occurring at other, neighbouring synapses.
A second type of LTP occurs at the first and third synapses of the trisynaptic loop. In these two 
synapses, LTP is induced by strong, high-frequency presynaptic stimulation and also by weak 
stimulation that occurs at the same time that the postsynaptic membrane is depolarised, 
either by injection of currents or by stimulation of nearby excitatory synapses. This form of LTP 
is called heterosynaptic or associative LTP because stimulation of one set of synapses 
increases the probability that other synapses on the same neurone will be potentiated if the 
synapses are activated at the same time or a few milliseconds later. In brief, when glutamate is 
released from presynaptic terminals, as occurs during a high-frequency tetanus that induces 
LTP, It acts on non-NMDA ionotropic glutamate receptors depolarising the postsynaptic 
membrane, relieving NMDA receptors from their Mg2+ blockade and allowing Na\ K+ and Ca2+ 
to flow through the NMDA channels. The resulting rise in Ca2+ in the dendritic spine triggers 
calcium-dependent kinases (calcium/calmodulin kinase and kinase C) that induce LTP. 
Once LTP is induced, the postsynaptic cell releases a retrograde messenger (in ways that are 
still not understood) that is thought to act on kinases in the presynaptic terminal to produce the 
sustained enhancement of transmitter release tha^ contributes to the persistence of LTP. 
This second form of LTP provides a possible cellular mechanism for encoding associations 




Hippocampal nAChR and glutamate release
For many years, the lack of specific agonists and antagonists for particular neuronal nAChR 
subtypes and the fast kinetics of inactivation of some of them (see Sargent, 1993; 
Lindstrom, 1996; Albuquerque et al., 1997), limited the identification of functional nAChR in 
various brain areas. With the development of systems that allow fast application and removal of 
agonists (e.g. Radcliffe and Dani, 1998), and with the discovery of new pharmacological tools, 
it became possible to identify various subtypes of functional nAChR present on neurones from 
different brain areas, including the hippocampus (Alkondon and Albuquerque, 1993). 
Electrophysiological studies (Alkondon and Albuquerque, 1993) have shown that rapid 
exposure of ~85% of cultured hippocampal neurones to nicotinic agonists result in activation of 
fast-decaying currents that were named type IA currents. Type IA currents 
1) are sensitive to blockade by a-Bgt, MLA or a-conotoxin-lml, 2) show an inward rectification 
that depends on the intracellular level of Mg2+, 3) display a rundown that can be prevented by 
the presence of ATP-regenerating compounds in the intracellular solution and 4) are sensitive to 
modulation by extracellular concentration of Ca2\  Only 10% of the cultured hippocampal 
neurones respond to nicotinic agonists with slowly decaying currents that are sensitive to 
blockade by DHpE and are referred as type II, and no more than 2% of the neurones respond to 
such agonists with slowly decaying currents that are sensitive to blockade by mecamylamine 
and are referred to as type III (Alkondon and Albuquerque, 1993). The pharmacological and 
kinetic characteristics of type IA, type II and type III, when compared with the properties of 
nAChR subunit combinations ectopically expressed in Xenopus oocytes, suggest that they are 
subserved by a7 nAChR, a4p2 nAChR and a3p4 nAChR respectively
(Alkondon and Albuquerque, 1993). The original classification of the nicotinic responses 
recorded from cultured hippocampal neurones has been recently expanded (Zoli etal., 1998).
Many of the biological roles identified to date for neuronal nAChR have been associated with 
receptor mediated-changes in intracellular calcium (e.g. modulation of neurotransmitter release 
- see 1.2.2). Moreover, increasing evidence suggests that CNS nAChR are involved in cognitive 
processes such as learning and memory. In fact, it seems that the brain cholinergic system 
(Aigner and Mishkin, 1986; Dunnet and Fibiger, 1993) and the hippocampus (Squire, 1992; 
Bunsey and Eichenbaum, 1996 - see above) are vital "pieces" for memory processing in the 
mammalian CNS. Not only are nicotinic agonists able to improve cognition in experimental 
animals (reviewed by Stolerman et al., 1995), but also the number of neuronal nAChR is 
markedly decreased in the cortex and hippocampus of patients with Alzheimers' disease, a 
pathological condition characterised by progressive neurodegeneration and cognitive
impairment (reviewed by Kellar and Wonnacott, 1990; Schroder et al., 1991;
Maelicke and Albuquerque, 1996).
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At hippocampal glutamatergic synapses, low concentrations of (-)-nicotine were found to 
increase the frequency of mEPSCs (Gray et al., 1996; Radcliffe and Dani, 1998 - 
also see 1.2.2.6). In those cases, presynaptic a7-containing nAChR were capable of directly 
mediating a Ca2+ influx that initiated the enhanced glutamate release. Moreover, 
Radcliffe and Dani (1998) went further and demonstrated in cultured hippocampal neurones that 
the same information arriving along the same glutamatergic afferents is processed differently 
when properly timed nicotinic activity converges onto the glutamatergic presynaptic terminals. 
These results suggest that influencing information processing at glutamatergic synapses may 
be one way in which nicotinic cholinergic activity influences cognitive processes and that 
disruption of these nicotinic cholinergic mechanisms may contribute to deficits associated with 
the degeneration of cholinergic functions during e.g. Alzheimers' disease.
Section I of this thesis describes initial experimental attempts aimed to examine the 
involvement of rat a7 nAChR in nicotinic agonist-evoked glutamate release from hippocampus. 
The aim of chapter 2 was the biochemical, pharmacological and functional characterisation of 
native and heterologously expressed rat a7 nAChR whereas chapter 3 attempted the study of 
nicotinic-evoked glutamate release in rat hippocampus.
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2 Heterologous expression of rat a7 nAChR 
2.1 Introduction
2.1.1 Ectopic expression of nAChR subtypes
The coexistence in the same brain area (and even in the same neurone) of different nAChR 
subtypes makes the in vivo study of the properties of individual nAChR subtypes extremely 
difficult. That is why heterologous expression of nAChR has been extensively used, 
and provided much of our knowledge concerning the electrophysiological and pharmacological 
properties of the subtypes. Although the results from these studies may not fully represent the 
situation in the vertebrate brain, they at least indicate that some subunit combinations are 
functional whereas others are not. Such studies have been carried out in Xenopus oocytes and 
mammalian transfected cell lines.
2.1.1.1 Xenopus oocytes
Electrophysiological studies have demonstrated that various functional nAChR can be 
generated by injecting neuronal mRNAs or cDNAs encoding a2, a3 or a4 subunits in pairwise 
combinations with p2 or p4 subunits. The resulting nAChR subtypes have different biophysical 
and pharmacological properties, some of which may match those of native nAChR. 
When the same subunits are expressed alone, they are not capable of forming functional 
receptors, thus suggesting that this class of receptors can only form heteromeric receptors 
(reviewed by Sargent, 1993; McGehee and Role, 1995).
These heterologous studies have demonstrated that both a  and p subunits determine the 
pharmacological and functional properties of the expressed subtype. For example the channels 
formed when the p2 subunit is expressed in combination with either a2, a3 or a4 subunits, 
differ in their average open times, single channel conductances and antagonist sensitivity. 
The p subunit apparently regulates the rate at which the agonists and antagonist dissociate from 
the subtypes, as well as the rate at which agonist-subtypes open (Papke, 1993; 
Papke and Heinemann, 1991; 1994).
A further complexity of the structure of nAChR is contributed by the a5 subunit. 
When expressed alone or with any other p subunit, a5 fails to generate functional channels. 
It only gives rise to a functional receptor when coexpressed with a4 and p2 subunits 
(chick a5 - Ramirez-Latorre et al., 1996), with a3 and p2 or with a3 and p4 subunits 
(human a5 - Wang et al., 1996; Gerzanich et al., 1998). Moreover, it has been reported that 
a3, p2 and p4 cDNAs form heterotrimeric neuronal nAChR when coinjected into 
Xenopus oocytes. Recently, Gerzanich et al. (1997) showed that chicken a6 only generates 
detectable functional nAChR when coexpressed with the human p4 nAChR subunit.
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Unlike the heteromeric nAChR expressed in oocytes, the injection of a7, a8 or a9 cDNA alone 
produces homomeric receptors that are activated by ACh and blocked by nanomolar 
concentrations of a-Bgt (Gerzanich etal., 1994; Elgoyhen etal., 1994).
These expression studies have demonstrated that both homomeric and heteromeric receptors 
share two pivotal properties: 1 ) they are not only permeable to monovalent cations but also to 
Ca2+ and 2) they are modulated by changes in extracellular Ca2+ regardless of any increase in 
intracellular Ca2+, suggesting that neuronal nAChR play a relevant role in Ca2+ signalling.
2.1.1.2 Mammalian cell lines
A number of transiently and stably transfected cell lines expressing different combinations of 
nAChR subunits have been recently created and used to characterise the pharmacology and 
functional properties of the possible subtypes present in neurones. The chick and rat 
a4p2 nAChR subtype have been stably transfected in M10 (Whiting et al., 1991) and 
HEK-293 cells (Gopalakrishnan et al., 1996). The rat a3p4 subunit combination, which is 
thought to represent a ganglionic subtype, have been transiently (Wong etal., 1995) and stably 
(Stetzer et al., 1996) transfected in HEK-293 cells. Moreover, Eusebi and colleagues have 
successfully used the human cell line BOSC 23 to transiently express an interesting variety of
subunit combinations: human and rat a3p4, chick a3p2, a4p2, a4p4, a l, a 8 , a3p4a5, a6p2,
a6p4 and a3p4a6 (Ragozzino et al., 1997; Fucile et al., 1997; 1998).
Recently, Forsayeth and Kobrin (1997) reported the assembly of p3 into a functional receptor of 
probable stoichiometry (a4)2p2p3p4 upon transfection in COS cells. The a7 nAChR subunit has 
been stably expressed in the following mammalian cell lines: SH-SY5Y (Puchacz et al., 1994), 
HEK-293 (Gopalakrishnan et al., 1995); G H ^  (Quick et al., 1996) and QT6  
(Kassnerand Berg, 1997).
2.1.2 A neuronal LGIC that binds a-Bgt: the a7 nAChR.
Studies performed in 1985 by Raftery and colleagues with a-Bgt binding proteins 
affinity-purified from chick brain, generated four partial amino-acid sequences. 
Only the N-terminal region of one of them revealed homology to nAChR
(Conti-Tronconi et al., 1985). Using an oligonucleotide probe corresponding to this 
N-terminal protein sequence (Conti-Tronconi et al., 1985), Lindstom and colleagues identified a 
cDNA for a subunit that they originally named a-Bgt binding protein a1 (Schoepfer et al., 1990 - 
subsequently named the a7 subunit by Couturier et al., 1990). This cDNA sequence was in turn 
used to identify another cDNA from chicken brain that exhibited a very similar sequence 
(82% similarity as determined by Schoepfer etal., 1990) and encoded the a-Bgt binding protein 
a2, later renamed as the a8 nAChR subunit. Since then, a7 has also been cloned from rat 
(S6 gu6 la et al., 1993), human (Doucette-Stamm, 1993; Peng et al., 1994; Chini et al., 1994)
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and mouse (Orr-Urtreger et al., 1995). The a7 and a8 subunits are homologous in sequence to, 
but about equally distinct from, muscle a1 and neuronal a2-a6 (Schoepfer et al., 1990). 
The a8 protein has not yet been found in other species, but while searching for it in rats, 
a9 was discovered (Elgoyhen et al., 1994). In 1990, Ballivet and coworkers first reported that 
a7, when expressed in Xenopus oocytes, was capable of forming functional homomeric nAChR 
which were blocked by a-Bgt (IC5o= 0.7 nM - Couturier et al., 1990; Eisel6  et al., 1993).
2.1.3 Is the wild type a7 nAChR an homomer?
There is no doubt that the a-Bgt sensitivity of (-)-nicotine-evoked responses in Xenopus oocytes 
injected with a7 (this study Figure ), are of the purely homomeric rat a7 nAChR. 
In the initial instance, when the chicken a7 subunit gene was cloned and expressed 
(Couturier et al., 1990), control studies were performed to evaluate a possible interference of 
nAChR a-like subunits that might be endogenously expressed in the oocytes 
(Buller and White, 1990; Hartman and Claudio, 1990). To check this possibility, oocytes were 
injected with equimolar mixtures of muscle p, y and 8 cDNAs or with p2, p3, or p4 cDNAs. 
All such oocytes failed to respond to ACh (100 pM), conversely a ip iy 8  and a4p2 combinations 
were responsive when challenged with 1 pM ACh. Similarly, expression of the a7 cDNA 
coinjected with other neuronal nicotinic subunits known to be expressed in PC12 cells 
(a3, a5, p2 or p4), did not lead to the formation of receptors pharmacologically distinct from 
a7 alone (S6 gu6 la etal, 1993). Supporting this view, it was also found that the current recorded 
was only proportional to the amount of a7 mRNA or cDNA injected and was not proportional to 
the total amount of message injected (SeguSla etal., 1993).
Anand et al. (1993) used sucrose gradient sedimentation analysis to compare chicken a7 
protein expressed in Xenopus oocytes and native detergent-solubilised brain 
a7 nAChR. All the [125l]-a-Bgt labelled receptors cosedimented at ~1 OS implying a common size 
and "shape". By immunoisolating [^Sj-methionine labeled a7 subunits it was also demonstrated 
that the a7 subunits do not appear to assemble with endogenous Xenopus nAChR subunits 
(assuming that the oocyte does not express subunits (known or unknown) with the size and 
"shape" of al). The same study revealed subtle pharmacological differences between 
native chick brain nAChR containing the al gene product and those resulting from heterologous 
expression of the chick al gene in Xenopus oocytes, and the differences were cited as 
evidence that the native receptors are heteromeric (Anand et al., 1993). 
A study by Keyser et al. (1993) supported this observation. They immunoprecipitated three 
subtypes of a-Bgt-binding nAChR from extracts of chick brain and retina: 
1) homomeric al nAChR (predominant in chick brain), 2) homomeric a 8  nAChR (predominant 
in chick retina) and 3) a7a8 nAChR, a minor subtype in both brain and retina.
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The first report of heterologous expression of a7-containing heteromeric nAChR was published 
by Helekar et al. (1994). They demonstrated that the rat a7 is capable of coassembling with 
muscle nAChR subunits under certain particular conditions when coexpressed in 
Xenopus oocytes. Recently, and using an approach similar to that used by Anand 
(Anand et al., 1993), Marika Quik et al. (1996) compared the properties of rat a-Bgt-binding 
sites stably expressed in the pituitary cell line G H ^  with those present in rat brain membranes. 
Their studies showed that the pharmacological properties, molecular size and regulation of 
stably expressed rat brain a-Bgt binding sites in a7-GH4C1 cells, closely resemble those of 
native rat brain receptors. Finally, they suggested that rat brain a-Bgt receptors are homomeric 
or, if these receptors are heteromeric, that at least the a7 subunit is a key element in 
determining this receptor properties.
However, the first studies reporting native a7 heteromeric nAChR came from Loma Role’s lab 
(Yu and Role, 1998a; 1998b). They presented evidence that in embryonic chick sympathetic 
neurones, the a7 subunit contributes to the function of at least three subtypes of native nAChR 
that differ from each other in their sensitivity to block by a-Bgt and MLA.
Also in Cuevas and Berg (1998) it is suggested that the particular features
(e.g. slow desensitisation and reversible a-Bgt blockade) of a a7-containing nAChR found in 
intracardiac ganglia could be due to the presence of non-a7 subunits in the pentamer.
2.1.4 Channel properties of the a7 nAChR
The ion channel properties of the a7 nAChR could be summarised by 1) high permeability 
to Ca2\  2) rapid desensitisation and 3) strong inward rectification. The a7 nAChR has an 
unusual high permeability to calcium compared to other nAChR subtypes
(Vijayaraghavan etal., 1992; Rathouz etal., 1996; Delbono etal., 1997) and they are at least as 
selective for Ca2+ as are NMDA channels (S6 gu6 la et al., 1993). By replacing all extracellular 
cations with 200 mM sucrose and leaving 1.8 mM CaCI2 in the bathing solution, 
Lindstrom (1995) showed that the fraction of current carried by Ca2+ for a7, a4p2 and 
muscle nAChR expressed in oocytes is: 11%, 3% and 1%, respectively.
The kinetic behaviour of neuronal nAChR is also modulated by external Ca2+
(Vernino et al., 1992). In contrast to the muscle receptor where external Ca2+ decreases the 
current carried by monovalent cations, in neuronal nAChR ACh-induced currents increase as 
the extracellular Ca2+ concentration increases (Vernino et al., 1992). Recently, the a7 nAChR in 
particular has been shown to be sensitive to changes in the [Ca2+]0. Extracellular Ca2+ 
modulates the affinity of the a.7 nAChR for ACh, the cooperativity between ACh-binding sites, 
as well as the inward rectification and the decay and rundown of a7 nAChR mediated type IA 
currents (Bonfante-Cabarcas et al., 1996; Albuquerque et al., 1997). 
Both the rapid desensitisation and the inward rectification combine to minimise sustained influx
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through these nAChR. These self-limiting features are specially interesting when considering 
the possible functional roles of such nAChR.
2.1.5 Functional role of a-Bgt-sensitive nAChR
The a7 nAChR have been histologically localised by binding of labelled a-Bgt 
(Clarke et al., 1985), mAbs (Britto et al., 1992; Keyser et al., 1993; 
Dominguez del Toro et al., 1994) and in situ hybridisation (S6 gu6 la et al., 1993). 
In rat brain, a7-containing nAChR, or [125l]-a-Bgt binding sites, have been found at relatively 
moderate to high density in many regions, including olfactory regions, the hippocampus, 
the amygdala, the hipothalamus and the cerebral cortex (Clarke et al., 1985; 
S6 gu6 la etal., 1993; Alkondon etal., 1996).
Despite morphological, biochemical, and electrophysiological analysis, the functions of neuronal 
a-Bgt binding sites and nAChR in the mammalian brain remain largely unknown. 
Various neuronal nAChR are involved in nicotine addiction (Dani and Heinemann, 1996), and 
there is evidence that nicotine can improve attention, rapid information processing and working 
memory (Levin, 1992; Ohno et al., 1993; Piccioto et al., 1995; McGehee and Role, 1996). 
Cholinergic mechanisms may be involved in neurobehavioural disorders including seizures and 
schizophrenia (Steinlein et al., 1995; Freedman et al., 1997). A locus for juvenile myoclonic 
epilepsy is mapped near the a7 gene in humans (Elmslie et at., 1997). 
Some functions attributed to the a-Bgt sites and/or the a7 subunit include synapse 
formation/modulation of neurite outgrowth (Fuchs, 1989, Pugh and Berg, 1994; 
Broide et al., 1995), mediation of (-)-nicotine-induced seizures (Miner and Collins, 1989; 
Stitzel et al., 1997), control of synthesis and/or release of neurotrophins, regulation of early 
genes (e.g c-fos) transcript levels (Greenberg et al., 1986), activation of second messengers 
(e.g. Vijayaraghavan et al., 1995), presynaptic modulation of neurotransmitter release 
(e.g. McGehee etal., 1995; Gray etal., 1996; Radcliffe and Dani, 1998) as well as mediation of 
synaptic transmission (e.g. Alkondon etal., 1997; Frazier et al., 1998a).
The main objective of chapter 2 was to compare the pharmacological and functional properties 
of homomeric rat a7 nAChR heterologously expressed in mammalian cell lines with those of 
native a-Bgt-sensitive nAChR. This chapter presents these attempts to heterologously express 




2.2.1 Molecular biology: subcloning the rat a l  cDNA into the 
pCDNA3 plasmid
2.2.1.1 Source of the rat a7 nAChR gene
The rat a7 nAChR cDNA, cloned by S6 gu6 la et al. (1993), was generously provided in 
the pSM vector by Dr Jim Patrick (Baylor College of Medicine - Houston, TX USA).
2.2.1.2 Preparation and transformation of competent Escherichia coli
A single E.coli (strain XL1-Blue) colony forming unit (cfu) was picked from an agar plate 
(15 g bacto-agar (Sigma - Poole, Dorset UK) / I Luria-Bertani broth (LB: 10 g NaCI, 
5 g yeast extract (Sigma), 10 g tryptone (Sigma) in 1 I sterile water, pH 7.5)) freshly grown 
overnight at 37°C and transferred into 100 ml LB. The culture was incubated for 3 h at 37°C with 
vigorous shaking (300 cycles / min in a rotary shaker). Under sterile conditions, the cells were 
transferred to ice-cold 50 ml polypropylene tubes and kept on ice for 10 min. Cells were pelleted 
by centrifugation at 4000 rpm for 10 min at 4°C and the supernatant fraction was discarded. 
Each pellet was washed with 10 ml ice-cold 0.1 M CaCI2 (in sterile water, pH 8 .0 ) and 
resuspended in 2 ml ice-cold 0.1 M CaCI2 for each 50 ml of original culture. The cell suspension 
was retained on ice for at least 1 h. Then competent cells, 200 pi of each suspension, were 
transferred to sterile 1.5 ml E-cups. The pSMa7 plasmid incorporating the rat a7 cDNA 
(in sterile water) was mixed (~10 ng / pi) with this solution of permeabilised cells (4°C, 30 min). 
The reaction mixture was then placed in a 42°C water bath for 3 min. Immediately after, 
LB (1 ml) was added and the E-cups incubated on ice for 2 min. Cells were then maintained at 
37°C for 1 h with occasional gentle mixing.
Successful transformants were selected by their resistance to ampicillin (Sigma). The ampicillin- 
resistance gene is included in the pSM plasmid. Bacterial cells treated as above were spread on 
selective agar plates media (containing 100 pg ampicillin / ml), inverted and maintained at 37°C 
(12-16 h). Plates were stored at 4°C. Resistant cfu were picked and inoculated into ampicillin- 
containing LB (one cfu per vial containing 3 ml LB + 100 pg ampicillin / ml) and these bacterial 
suspensions incubated overnight in a shaker at 37°C.
2.2.1.3 Preparation of bacteria glycerol stocks
Bacteria (transformed or not) were stored at for up to 1 year in cultures containing glycerol. 
Bacteria glycerol stocks were prepared by adding to 0.50 ml of bacterial culture 0.50 ml of 
sterile glycerol (Sigma - Poole, Dorset UK). After vortexing the tube to ensure that the glycerol 
was evenly dispersed, the culture was frozen in ethanol-dry ice and transferred to 
-80°C for long term storage.
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2.2.1.4 Alkaline lysis miniprep
Transformed cells from a single bacterial colony were inoculated into 5 ml ampicillin-containing 
LB (100 pg antibiotic / ml LB) and grown to saturation at 37°C with vigorous shaking (overnight). 
The bacterial suspension (1.5 ml) was harvested by centrifugation at 8000 rpm for 5 min at 4°C. 
The supernatant was discarded. The pellet was resuspended in 100 pi TE (10 mM Tris.CI 
(Sigma - Poole, Dorset UK), 1 mM EDTA (Sigma), pH 7.8), and kept at room temperature for 
~5 min. Then, 200 pi NaOH / SDS solution (0.2 M NaOH, 1 % (w/v) SDS (Sigma)) was added, 
the tube content gently mixed and kept on ice for 5 min. Addition of 150 pi ice-cold 5M 
potassium acetate (pH 4.8 in 3M acetic acid) and thorough inversion precipitated the larger cell 
remnants (4°C, 10 min).
Chromosomal DNA and cell debris were spun down at high speed (13000 rpm, 4°C, 20 min) 
leaving the plasmid DNA in the supernatant. Plasmid DNA was recovered by precipitation with 
absolute ethanol (2 vol, -70°C for 20 min), spun down (13000 rpm, 4°C, 60 min) and the pellet 
washed with ice-cold 70 % ethanol (aq.) before eventually being dried and redissolved in 50 pi 
sterile water.
A commercially available kit (Promega's Wizard Miniprep DNA purification system - 
Madison, Wl USA) was also used to perform small-scale plasmid DNA purifications 
(LB culture volume: 1-3 ml - Expected DNA yield: 1-10 pg).
2.2.1.5 DNA digestion with restriction enzymes
The rat a7 sequence was originally inserted into the EcoRI restriction site of the multiple cloning 
site of the pSM plasmid (Baylor College of Medicine - Houston TX USA). Digestion with this 
enzyme should yield two fragments of lengths ~1.9 Kb and ~3.0 Kb corresponding to 
the rat a7 cDNA and the pSM plasmid, respectively. pSMa7 DNA (5 pi: 4 pg DNA) was mixed 
with EcoRI restriction enzyme (1pl (10 units) - Promega, Madison, Wl USA), the appropriate 
buffer (2pl 10X buffer H - Promega) and made up to 20 pi with sterile water. The reaction was 
incubated at 37°C for 2 h and stopped by heating it at 70°C for 20 min. Fragmented DNA was 
extracted with phenol : chloroform : isoamyl alcohol. In brief, an equal volume of 
phenol : chloroform : isoamyl alcohol (25:24:1) was added to the nucleic acid sample. 
To separate the organic and the aqueous phases, the mixture was centrifuged at 13000 rpm 
for 1 min. The aqueous phase was transferred to a fresh tube. An equal volume of chloroform 
was added and the aqueous phase recovered after centrifugation (13000 rpm for 1 min). 
Nuclei acids were precipitated by adding 3 M sodium acetate pH 5.4 (0.1 vol), cold absolute 
ethanol (2.0 vol) and further cooling at -70°C for 20 min. Precipitate was centrifuged 
(13000 rpm, 4°C, 60 min) and the pellet washed in ice-cold 70 % ethanol (aq.) before being 
dried and redissolved in sterile water (50 pi).
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2.2.1.6 Agarose gel electrophoresis
Digested DNA (5pl) was added to 1 pi Gel Loading Buffer (GLB: 30 % glycerol (v/v) 
(Sigma - Poole, Dorset UK), 0.25 % xylene cyanol (v/v) (Sigma), 0.25 % bromophenol blue (v/v) 
(Sigma)) and run on a 1 % agarose (Sigma), gel along with 1 Kb DNA ladder 
(Gibco BRL Life Technologies - Paisley, Scotland) at 15 V / cm for 30 min. Gel running buffer, 
TBE (89 mM Tris.CI (Sigma), 89 mM borax (Sigma), 2 mM EDTA (Sigma)), included 
ethidium bromide (0.5 pg / ml - Sigma). Bands were visualised using a UV transilluminator and 
results documented on Polaroid film Type 667 (Sigma).
2.2.1.7 Large-scale plasmid DNA purification: maxi preps
A commercially available system, QIAfilter Plasmid Maxi Kit (Qiagen - Dorking, Surrey UK), 
was used to perform large-scale plasmid DNA purifications (LB culture volume: 100 ml - 
Expected DNA yield: 300-500 pg).
2.2.1.8 Dephosphorylation of linearised pCDNA3 plasmid DNA
The pCDNA3 plasmid (Invitrogen - San Diego, CA USA) was linearized (~5.4 Kb) with EcoRI 
(Promega - Madison, Wl USA). The entire coding sequence for the rat a7 nAChR subunit 
(~1.9 Kb) was excised from the plasmid pSMa7 (~4.9 Kb) with the same restriction enzyme 
(see 2.2.1.5). The a7 sequence (~2.3 pg DNA) was extracted from a preparative agarose gel 
(0.8 %, TBE) with the Sephaglas Bandprep Kit (Pharmacia Biotech - Uppsala, Sweden) and 
resuspended in 60 pi TE buffer.
Calf intestinal alkaline phosphatase (CIP) was used to remove 5'-phosphate groups from linear 
pCDNA3. After addition of 4.5 pi CIP dephosphorylation buffer (10X) and 1 pi CIP 
(1 U - Boehringer Mannheim - Lewes, East Sussex UK) to 40 pi (~1.5 pg) linear pCDNA3, the 
mixture was incubated for 30 min at 37°C. At the end of the incubation period, the CIP was 
inactivated by heating to 75°C for 10 min in the presence of 5 mM EDTA (pH 8.0 - Sigma - 
Poole, Dorset UK).
Dephosphorylated pCDNA3 was purified by extraction with phenol: chloroform : isoamyl alcohol 





Rat al DNA was mixed with dephosphorylated linear pCDNA3 to a final molar ratio of 1.9. 
After addition of bacteriophage T4 DNA ligase buffer (10X - Promega - Madison, Wl USA), 
bacteriophage T4 DNA ligase (0.1 Weiss unit - Promega) and sterile water to a final volume of 
20 pi, the reaction mixture was incubated at 16°C overnight. The reaction product (1-2 pi) was 
used to transform competent Ecoli as described in 2.2.1.2. Two control reactions containing 
only 1 ) the vector or 2 ) al, were also set up.
2.2.1.10 Spectrophotometric determination of nucleic acid concentration and purity
DNA concentration and purity was determined using an Unicam Helios Gamma 
spectrophotometer (Unicam Ltd. - Cambridge, UK). The optical density (OD) at 
wavelength (X) = 260 nm and X = 280 nm was measured for dilutions of the plasmid DNA 
solution following standardisation with sterile water. A complete scan was performed between 
X = 240 -320 nm. The OD26o / OD28o ratio was used to determine the purity of the DNA product. 
Pure preparations of DNA had a ratio between 1. 8  and 2.0, contaminants significantly reduced 
this value. An OD of 1.0 at X = 260 nm corresponds to ~50 pg / ml for double-stranded DNA.
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2.2.2 Electrophysiology of the homomeric rat a7 nAChR expressed in 
Xenopus oocytes
Preparation of Xenopus laevis oocytes, injection with receptor cDNA, and measurement of 
a l  nAChR responses using two-electrode voltage-clamp have been previously described 
(Bertrand etal., 1992; Segu6 la etal., 1993).
2.2.2.1 Xenopus oocyte preparation
2.2.2.1.1 Animals and removal of oocytes
Adult Xenopus laevis. females (Xenopus Ltd. - Nutfield Ridge, Surrey UK) were kept in groups 
of up to eight animals for at least 3 months in a 12 h light: dark cycle at 18°C with access to 
diced heart or liver on alternate days. Removal of oocytes was earned out under 
Home Office Project License PPL 30/1551 by Mr Ewan Basterfield who holds a 
Personal License PIL 30/69 covering this procedure. Briefly, on the day of use, a frog was 
anesthesized by immersion in a 0.15 % tricaine solution (w/v - Sigma - Poole, Dorset UK) at 
room temperature for 60 min. Successful anesthesia was indicated by lack of response to an 
abdominal pinch. The anesthesized frog was then placed ventral side up on an ice bed and a 
small incision (0.5-1.0cm) was made in the lower abdomen. An ovarian lobe was pulled out 
through the incision, sutured to prevent internal bleeding and removed into SOS (100 mM NaCI, 
2 mM KCI, 1.8 mM CaCI2, 1 mM MgCI2, 5 mM Hepes (Sigma), pH 7.6) at room temperature. 
Then the frog was sutured and returned to fresh water. After several weeks the frogs were fully 
recovered and were reused once and killed by a Schedule 1 method. All procedures were 
carried out under sterile conditions.
2.2.2.1.2 Oocyte isolation
Removal of the follicular layer was performed by incubation with collagenase type IA 
(Sigma - Poole, Dorset UK) followed by manual removal of the partially degraded tissue. 
The ovarian lobe was divided into clumps of 10-20 oocytes, transferred to a solution of 
collagenase (2 mg/ml) in SOS and incubated at 18°C until the follicular layer was completely 
removed (90 - 120 min). Oocytes used were at stage V or VI of development, characterised by 
a distinctive boundary between animal and vegetal poles, uniform coloration within each pole, 
and were ~1mm in diameter, spherical with intact membranes. Oocytes dissected in this way 
were generally washed at least five times in SOS and left overnight at 18°C to identified 
damaged eggs which were apparent as ruptured cells by the following morning. Approximately 
three times the number of cells to be injected were routinely isolated in order to compensate for 
such loses and to provide sufficient controls.
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2.1.2.2 Oocytes: nuclear injection of a7 cDNA
The rat a7 subcloning procedure into the pCDNA3 plasmid was detailed in 2.2.1. Samples of 
pCDNA3a7 were stored at -20°C and thawed on the day of use before dilution in sterile water to 
a final concentration of 250 ng / pi. Injection needles were pulled on a 763 programmable 
micropipette puller (Campden Instruments - Loughborough, UK) using 3.5" borosilicate 
capillaries (10 pi - Drummond Sci.Co. - Broomall, PA USA). Tip diameters were typically 
<10pm. Needles were sealed with mineral oil and cDNA (total volume ~2pl) was drawn slowly 
into the needle using a "Nanoject variable" automatic injector (Drummond) secured to a 
micromanipulator. Approximately 14 nl (c. 108 copies of plasmid DNA) were injected into the 
oocyte nucleus under binocular magnification.
2.2.2.3 Oocyte incubation
Injected oocytes were transferred to 96 well titre plates, 1 oocyte per well containing 250 pi 
Incubation SOS (SOS containing 50 IU penicillin / ml - 50 pg streptomycin / ml 
(Gibco BRL Life Technologies Ltd. - Paisley, Scotland) and 50 pg gentamicin (Sigma - Poole, 
Dorset UK) / ml; 2.5 mM pyruvic acid (Sigma)) and incubated at 18°C under sterile conditions. 
Functional receptors (as judged by (-)-nicotine-induced responses) appeared in the oocyte 
membrane about two days after nuclear injection of cDNA. Incubation medium was replaced 
every 2-3 days.
2.2.2.4 Whole cell electrophysiology of injected oocytes
2.2.2.4.1 Perfusion chamber
A small volume chamber was used for the application of (-)-nicotine 
(Sigma - Poole, Dorset UK) during electrophysiological recording of a7 responses. 
In this setup, the bath volume was 300 pi and the chamber consisted of a plastic groove with a 
small recess in which the oocyte was placed (Figure 2.Error! Unknown switch argument.). 
Rapid solution exchange was achieved through the close proximity of perfusion inlet and outlet 
to the oocyte.
The superfusion was based on gravity flow. Drug solutions and perfusion medium 
(SOS containing 0.5 pM atropine (Sigma), 100 pM fluflenamic acid (Sigma) and 
100 pM niflumic acid (Sigma)) were placed above the level of the recording chamber. They 
were connected to the chamber via continuous siliconized rubber tubing. Switching between 
reservoirs of the drugs and perfusion solution was achieved using a manually operated pinch- 
valve system. The dead volume between reservoirs and chamber was kept to a minimum and 
no mixing between solutions was possible. The outlet from the chamber was a polyethylene 
tube leading to a trap connected to a vacuum pump.
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Figure 2.Error! Unknown switch argument.. Schematic diagram of a voltage-clamp 
recording apparatus. In a voltage clamp experiment one controls the membrane potential and 
measures the transmembrane current required to maintain that voltage. The oocyte membrane 
potential is monitored by the recording electrode ( V ). A reference electrode ( R E  ) is also 
connected to a subtractor amplifier
(not shown) where the value of the reference electrode is subtracted from that of the recording 
one ( V0 = V - R ). The subtractor amplifier is connected to the VF-102 amplifier (Biologic). 
The output of this device is fed into the CA-100 clamping amplifier (Biologic) which compares 
V0 to the command voltage ( Vc ). The difference between these two values ( V| = Vc - Vc ) 
is then converted by the VF-180 amplifier into a current ( V| -> l| ) that is fed to the 
current-injecting electrode ( C ). Vj is monitored on an oscilloscope.
2.2.2A.2 Dual electrode voltage-clamp electrophysiology
Current, voltage and reference electrodes were pulled on a 763 programmable micropipette 
puller (Camden Instruments - Loughborough, UK) using borosilicate glass capillaries with inner 
filament (Clark Electromedical Instruments - Reading, UK) and filled with 3M KCI. 
Electrical connection to the recording equipment was established through silver chloride wire 
insulated with Teflon. Typical electrode tip resistances were 2-3 MQ, i.e. small enough to inject 
current effectively and minimize damage to the oocyte.
Ligand-induced currents were measured using conventional two-electrode voltage-clamp 
(Figure 2.1). The resting potential of the cell was measured using a recording (Voltage: V) 
electrode connected to the input of a VF-102 dual microelectrode amplifier 
(Biologic - Claix France). A second (Reference: RE) electrode was connected to a subtractor
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amplifier where the value of the reference was subtracted from that of the Voltage. 
This signal was fed into a CA-100 clamping amplifier (Biologic) and was used to set the required 
current to be injected into the oocyte to attain the desired holding potential. The output of the 
CA-100 amplifier was the input of the VF-180 microelectrode amplifier (Biologic) to which a third 
(Current: C) electrode was connected. The CA-100 amplifier output was monitored on an 
oscilloscope and also captured and stored on a DTR-1200 analogue-to-digital DAT recorder 
(Biologic) and on chart paper.
For data acquisition, recordings were selected from the DAT tape and fed into an AT486 IBM 
compatible PC. They were acquired using an AT-MIO-16DL adapter board 
(National Instruments Corp. - Austin, TX USA) controlled through the application programming 
interface "NI-DAQ software" version 4.4 (National Instruments Corp. - Austin, TX USA). 
The resulting 12-bit binary files were then plotted and analysed using Sigma Plot for 
Windows version 2.0 (Jandel Scientific - Germany).
2.2.2.4.3 Drugs and their application
All the solutions were prepared on day of use. To allow nAChR recovery from desensitisation, 
oocytes expressing the a7 nAChR were washed in SOS for a minimum of 5 min between 
agonist applications (3 s 200 pM (-)-nicotine -  Figure 2.6). For inhibition studies with 
a-bungarotoxin (40 nM - Sigma), the antagonist was incubated with the oocyte in the chamber 
for a period of 30 min before stimulation with (-)-nicotine. In order that antagonist would not be 
washed off during agonist perfusion, the same concentration of the antagonist was included in 
the agonist solution pulse (3 s).
2.2.2.4A Current-vottage (l-V ) relationships
The l-V characteristics for currents evoked by (-)-nicotine (200 pM - Sigma - Poole, Dorset UK) 
were determined by holding the membrane potential at a constant voltage and perfusing agonist 
to evoke a response. The holding membrane potential was then stepped to new values and the 
drug applied to each step. A wash period of 10 min was allowed between each 3 s (-)-nicotine 
pulse. The l-V curve was obtained by plotting the amplitude of the 
ligand-evoked currents as a function of the holding potential.
2.2.2.4.5 Data handling
The rat a l  l-V curve was constructed by normalising currents from an specific oocyte to the 
largest current evoked by (-)-nicotine (200 pM - Sigma - Poole, Dorset UK). The amplitude of 
the currents was determined by comparison with the amplitude of control pulses 
(1 pAA/) injected into the CA-100 amplifier using a Digitimer Isolated Stimulator DS2A 
(Digitimer Ltd. - Hertfordshire UK).
42
Chapter 2
2.2.3 Primary culture of E18 hippocampal neurones
High-density hippocampal neuronal cultures were prepared from E18 Sprague-Dawley rat 
foetuses (University of Bath Animal House) as previously described (Goslin et al., 1991; 
Barrantes et al., 1995). Hippocampi were dissociated and plated in polyethylenimine 
(PEI)-coated dishes (50 pg PEI (Sigma - Poole, Dorset UK) / ml borate buffer pH 8.3) at a 
plating density of ~1.5 x 105 ceils / cm2 in 10 % foetal calf serum supplemented chemically 
defined medium (Dulbecco’s Modification Eagle’s Medium : Ham’s F12 medium = 3 : 1  (ICN 
Biomedicals Inc. - Costa Mesa, CA USA), supplemented with: 100 pg / ml human transferrin 
(Sigma); 100 pM putrescine (Sigma); 5 pg insulin (Sigma) / ml; 20 nM progesterone (Sigma); 
30 nM sodium selenite (Sigma); 2 mM L-glutamine (Gibco BRL Life Technologies Ltd. - 
Paisley, Scotland); 100 IU penicillin / ml and 100 pg streptomycin / ml 
(Gibco BRL Life Technologies Ltd.)). After two hours to allow cell attachment, 
the original medium was replaced with serum free chemically defined medium. 




2.2.4 Heterologous expression of rat a7 in mammalian cell lines
2.2.4.1 Cell culture of mammalian cell lines
Human embryonic kidney 293 cells (ECACC No. 85120602 - Salisbury, Wiltshire UK) were 
grown in Dulbecco's modified Eagle’s medium (ICN Biomedicals Inc. - Costa Mesa, CA USA) 
supplemented with 10 % foetal bovine serum (Gibco BRL Life Technologies Ltd. - Paisley, 
Scotland), 2 mM L-glutamine (Gibco BRL Life Technologies Ltd.), 1x non essential amino acids 
(ICN Biomedicals Inc.), 100 units penicillin / ml and 100 pg streptomycin / ml 
(Gibco BRL Life Technologies Ltd.) in a humidified atmosphere containing 5 % C0 2 at 37°C.
SH-SY5Y cells (ECACC No. 94030304 - Salisbury, Wiltshire UK) were grown in a 1:1 mixture of 
Ham's F12 medium (ICN Biomedicals Inc.) and Dulbecco’s Modified Eagle’s Medium 
supplemented with 15 % foetal bovine serum, 2 mM L-glutamine, 1x non essential amino acids, 
1 0 0  units penicillin / ml and 1 0 0  pg streptomycin / ml, in a humidified atmosphere containing 
5 % C0 2 at 37°C.
2.2.4.2 Lipotransfection of mammalian cell lines with pCDNA3a7
In brief, the entire coding sequence was excised from the plasmid pSMa7 with EcoRI 
(Promega - Madison, Wl USA) and ligated into the EcoRI site of the expression vector pCDNA3 
(Invitrogen - San Diego, CA USA) containing the constitutive human cytomegalovirus promoter 
to obtain the plasmid pCDNA3a7 (see 2.2.1).
HEK-293 (Harrison et al., 1977; Graham et al., 1977) and SH-SY5Y (Biedler et al., 1973; 
Ross et al., 1983) cells were transfected using the lipofectAMINE reagent 
(Gibco BRL Life Technologies Ltd. - Paisley, Scotland) as previously described by 
Gopalakrishnan et al. (1995), with some modifications that bore in mind the manufacturer’s 
suggested protocol. The transfection conditions for the HEK-293 cell line were optimised (ratio 
pCDNA3a7 (pg) : lipofectAMINE reagent (pg); time of complex DNA-lipid formation; hours of 
incubation (cells + complex DNA-lipid); cell confluency; days of expression; presence of 
d-tubocurarine (dTC - Sigma - Poole, Dorset UK) in the medium).
Briefly, pCDNA3a7 (1.5 pg) was mixed with 20 pg of lipofectAMINE in serum free medium 
(transfection medium) at room temperature (30 min) to allow complex DNA - lipid formation. 
This complex was used to transfect cells previously grown to e.g. 30 - 40 % confluency. 
After 6  hours of incubation with this suspension, 20 % serum supplemented medium was 
added. Control HEK-293 cells (geneticin sensitive) were prepared by incubation with 
lipofectAMINE only. Twenty-four hours later, the cells were split 1:5. The basic transfection 
procedures are shown in Figure 2.2.
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Figure 2.2 Diagram of lipotransfection procedure. For transient expression of DNA in the
nucleus, plasmid DNA (e.g. pCDNA3a7) is complexed with a liposome suspension 
(e.g. lipofectAMINE) in serum-free medium (transfection medium: TM). These DNA-liposome 
complexes are added directly to cells grown in tissue culture plates and after 4-6 hours 
incubation period, fresh medium containing serum (20% FCS TM) is added. The cells are 
incubated to allow expression of the rat a7 gene and assayed. Stable transformation of 
mammalian cells using liposome-mediated transfection is similar to the protocol for transient 
expression except that after recovery from transfection, the cells are grown in selection medium 
(+ antibiotic) for expression of the desired marker (e.g. geneticin-resistance gene).
Transient and stable transfections were carried out. In transient transfections, 2+ days after 
treating the cells with the DNA - lipid complex, the cells were assayed for [125l]-a-Bgt binding. 
In stable transfections, the transfected cells were cultured in selection medium 
(containing 500 pg geneticin (Sigma ) / ml) to select for resistant clones. The purpose of this 
selection was to isolate those cells that had incorporated the genes (protein gene and 
resistance gene, or at least the latter) into their genomes. In several experiments, the medium 
was also supplemented with 10 pM d-tubocurarine (dTC). After 2-3 weeks, control HEK-293 
cells were dead and geneticin-resistant clones were picked at random using the dilution or 
cloning-ring technique. When confluent, geneticin-resistant cells were assayed for rat a7 mRNA 
and a-Bgt binding sites.
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2.2.4.3 RT-PCR: detection of a7 mRNA
Total cellular RNA was isolated from untransfected and transfected cells using a commercially 
available kit: Rneasy (Qiagen - Dorking, Surrey UK). The yield of total RNA was determined 
spectrophotometrically at X = 260 nm (1 OD26o = 40 pg single-stranded RNA / ml). Pure RNA 
exhibited OD26o / OD28o ratios of or close to 2 .0 . The integrity of the purified RNA was tested by 
denaturing agarose gel electrophoresis (0.66M formaldehyde 0.8% agarose, 
0.24 - 9.46 Kb RNA ladder (Gibco BRL Life Technologies Ltd. - Paisley, Scotland)). 
When resolved by this electrophoretic method, the 28S and 18S eukaryotic ribosomal RNAs 
exhibited a near 2 : 1  ratio of ethidium bromide staining, indicating that no significant degradation 
of RNA had occurred.
RT-PCR reactions (Titan RT-PCR System - Boehringer Mannheim - Lewes, South Sussex UK) 
were performed using as a template 0.6 - 0.8 pg total RNA / reaction and
11.2 picomoles / reaction of rat a7 forward (a7F) and a7 reverse (a7R) primers. The reaction 
mixture was cycled once at 50°C for 30 min and then 30 times at 94°C for 60 s, 54°C for 60 s 
and 6 8 °C for 90 s in a PT-100 Programmable Thermal Cycler (MJ Research Inc. - 
Watertown, MA USA). After amplification, DNA products were analysed by agarose gel 
electrophoresis (see 2.2.1.6 ). The oligonucleotide primers derived from a published rat a7 
nAChR subunit sequence (Entrez DNA S53987) and were designed using Vector NTI software 
version 4.0 (Informax - Gaithersburg, MD USA). ). Numbering of nucleotides (bp) and 
amino acids (aa) begin with the first ATG codon (methyonine) of the a7 subunit sequence 
longest open reading frame (SeguSla etal., 1993). The sequences of the specific primers used 
were: a7F 5'-TGCTGCACGTGTCCTGC-3' (bp47 (aa17) - bp64 (aa22)), and
<x7R 5-GTGTCCTACGGCGCATGG-3' (bp674 (aa225) - bp691 (231)). The RT-PCR product 
(645 bp) encodes for the last 6  amino acids of the predicted signal peptide (22 amino acids) and 
the whole predicted amino terminal extracelullar domain (208 amino acids). To ensure that the 
obtained RT-PCR product was not the result of DNA amplification, total RNA samples were 
previously treated with DNAsel (1 Unit / pi reaction - 37°C for 15 min - 
Boehringer Mannheim). The identity of the RT-PCR product (645 bp) was confirmed by 
digestion with the restriction enzyme Pstl (Promega - Madison, Wl USA). This digestion yielded, 
as predicted by sequence analysis using the Vector NTI software, two fragments of ~509 bp 
and ~131 bp, respectively.
46
Chapter 2
2.2.4.4 [125l]-a-bungarotoxin binding assays: detection of the a 7 nAChR
2.2.4.4.1 lodination of a-bungarotoxin
a-Bungarotoxin (Sigma - Poole, Dorset UK) was iodinated by the chloramine T method 
(McConahey and Dixon, 1980) to a specific activity of 700 Ci / mmol, and stored in 
10 mM potassium phosphate, pH 7.5, at 4°C for up to 4 weeks 
(Wonnacott et al., 1980). Na[125l] was purchased from Amersham International
(Amersham - Buckinghamshire UK).
1252.2.4.4.2 [  l]-a-Bungarotoxin binding assay with celis attached to a substrate
[125l]-a-Bungarotoxin binding assays were performed on E18 hippocampal neurones 
(grown for 7 days - see 2.2.3) and transfected HEK-293 cells cultured in different cell culture 
plasticware treated and not treated with attachment factors (poly-L-lysine MW 70000-150000 
(Sigma - Poole, Dorset UK); fibronectin (Sigma); polyethylenimine (Sigma)).
The cultures were washed three times in medium prior to assay. For [125l]-a-Bgt binding, 
triplicate cultures (on average) were incubated with 10 nM [125l]-a-Bgt (20 nM for untrasfected 
and transfected mammalian cell lines). Non-specific binding was determined in presence of 
1 pM a-Bgt (2 pM for mammalian cell lines). After 120 min at 37°C, the cultures were rapidly 
washed three times with PBS (10 mM phosphate, 0.18 M NaCI, pH 7.4). The cells were 
solubilised overnight in Markwell A solution (2 % (w/v) Na2C03, 0.4 % (w/v) NaOH, 0.16 % (w/v) 
Na+/K+ tartrate (Sigma), 1 % SDS (Sigma)) and counted for y radioactivity
(Packard - COBRA II - Auto gamma counter). The protein concentration in each sample was 
determined by the method of Markwell etal. (1978).
2.2.4.4.3 [125l]-a-Bungarotoxin binding assay with celts in suspension
Confluent transfected HEK-293 cells were washed with PBS and detached from the flask using 
5 mM EDTA PBS. To pellet the cells, the cell suspension was centrifuged at 1000 rpm for 
10 min. After that, the cells were resuspended in 0.1 % BSA (Sigma - Poole, Dorset UK) 
K+-Ringer (140 mM KCI, 5.4 mM NaCI, 1.8 mM CaCI2 .2H2Of 1.7 mM MgS04 .7H20, 
25 mM Hepes, pH 7.4) and divided into aliquots. One aliquot was reserved for protein 
determination (Markwell etal., 1978).
The cell suspensions were incubated in a final volume of 150 pi with 10 nM [125l]-a-Bgt for 
120 min at 37°C. Specific binding was defined by the addition of 1 pM unlabeled a-Bgt (Sigma) 
to a duplicate set of tubes. After the incubation, cells were pelleted by centrifugation and 
washed four times with K*-Ringer. Then, the pellets were counted for y radioactivity.
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2.2A.4.4 Membrane preparation and[125l]-a-bungarotoxin binding assay
Confluent transfected HEK-293 or SH-SY5Y cells were washed with ice-cold binding buffer 
(50 mM KH2PO4 , 1 mM EDTA, 0.1 mM PMSF (Sigma - Poole, Dorset UK), pH 7.4 at 
room temperature), mechanically disaggregated and homogenised using a polytron for 1 0  s. 
The homogenate was centrifuged at 45000 x g for 30 min at 4°C and the pellet resuspended in 
ice-cold buffer at a concentration of 50 - 80 pg protein / sample.
Membranes were incubated in a final volume of 250 pi with 20 nM radioligand for 120 min 
at 37°C. Non-specific binding was determined by addition of 2 pM a-Bgt (Sigma) to duplicate set 
of samples. Incubations were terminated by rapid vacuum filtration through GF/C glass fibre 
filters presoaked in 0.5 % polyethylenimine, and filters washed four times with 
5 ml of ice-cold buffer (Gopalakrishnan et al., 1995). Bound radioactivity was quantitated by 




2.3.1 Subcloning rat a7 cDNA into pCDNA3
The first step in the project was to subclone the rat a l  cDNA into a vector capable of being used 
for heterologous protein expression both in Xenopus oocytes and mammalian cell lines. 
The plasmid chosen was the commercial vector pCDNA3 (Invitrogen) because previous studies 
demonstrated its successful use with the expression systems mentioned above 
(Seguela etal., 1993; Gopalakrishnan etal., 1995, 1996; Stetzer et al., 1996).
The entire coding sequence for the rat a l  subunit was excised from the plasmid pSMa7 with 
the EcoRI restriction enzyme and ligated into the same restriction site of the expression vector 
pCDNA3 . To ligate only one copy of the a7 gene with one copy of pCDNA3, an optimal ratio 
2:1 for a7:pCDNA3 during the ligation step was determined. The correct orientation of the insert 
was tested by digestion of correct sized ligation products (~7.3Kb pCDNA3a7) with the Eco RV 
restriction enzyme (© correct orientation © incorrect orientation -  Figure 2.3 and Figure 2.4). 
To check the length of pSMa7, pCDNA3 and pCDNA3a7; these plasmids were linearised by 
digestion with the Xbal restriction enzyme (Figure 2.3 and Figure 2.5).
EcoRV 










pCDNA3 (5.4Kb) pSM (3.0 Kb)
EcoRV
I  I  IN I












Figure 2.3 Flow diagram representing the subcloning of the rat a l  nAChR subunit cDNA 
into the pCDNA3 vector.
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Figure 2.4 a7-insert orientation (0.7% agarose gel). Lanes A & K) 1 Kb DNA ladder 
Lanes C H) pCDNA3a7 digested with Eco RV to test orientation of the insert. Lanes B, E, H, 
I & J: -  6.3Kb band, -0.6 Kb band (<) and -  0.4 Kb band (© incorrect orientation of the insert). 
Lanes C, D, F & G: -6.0 Kb band, -0.9 Kb band (<) and -0.4 Kb band (© correct orientation of 
the insert) (see Error! Unknown switch argument.).










-510  bp 
396 bp
Figure 2.5 Rat a l  subcloning: summary (0.7% agarose gel). Lanes A & H) 1 Kb DNA ladder 
Lane B) pCDNA3a7 digested with Xba I: -7.3 Kb band Lane C) pCDNA3a7 digested with 
Eco Rl: -5.4 Kb band (pCDNA3) and -1.9 Kb band (a7 insert) Lane D) pCDNA3a7 digested 
with Eco RV: -6.0 Kb band (<), -0.9 Kb band (<) and -0.4 Kb band (<) showing the correct 
orientation © of the insert Lane F) pSMa7 digested with Xba I: - 6 . 8  Kb (-3.0 Kb of pSM + 
-3.8 Kb (2 copies of a l  insert) Lane G) pSMa7 digested with Eco Rl: -3.0 Kb band (pSM) and 
-1.9 Kb band { a l  insert) (see Error! Unknown switch argument.).
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2.3.2 Two electrode voltage clamp recording
The suitability of the pCDNA3a7 construct was ascertained by examining its expression in 
Xenopus oocytes using the two electrode voltage clamp (TEVC) technique. Following nuclear 
injection of pCDNA3a7 into Xenopus oocytes, responses to (-)-nicotine could be recorded from 
~40% of eggs after 2+ days (usually, experiments were carried out on the third day after nuclear 
injection of rat a7 cDNA). To prevent secondary activation of Ca2+-dependent Cl' currents 
(Seguela et al., 1993), all experiments were performed in the presence of 100 pM fluflenamic 
acid and 100 pM niflumic acid. The buffer also contained 0.5 pM atropine to inhibit muscarinic 
acetylcholine receptors (Kusano et al., 1977). Typically, the oocytes had resting potentials of 
-44±13 mV (n=67). Currents (0.1pA-0.5pA) were recorded on application of saturating doses 
(high micromolar concentrations e.g. 200 pM) of (-)-nicotine to cells held at -70 mV. 
This holding potential was sufficiently far from the reversal potential to ensure reproducible 
currents evoked by (-)-nicotine stimulation (Figure 2.6). This holding potential also ensured the 
physiological stability and survival of the oocyte during prolonged periods of examination 
(e.g. during the construction of the l-V curve). Eggs injected with sterile water were insensitive 
to (-)-nicotine (n = 7 - data not shown). Receptor activation at high concentrations of (-)-nicotine 
was fast and displayed rapid desensitisation within the 3 s application time (Figure 2.6), 
according to published results for the same reconstituted homomeric receptor 
(Seguela et al., 1993).
Functional characterisation of a7 nAChR has relied for a long time on a-Bgt for its discrimination 
(Couturier et al., 1990; Seguela et al., 1993). Currents evoked by (-)-nicotine (200 pM) were 
completely abolished after incubation (30 min at room temperature) of the a7-injected oocytes 







Figure 2.6 Nicotinic activation of the a7 nAChR expressed in Xenopus oocytes.
(-)-Nicotine (200 pM) was given as a 3 s pulse (bar). This evoked an inward current (a) 
that could be reproduced by a second agonist application after 5 min wash with buffer to allow 
full nAChR recovery from desensitisation (b). The response was abolished by 30 min incubation 
at room temperature with 40 nM a-Bgt (c).
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The relationship between holding potential (VH) and the extent of the agonist evoked current (I) 
was determined as described in 2.2.2.4.4. (-)-Nicotine (200 pM) was applied as the membrane 
potential was stepped between -110 mV and +10 mV, in 20 mV increments (Figure 2.7). 
The rat a7 nAChR showed a strong linear dependence of current responses with membrane 
potentials between -110 mV and about -30 mV. a7 nAChR are strongly voltage sensitive at 
depolarised potentials: above -20 mV the current-voltage curve rectifies so thoroughly that no 
reversal potential is detectable.








Figure 2.7 Voltage dependence of (-)-nicotine-induced currents in a7 channels. 
Left) Individual a7 currents in a single oocyte challenged with 200 pM (-)-nicotine between 
-110 mV and +10 mV. Right) Current-voltage values were obtained by consecutive 200 pM 




2.3.3 Endogenous expression of a7 nAChR
Ligand binding (rather than electrophysiology as in Xenopus oocytes) is a convenient way of 
screening transfected cells. The ligand binding approach for a7 nAChR was verified assaying 
cells that endogenously express surface a-Bgt-binding sites: the human neuroblastoma 
SHSY5Y cell line and rat E18 hippocampal neurones.
2.3.3.1 SH-SY5Y cell line: human a7 nAChR.
The equilibrium binding of [125l]-a-Bgt to human neuroblastoma cells (SH-SY5Y cell line - 
passages 7 & 8 ) was studied. Specific binding of [125l]-a-Bgt to cells in situ was saturable over 
the concentration range 0.1-20.0 nM (Figure 2.8). The data are consistent with binding to a 
single population of sites: apparent equilibrium dissociation constant, Kd = 1.04±0.25 nM; 
total number of surface [125l]-a-Bgt binding sites, Bmax = 31.9 ± 0 . 2  fmol / mg protein 
(mean±SD, n=2).
Figure 2.8 [125l]-ot-Bgt binding to SH-SY5Y cells. A representative saturation binding 
experiment for [125l]-a-Bgt binding to human neuroblastoma cells ((triangles) total binding; 
(circles) specific binding; (squares) non-specific binding). The binding parameters determined 
by curve fitting to a rectangular hyperbola are Bmax = 31.7 fmol / mg protein, Kd = 0.86 nM. 
Insert: Scatchard analysis of these data. Each point is mean±S.D. of triplicate determinations.
Bound
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2.3.3.2 Rata7 nAChR expression in E18 hippocampal neurones
High density (150000 cells / cm2) hippocampal neuronal cultures were plated on 
polyethylenimine-coated dishes in serum supplemented medium and maintained in serum-free 
chemically defined medium for a week (Barrantes et al., 1995). Cells strongly attached to 
pretreated surfaces and were assayed for surface expression of a-Bgt binding sites. 
For maximum [125l]-a-Bgt binding, cultures were incubated with 10 nM [125l]-a-Bgt 
(final concentration) for 120 min at 37°C. Non-specific binding was determined in the presence 
of 1 pM a-Bgt and accounted for 50% of total binding. The total number of specific [*2^ l]-a-Bgt 
binding sites was 97±14 fmol / mg protein (mean±S.D., n=4).
2.3.4 Heterologous expression of a7 in mammalian cell lines
2.3.4.1 The HEK-293 cell line
2.3.4.1.1 Culture of HEK-293 cells
HEK-293 cells, as described in Graham et al. (1977), had a general epithelial morphology, 
with a tendency to continue dividing after reaching confluency and grow in islands or clumps. 
They also showed a wide variation in cell size. One relevant feature to point out, because of its 
effect in the radioligand binding assays performed, was the poor attachment of these cells to 
substrates (in opposite to SHSY5Y cells and rat E18 hippocampal neurones).
HEK-293 cells were routinely maintained on standard cell culture-treated polystyrene surfaces. 
However, to perform [125l]-a-Bgt binding assays, which involve several washing steps, 
the surfaces were pretreated with attachment factors (Table 2.1). HEK-293 cells were also 
grown on a commercially modified polystyrene surface: PRIMARIA surface (Falcon - Becton 
Dickinson Labware - Lincoln Park, NJ USA). This surface has a chemistry similar to those 
coated with poly-L-lysine, collagen I + IV and extracellular matrix. The different attachment 
conditions were tested and compared by naked eye visual inspection or under a visible light 
microscope.
When cells were plated on pretreated or PRIMARIA surfaces, 90+% of these cells settled and 
attached to the bottom of the dish within 20-30 min. When standard surfaces were used, 
up to 3 h had to be allowed to get the same cell adhesion percentage. 
The best results were achieved by treating the surfaces overnight with either 
10 pg fibronectin / ml or 100 pg poly-L-lysine (MW 70000-150000) / ml. It was decided to treat 
the surfaces with the latter for economic reasons. Although there was a significant improvement 
in cell adhesion (rate and strength) to pretreated surfaces when compared to nontreated ones, 
did not prevent cell detachment during washing steps.
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Attachment factor Surface treatment ( h )
500 pg polyethylenimine / ml 2, 6  & 14 (overnight)
10 & 100 pg poly-L-lysine (MW 70000 -150000) / ml 2 & 14 (overnight)
1 0  pg fibronectin / ml 14 (overnight)
Table 2.1 Attachment conditions tested to improve HEK-293 cells adherence to substrate.
Attachment factors were prepared in borate buffer (150 mM borax, pH 8.3). 
Surfaces were washed 5 times (5 min each, at room temperature) with sterile water before 
plating the cells.
2.3.4.1.2 HEK-293 lipotransfection with pCDNA3a7 
Transient transfection
Thirteen transient transfections of HEK-293 cells (internal passage <14) with pCDNA3a7 were 
performed. Cells were grown, as described in 2.2.4.1, in 24 well plates pre-treated with 
100 pg poly-L-lysine / ml borate buffer (overnight). To test the transfected cells for surface 
expression of a-Bgt binding sites, [125l]-a-Bgt binding assays on attached cells (see 2.2.4.4.2) or 
cells in suspension (see 2.2.4.4.3) were performed. Expression levels lower than 
10 fmol a-Bgt binding sites / mg protein were considered non-significant. Untransfected 
HEK-293 cell did not show any specific [125l]-a-Bgt binding (total cpm = non-specific cpm, 
p>0.05 one way ANOVA - n=2). For maximum [125l]-a-Bgt binding, cultures were incubated with 
20 nM [125l]-a-Bgt (final concentration) for 120 min at 37°C. Non-specific binding was 
determined in the presence of 2 pM a-Bgt. The transfection conditions were optimized for the 
highest expression of surface a-Bgt binding sites and lower reagents' toxicity. 
The conditions optimised included DNA and lipid concentrations, time for DNA-lipid complexes 
formation, cell confluency, time of exposure of cells to DNA-liposome complexes, dTC addition 




pg DNA / ml transfection suspension 0.5, 1.0, 2.5, 5.0 or 10.0
pg lipofectAMINE / ml transfection suspension 6,12, 24 or 48
DNA-lipid complexes formation ( min ) 30, 40 or 50
Cells confluency (% ) (20-30), (50-60) or (90+)
Cells exposure to DNA-lipid complexes ( h ) 4 or 6
Cell culture medium with or without 10 pM dTC
Expression time after transfection ( days ) 2 , 3 or 5
Table 2.2 Optimisation parameters tested for liposome-mediated transient transfections.
Expression of surface a-Bgt binding sites, after transient transfection of HEK-293 cells with 
pCDNA3a7, was largely (10/11) unsuccessful (total binding = non-specific binding, p>0.05 
one way ANOVA). From these observations it can be concluded that:
a ) up to 6  h exposure to DNA-lipid complexes (any ratio tested), in the absence of serum, 
was not toxic for HEK-293 cells.
b ) the addition of dTC (10 pM) to the culture medium did not improve a7-surface expression, 
neither by protecting a7-expressing cells from putative expression-cytotoxic effects nor 
by up-regulating possible a-Bgt binding sites.
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Only in one experiment an increase in specific surface expression of a-Bgt binding sites was 
observed. Figure 2.9 shows the highest expression level achieved in transient transfections of 
HEK-293 cells with pCDNA3a7: 12.3 fmol [125l]-a-Bgt binding sites / mg protein. 


















Figure 2.9 Effects of pCDNA3a7 concentration and HpofectAMINE:pCDNA3a7 ratio 
on transient surface expression of a-Bgt binding sites in HEK-293 cells. This 3D-graph 
presents the results of the only successful assay in which specific surface binding of [125l]-a-Bgt 
was detected. The highest expression level (arrow: 12.3 fmol a-Bgt binding sites / mg protein) 
was obtained using 2.5 pg pCDNA3a7 / ml transfection medium and a ratio lipid:DNA of 2.4. 
Higher DNA concentrations or lipid:DNA ratios decreased expression. DNA-lipid complexes 
were allowed to form for 40 min. Cells (90% confluent) were incubated with the DNA-lipid 





At the same time as transient transfections were being carried out, stable transfection was also 
investigated. Four stable transfections of HEK-293 cells (internal passage <20) with pCDNA3a7 
were performed. HEK-293 cells were grown as for transient transfections. To test the
125transfected cells for expression of a-Bgt binding sites, we performed [ l]-a-Bgt binding assays 
on attached cells (see 2.2.4.4.2) or membrane preparations (see 2.2.4.4.3). Expression levels 
lower than 3 fmol a-Bgt binding sites / mg protein were considered non-significant. 
For maximum [125l]-a-Bgt binding, cultures or cell membranes were incubated with 
20 nM [125l]-a-Bgt for 20 min at 37°C. Non-specific binding was determined in the presence of 
2 pM a-Bgt.
To achieve the high expression levels in HEK-293 cells reported with the human a7 subunit 
(Gopalakrishnan et a/., 1995), their transfection conditions were reproduced (Table 2.3 in bold).
Parameter Tested
pg DNA / ml transfection suspension 1.5
pg lipofectAMINE / ml transfection suspension 1 0  or 2 0
DNA-lipid complexes formation ( min) 40
cells confluency (% ) (20-30), (50-60) or (90+)
cells exposure to DNA-lipid complexes ( h ) 5 or 10
cell culture medium With or without 10 pM dTC
Table 2.3 Optimisation parameters for HEK-293 liposome-mediated stable transfections.
Transfected cells were selected in medium containing 0.5 mg geneticin (G418) / ml. Transfected 
G418-resistant cells did not lose the resistance to G418 for as long they were cultured 
(up to three months). Control HEK-293 cells (see2.2.4.2), when cultured in medium containing 
G418, died within 4-7 days. Between 6  and 10 clones were isolated and assayed for each 
condition (number of conditions tested: 24 (see Table 2.3)). Rat a7-mRNA expression was 
detected by RT-PCR in HEK-293 clones stably transfected with pCDNA3a7 (Figure 2.10).
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Figure 2.10 a7-mRNA expression in stably transfected HEK-293 cells. Left) Denaturing gel 
(0.66M formaldehyde 0.8% agarose) showing the 28S and 18S eukaryotic ribosomal RNAs 
from: Lane B) G418-resistant cells, and Lane C) untransfected HEK-293 cells. Lane A) 
0.24 - 9.49 Kb RNA Ladder. Right) Electrophoresis of RT-PCR products (0.8% agarose gel) - 
Lane A') 1 Kb DNA Ladder - Lane B’) Expected RT-PCR product (645 bp) using as a template 
total RNA showed in Lane A - Lane C') Fragments (arrows: 509 bp & 131 bp) after digestion 
with Pstl of the fragment showed in Lane B' - Lanes D' & E') Same as Lanes B' & C' but using 
as a template total RNA isolated from untransfected HEK-293 cells (Lane C).
Although the isolated clones evidently incorporated the G418-resistance gene into their 
genomes and expressed rat <x7-mRNA, it was not possible to detect clones expressing 
significant levels of a-Bgt binding sites either on intact cells or cell membrane preparations 
(total binding = non-specific binding, p>0.05 one way ANOVA).
2.3.4.2 The SH-SY5Y cell line
Two stable transfections of SH-SY5Y cells (passages 11 & 16) with pCDNA3a7 were performed 
following report by Gopalakrishnan et at. (1995). SH-SY5Y cells were grown as described in 
2.2.4.1. To test SH-SY5Y cells for expression of a-Bgt binding sites, [125l]-a-Bgt binding assays 
on transfected and untransfected attached cells were performed (see 2.2.4.4.2). 
For maximum [125l]-a-Bgt binding, cultures were incubated with 20 nM [125l]-a-Bgt for 120 min 
at 37°C. Non-specific binding was determined in the presence of 2 pM a-Bgt. 




ng DNA / ml transfection suspension 1, 10 or 20
jxg lipofectAMINE / ml transfection suspension 2.4, 24.0 or 48.0
DNA / lipid ratio 2.4
DNA-lipid complexes formation ( min ) 40
cells confluency (% ) (50-60)
cells exposure to DNA-lipid complexes ( h ) 5
Table 2.4 Optimisation conditions tested for SH-SY5Y liposome-mediated stable 
transfections.
Transfected cells were selected in medium containing 0.5 mg geneticin (G418) / ml. 
G418-resistant cells did not lose the resistance to this antibiotic for as long they were cultured 
(up to nine weeks). Control (untransfected) SH-SY5Y cells, when cultured in medium containing 
G418, died within 4-7 days. Transfection efficiency (number of G418-resistant clones per plate) 
was proportional to the concentration of DNA used in the transfection. G418-resistant clones 
(6 per condition) were isolated and assayed for surface [125l]-a-Bgt-binding 
(number of conditions tested: 3 (see Table 2.4)).
Although the isolated clones were resistant to 0.5 mg G418 / ml medium,- it was no possible to 
detect increased levels of surface a-Bgt binding sites when compared with untransfected 




This chapter presents attempts to heterologously express the rat a7 nAChR 
in mammalian cell lines. The ultimate purpose of constructing such a7 expression systems, 
was to compare the pharmacological and functional properties of native
(i.e. a-Bgt binding sites expressed on the surface of rat E18 hippocampal neurones)
and heterologously expressed rat a7 nAChR. The results emerging from these comparisons 
would have been applied to the study of presynaptic nAChR mediating glutamate release from 
rat hippocampal synaptosomes (chapter 3). At the time that these studies were initiated (1996), 
there was electrophysiological evidence (McGehee et al., 1995; Gray et a/., 1996)
for the involvement of a-Bgt-sensitive receptors in the presynaptic modulation of
glutamate release. In this chapter, the construction of the expression vector pCDNA3a7 was 
described (2.3.1). This was shown to be functional in Xenopus oocytes (2.3.2) but failed to 
result in expression of surface receptors (as defined by [125l]-a-Bgt binding) 
in mammalian cell lines, although a7 mRNA was detected (2.3.4).
2.4.1 Heterologous expression of nAChR in Xenopus oocytes
The expression of pCDNA3a7 plasmid in Xenopus oocytes was carried out to verify its 
suitability as a functional expression vector. From the pharmacological point of view, 
the homomeric rat a7 nAChR expressed in Xenopus oocytes is moderately sensitive to ACh 
and displays the following order of agonist potency: (-)-nicotine > cytisine > DMPP > ACh 
(SSguela et al., 1993). Moreover, (-)-nicotine is a full agonist on a7-homomers expressed in 
Xenopus oocytes with EC50S of ~10 pM and ~40 pM for chick and human a l  homomers, 
respectively (Galzi et al., 1991; Eisel6  et al., 1993; Gerzanich et al., 1994; Peng et al., 1994). 
Therefore 200 pM (-)-nicotine was selected, as it should give maximal responses. 
Oocytes injected with pCDNA3a7 responded with fast, desensitising responses characteristic 
of a7-containing nAChR. Consistent with previous observations (e.g. Couturier et al., 1990), 
currents evoked by 200 pM (-)-nicotine were abolished by incubating pCDNA3a7-injected 
oocytes with 40 nM a-Bgt (30 min at room temperature). These results demonstrated that 
the pCDNA3a7 construct (2.3.1), when injected in Xenopus oocyte nuclei, was transcribed, 
translated and was also capable of forming surface functional rat a7 nAChR (2.3.2).
Xenopus oocytes are known to express Ca2+-activated Cl‘ conductances (Miledi, 1982; 
Barish etal., 1983) and these channels have been previously used to demonstrate qualitatively 
that neuronal nAChR are permeable to Ca2+ (e.g. Vemino et al., 1992). Because the reversal 
potential of the Ca2+-activated Cl" current in the oocyte is about -25 mV 
(Miledi and Parker, 1984), currents through both the a7-channel and the Cl' channel would 
appear as inward cationic currents at potentials below -25 mV. Then, these two currents would
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add at the holding potential of -70 mV used in Figure 2.6. To avoid this undesirable contribution 
to the pure nicotinic response, the experiments were performed in the presence of 
100 pM niflumic acid and 100 pM fluflenamic acid, compounds that block the Ca2+-activated 
Cl* conductance (White and Aylwin, 1990).
Another striking feature of the a7 nAChR is the rapidity with which the response desensitises. 
It has been shown that increasing concentrations of agonists increase the rates of both the rise 
and desensitisation of the response (Revah et al., 1991; Gerzanich et al., 1994). 
In this study, the time course of recovery from desensitisation was estimated using a paired 
application protocol in experiments where the agonist was applied again at intervals after a 
control application. For saturating concentrations of (-)-nicotine (200 pM) the interval between 
applications was increased to a minimum of 5 min (Figure 2.6). Endogenously expressed 
("native") a7 nAChR have also been reported to desensitise so rapidly that especially fast 
agonist application and fast electronics are required to measure channel opening accurately 
(Alkondon et al., 1996; Frazier et al., 1998a; Radcliffe and Dani, 1998). 
In oocytes (Couturier et al., 1990; Revah et al., 1991; S6guela et al., 1993; this study), 
the relative slowness with which the large cells can be perfused may prolong the response and 
be used to experimental advantage. Recently, Papke and Thinschmidt (1998) reported that 
rapid desensitisation of a7 nAChR combined with relative slow agonist application could 
potentially confound the interpretation of concentration-response relationships obtained for 
this nAChR when assayed using the TEVC technique in Xenopus oocytes. They suggested that 
estimates of EC50 derived from conventional analysis may overestimate the actual EC50 values 
by a factor of 10 and underestimate Hill slopes by a factor of 2-3. However, if these 
observations apply to this study, they do not affect the fact that pCDNA3a7, when injected in 
Xenopus oocytes, is capable of generating functional a-Bgt-sensitive nAChR (Figure 2.6).
Finally, by contrast with muscle nAChR, neuronal nAChR (including the a7 subtype) exhibit 
inward rectifying channel properties (Figure 2.7). Both the rapid desensitisation and the inward 
rectification combine to minimise sustained influx through these nAChR. These self-limiting 
features could be especially relevant when considering the possible functional roles of 
such nAChR (seen in 2.1.5).
62
Chapter 2
2.4.2 Heterologous expression of rat a7 in mammalian cell lines
As seen in chapter 1, neuronal nAChR exist as multiple subtypes and display 
functional diversity (reviewed in Sargent, 1993; Albuquerque et al., 1995; Lindstrom, 1996; 
Dani and Heinemann, 1996). As has been concluded from subunit expression studies in 
Xenopus oocytes and mammalian cell lines, functional neuronal nAChR are heteropentamers of 
a  and p subunits (Elliott et at, 1996; Ramirez-Latorre et at, 1996; 
Colquhoun and Patrick, 1997), or homopentamers of a  subunits (Couturier et at, 1990; 
S§gu6 la et at, 1993; Gerzanich et at, 1994; Elgoyhen et at, 1994). Because native neurones 
(e.g. Alkondon etat, 1993; Yu and Role, 1998) and neuronal cell lines (e.g. Rogers et at, 1992; 
Lukas et at, 1993) usually coexpress several nAChR, the assignment of neuronal nicotinic 
responses to particular nAChR subtypes is progressing slowly. However, 
heterologous expression systems for individual nAChR subtypes offer an opportunity for 
investigating receptor structure and function. Transient expression using Xenopus oocytes or 
eukaryotic cells is particularly convenient for physiological studies (two-electrode voltage clamp 
and patch-clamp techniques). Injection of (transfection with) different nAChR subunit cDNA 
(and cRNA in Xenopus oocytes), either alone or in combination, has yielded information 
concerning receptor channel properties, agonists / antagonists interactions and desensitization 
(e.g. Revah et at, 1991; Bertrand et at, 1992; Galzi et at, 1992; Gerzanich et at, 1994; 
Palma et at, 1996; Fucile et at, 1997; Ragozzino et at, 1997). Reconstitution of purified 
receptors in planar lipid bilayers is another approach that has helped identify receptor function 
(Gotti etat, 1991,1994). On the other hand, stable receptor expression in somatic cells has the 
advantage that large numbers of cells expressing the desired receptor are available, 
more readily allowing for receptor biochemical and pharmacological studies 
(e.g. drug screening). However, with a few notable exceptions (Whiting et al., 1991; 
Gopalakrishnan et at, 1995, 1996; Stetzer et at, 1996; Quik et at, 1996;
Kassner and Berg, 1997), most ectopic expression systems for neuronal nAChR so far are 
based on transient expression (e.g. Fucile et at, 1997; Ragozzino et at, 1997).
It is not absolutely clear, at present, why stable heterologous expression of nAChR, in particular 
the a7 subtype, is more difficult to achieve than for other ionotropic neuroreceptors.
Since 1990, the year in which the chick a7 nAChR subunit was first cloned and characterised 
(Schoepfer et at, 1990; Couturier et at, 1990), the a7 gene has also been cloned from rat 
(S6 gu6 la et at, 1993), human (Doucette-Stamm et at, 1993; Peng et at, 1994;
Chini et at, 1994) and mouse (Orr-Urtreger et at, 1995). However, for five years,
only two papers (Gopalakrishnan et at, 1995; Quik et at, 1996) were published reporting 
stable expression of the a7 nAChR subunit in cell lines that do not endogenously express this 
subunit: the HEK-293 and GH4C1 cell lines. At the time the studies presented in this thesis 
were initiated (January 1996) there was no major reason to doubt the ability of the a7 nAChR 
sequence to express in mammalian cell lines. Nevertheless, although the stable expression of
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the a7 nAChR subunit has been the aim of several labs, none, including those that succeeded 
in expressing it, has conclusively explained the cause / s of so many failures.
In this study the rat a7 cDNA was used to stably transfect mammalian cell lines, 
because the rat nicotinic a-Bgt receptor has been extensively studied, and this would allow for 
direct comparisons between in vitro ("native" a7 nAChR on rat E18 hippocampal neurones, and 
heterologously expressed rat a7 nAChR) and in vivo work. The human SH-SY5Y and HEK-293 
cell lines were transfected with pCDNA3a7, a plasmid construct that has been also used in this 
study for the successful expression of the rat a l  subunit by nuclear injection into 
Xenopus oocytes (see 2.3.2). Neuroblastoma derived SH-SY5Y cells endogenously express the 
nAChR a3, a5, a7, 02 and 04 subunits (Lukas et al., 1993). On the other hand the HEK-293 
cell line does not express endogenous nAChR and are well established 
heterologous expression systems (Wong et ai., 1995; Gopalakrishnan et al., 1995, 1996; 
Stetzer et ai., 1996). HEK-293 cells also provide several advantages for the study of 
ligand gated ion channel expression. These cells exhibit fast exponential growth with a 
doubling time of about 24 hours (Graham et al., 1977), show relatively high 
transfection efficiency and high levels of transient / stable expression compared with other 
suitable hosts. In this study, the ability of the a7 nAChR to bind a-Bgt was used to examine its 
expression in these mammalian cell lines.
Insight into cellular mechanisms involved in receptor expression and turnover comes from 
successful heterologous expression of the nAChR of the vertebrate neuromuscular junction and 
the analogous "muscle-like" nAChR that is expressed in the electric organ of the fish Torpedo or 
the electric eel Electrophorus. The high affinity of a-Bgt for the vertebrate muscle and Torpedo 
electric organ nAChR has proved to be an important tool for the investigation of nAChR subunit 
folding and assembly (Green and Millar, 1995). Moreover, the folding of the muscle or Torpedo 
nAChR can be monitored by following the formation of ligand binding sites 
(e.g. the a-Bgt binding site) and conformational epitopes for monoclonal antibodies. Studies in 
the early 80s demonstrated that the muscle a subunit (the nAChR ligand binding subunit) 
transits a precursor pool before acquiring a-Bgt binding activity (Merlie and Sebbane, 1981; 
Merlie and Lindstrom, 1983). Studies of each of the four cloned Torpedo subunits (a, 0, y and 5) 
expressed individually in mouse fibroblasts have shown that, in the absence of correct 
interactions with other subunits, misfolded aggregates were formed (Paulson et al., 1991). 
In addition, all four peripheral nAChR subunits when expressed alone in fibroblast cells were 
degraded rapidly (Claudio et al., 1989; Green et ai., 1991) as were unassembled nAChR 
subunits, when expressed in the presence of other subunits. These observations have 
suggested that many subunits (-70 % for the nAChR) misfold after their synthesis, 
causing aggregation and rapid degradation of nAChR subunits (Merlie and Lindstrom, 1983; 
Ross et al., 1991). It is also clear that folding and oligomerization of the muscle nAChR subunits
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are the rate-limiting steps in transport to the cell surface (Smith et al., 1987; Ross et al., 1991; 
Green and Claudio, 1993; Green and Wanamaker, 1998).
The neuronal nAChR a7 subunit, like the muscle and Torpedo nAChR (Barnard et al., 1981; 
Mishina et al., 1984), is capable of forming a-Bgt-sensitive functional ion channels when 
expressed in Xenopus oocytes (this study; Couturier et al., 1990; S6 gu§la et al., 1993). 
In 1994, the functional hyperexpression of the rat a7 subunit in the human neuroblastoma 
cell line SH-SY5Y was reported (Puchacz et al., 1994). Interestingly, a comparison of 
transfected cell lines (Cooper and Millar, 1997) suggested that only cells expressing an 
endogenous a7 gene (namely SH-SY5Y and PC12 cells) could produce a-Bgt-binding protein 
from a transfected a7 gene. Other studies (Gopalakrishnan et al., 1995; Quik et al., 1996; 
Kassner and Berg, 1997) showed this not to be an absolute requirement, since HEK-293 
(Gopalakrishnan isolates!!), GH4C1 and QT- 6  transfectants could do so without expressing 
detectable levels of an endogenous a7 gene product.. Although this study corroborated the 
endogenous expression of human a7 in SH-SY5Y cells (see 2.3.3.1.), 
the hyperexpression of rat a7 in this cell line was not achieved (Puchacz et al., 1994; 
Cooper and Millar, 1997). Probably the use of transfection conditions not fully optimised and 
the low number of colony forming units (cfu) isolated per condition, 
reduced the probability of picking up a cfu expressing high levels of surface a-Bgt-binding sites.
Peng et al. (1994) observed that, despite the high sequence identity between the cloned 
a7 sequences from different species (e.g. 91% identity between human and rat a7 nAChR 
mature peptides - Elliott et al., 1996), there were large pharmacological differences between 
human and chicken a7 nAChR expressed in Xenopus oocytes. In 1995, Gopalakrishnan et al. 
transfected the human derived cell line HEK-293 with human a7 cDNA and successfully 
expressed a-Bgt binding sites. In this study, and although the same human cell line was 
transfected with rat a7 cDNA, no increase in a-Bgt binding sites was detected. Then, it was 
reasonable to think that the different outcomes observed with the human and rat a7 cDNAs 
when transfected in the HEK-293 cell line could be explained by sequence-specific differences. 
Cooper and Millar (1997) proved this hypothesis wrong by being unable to express human, rat 
or chicken al cDNA in the HEK-293 cell line.
The fact that the rat a7 cDNA is transcribed into a7 mRNA (as determined by RT-PCR 
in 2.3.4.1.2) and no a-Bgt binding sites were detected in HEK-293 cells transfected with 
pCDNA3a7 (2.3.4.1.2), points at the misfolding of the al subunit as the primary cause of 
the cell-dependent expression observed. The findings of Kassner and Berg (1997) support this 
view, since although high levels of al protein were produced by their HEK-293 transfectants, 
these cells were ineffective at assembling the protein into species capable of binding a-Bgt. 
Despite the inability of the HEK-293 cell line to fold correctly the al subunit
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(this study; Cooper and Millar, 1997; Kassner and Berg, 1997), it has been demonstrated that it 
can express other subunits such as the S-HTsa receptor subunit (Cooper and Millar, 1997) 
and a chimaeric subunit (Eisel6 et al., 1993) containing the N-tenminal region of the chick a7 
and the C-terminal region of the 5-HT3A subunit (a7/5-HT3A Cooper and Millar, 1997). 
These cells, therefore, must contain all of the intracellular machinery required for the 
posttranslational processing, folding and assembly of these other homomeric neurotransmitter- 
gated ion channels. It is interesting to point out that the same source of HEK-293 cells used in 
this study, was exploited by Dr Andrew Davies (Nicotine Research Lab - Bath University) 
to successfully express the a7/5-HT3A receptor (500-1000 fmol [3H]-MLA binding sites / mg 
protein, personal communication). The successful expression of the chimaeric 
a7-5-HT3A subunit in HEK-293 cells, also suggests that the C-terminal (putative transmembrane 
and intracellular) regions of a7 are responsible for cell-specific misfolding.
The hypothesis that the native a7 subunit may need to coassemble with other neuronal nAChR 
subunits to be "properly" expressed, has also been proposed. However, several lines of 
evidence suggest that the cell-specific phenomenon observed cannot be explained by a 
requirement for other nAChR subunits. These include the observation that the a7 subunit forms 
homomeric receptors in Xenopus oocytes in the absence of other subunits 
(Couturier etal., 1990; S6gu6la et al., 1993). Also, after overexpression of correctly folded a7 in 
PC12 and SHSY5Y cells, there is no evidence for the coprecipitation of other endogenous 
subunits with antibodies against a7 (Anand et al., 1993; Cooper and Millar, 1997). 
Moreover, Cooper and Millar have been unable to induce the "a7-nonpermissive" cells to fold 
correctly the a7 subunit by coexpressing this subunit with various combinations of all other 
cloned rat neuronal nAChR. The possible involvement of any, as yet, uncloned neuronal nAChR 
subunits is a possibility that cannot be rejected.
Changes in the activity of second messenger cascades can also modulate protein expression. 
It has been reported that the assembly effici^ocy of the cloned Torpedo electric organ, 
mouse muscle nAChR expressed in mouse fibroblast cells, a4J32 nAChR in M10 cells and 
a7 subunit in G H ^  and SHSY5Y cells, is elevated by about twofold in response to increased 
levels of intracellular cyclic AMP (Green et al., 1991; Ross et al., 1991; Rothhut et al., 1996; 
Quick et al., 1997; Cooper and Millar, 1997). However, despite this effect on SH-SY5Y cells, 
Cooper and Millar (1997) could not detect specific [125l]-a-Bgt binding when a7-transfected 
HEK-cells were grown in the presence of 8-bromo-cyclic AMP and isobutylmethylxantine 
(an inhibitor of phosphatases). An interesting link has also been recently established between 
the prolyl isomerase, cyclophilin, and the ability of oocytes to express homooligomeric ligand 
gated ion channels, such as the <x7 and 5 -HT3A (Helekar et al., 1994; 
Helekar and Patrick, 1997). Cooper and Millar (1997) studied the possible involvement of 
prolyl isomerases in the failure of cell lines like the HEK-293 to express correctly the oJ subunit.
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They coexpressed this subunit in HEK-293 cells, together with a cloned ER-specific cyclophylin 
but could not detect specific [125l]-a-Bgt binding under these experimental conditions. 
Similar negative results have been reported by Blumenthal et al. (1997), after coexpression of 
cyclophylin in an isolate of PC12 cells that failed to express correctly folded a7 subunit. 
The fact that it is possible to stably express the 5 -HT3A receptor in HEK-293 cells in the absence 
of cyclophylin (Cooper and Millar, 1997) and that cyclosporin A treatment had no effect on 
expression of a-Bgt-binding sites either by QT-6 transfectants or by ciliary ganglion neurones in 
culture (Kassner and Berg, 1997), supports the idea that cyclophylin is not essential for the 
correct folding and assembly of homomeric receptors in mammalian cell lines like 
HEK-293.
The effect of protein glycosylation on a7 nAChR subunit heterologous expression has also been 
studied. Merlie et al. (1982) reported that, in muscle BC3H-1 cells treated with tunicamycin, 
nonglycosylated a1 failed to assemble into toxin-binding receptors on 
the cell surface. Recently and supporting this observation, Chen et al. (1998) showed that 
asparagine-linked glycosylation is required for the expression of functional a7 receptors in 
Xenopus oocytes. However, it seems unlikely that differences in glycosylation account for 
the lack of a-Bgt binding sites expression in HEK-293 cells reported in this thesis, 
since Cooper and Millar (1997) reported similar apparent molecular weights for the a7 protein 
expressed in permissive and nonpermissive cells lines. Moreover, these values closely agreed 
with those determined for a7 purified from brain (Dominguez Del Toro et al., 1994), 
indicating glycosylation levels similar to those found for the endogenously expressed 
a7 subunit. Moreover, the functional expression of muscle nAChR, S-HTsa and a7/5-HT3A 
receptors on the surface of cells that failed to correctly fold the a7 subunit (e.g. HEK-293), 
suggests that glycosylation alone is not responsible for the "abnormal" a7 nAChR subunit low 
expression levels reported in certain cell lines.
Difficulties in expressing ligand gated ion channels with high Ca2+-conductances have been 
reported (Choi, 1988; Treinin and Chalfie, 1995; Grimwood et al., 1996). These problems, 
mainly found with glutamate-gated ion channels, have been attributed to the spontaneous 
opening of the channel leading to calcium entry and cell death. 
The high Ca2+ permeability of a7 nAChR may place stringent requirements on the neurone to 
avoid errors in the assembly of nAChR with a7 subunits that might risk Ca2+-mediated 
cytotoxicity (Choi, 1992). Recently, neurotoxicity associated with the expression of a mutated 
nAChR subunit (deg-3) was reported in the nematode Caenorhabditis elegans 
(Treinin and Chalfie, 1995). It is interesting to point out that the deg-3 gene encodes a 
nAChR a  subunit, which in the transmembrane domain II is most close (~52% identity) 
to the neuronal a7 subunits from rat and chicken. Although it is possible that a similar "problem" 
may occur to some extent with the homomeric a7 receptor, it is unlikely that this can explain
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the observations presented in this thesis. However, the above data could suggest that, 
expression of a7 nAChR may select (not kill) only those cells that express very low levels of 
"excitotoxic" receptors but also express the antibiotic-resistance gene to survive in selection 
medium. Apparently this is not true since Gopalakrishnan (1995), Quik (1996) and 
Kassner & Berg (1997) did not use nAChR antagonists to achieve their results. Moreover, 
in transient and stable transfections of HEK-293 cells with pCDNA3a7 (this study), the addition 
of dTC (10 pM) to the growth medium to block possible receptor activation, had no effect on 
the a-Bgt binding sites expression levels achieved.
The primary mechanism of regulating cell-specific expression of proteins appears to be at the 
level of mRNA synthesis, by cell-specific transcription factors. However, this thesis presents 
evidence that the transcription of the a7 sequence is not the limiting step in the heterologous 
expression of the a7 protein (at least in the HEK-293 cell line). This study reports the 
transcription of exogenous rat a7 gene in stably transfected HEK-293 (Errorl Unknown switch 
argument.), but consistent with previous studies (Cooper and Millar, 1997; Kassner and Berg, 
1997) failed to detect expression of specific [125l]-a-Bgt-binding sites. It is important to 
remember that the same
HEK-293 cells used in this study, heterologously expressed high levels of the chimeric 
a7/5-HT3A receptor (A.Davies - personal communication). The results presented in this thesis, 
together with the reports reviewed above, suggest that the difficulties found in heterologously 
expressing a7 nAChR in mammalian cell lines, arise as consequence of cell-specific misfolding 
of the neuronal a7 nAChR subunit. A reasonable explanation for the differences between the 
results obtained by Cooper and Millar (1997), Kassner and Berg (1997) and those of 
Gopalakrishnan et al. (1995) is that the HEK-293 cell isolates used in different laboratories are 
different in some way that remains to be established. Perhaps, after extensive propagation 
under different conditions, the cell line diverged and produced subpopulations having different 
kinds of components for assembling complex membrane proteins. Recently, pertinent to this 
last point, it is interesting that Blumenthal et al. (1997) have reported that different isolates from 
the PC12 cell line differ in the extent to which they express correctly folded a7 protein.
Finally, it is possible that the cell-specific regulation of posttranscriptional events, such as 
protein folding, subunit assembly and receptor stabilisation (as suggested by 
Kassner and Berg, 1997), may constitute an additional mechanism for regulating the 
cell-specific expression of some neurotransmitter receptor subtypes.
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3 KCI- and nicotine-evoked glutamate release in hippocampus
3.1 Introduction
As described in Section II, (-)-nicotine is thought to enhance cognition and the hippocampus is 
likely to be a locus of action for such effects. This brain region receives a rich cholinergic 
innervation (septohippocampal pathway) and displays a dense nicotinic expression especially of 
the a7-subtype (Seguela et al., 1993). Recent evidence supports the presence of 
a7-containing nAChR on GABAergic intemeurones (Alkondon et al., 1997; Frazier et al., 1998a: 
first demonstration of a functional cholinergic synapse in the mammalian brain in which the 
primary postsynaptic receptors are a-Bgt-sensitive nAChR). However, most evidence supports 
a presynaptic role for a-Bgt-sensitive nAChR in the CNS.
Presynaptic nAChR are likely on the terminals of cholinergic hippocampal afferents since they 
have been shown to modulate acetylcholine release in vitro (e.g. Wilkie et al., 1996). 
The a4p2-containing nAChR is a candidate for such modulatory action given the loss of 
this subtype as cholinergic projections degenerate in Alzheimers' disease (Nordberg, 1994; 
Maelicke and Alburquerque, 1996). Noradrenaline (Clarke and Reuben, 1996) and GABA 
(Lu et al., 1998) release have been also shown to be modulated by presynaptic nAChR. 
Glutamate is the major excitatory neurotransmitter in hippocampus and glutamatergic excitatory 
synaptic transmission is also a likely target for modulation by nAChR. 
In fact, electrophysiological studies revealed that (-)-nicotine was able to enhance glutamatergic 
synaptic transmission by activation of presynaptic a-Bgt-sensitive nAChR (i.e. Gray etal., 1996; 
Radcliffe and Dani, 1998). The aim of the present chapter was to examine this modulation using 
a neurochemical approach.
In this study, synaptosome preparations were used to study nicotinic agonist-evoked glutamate 
release in rat hippocampus. Synaptosomes, i.e. isolated nerve terminals, present distinct 
advantages for the investigation of the molecular mechanisms controlling the release of 
neurotransmitters. They are, at the same time, the simplest preparation in which 
Ca2+ -dependent release can be studied and the most complex preparation that is sufficiently 
homogeneous to be accessible to measurements of ion transport, membrane potentials, 
Ca2+ transients, bioenergetics, and intraterminal compartmentation.
To gain a better insight into how nicotinic agonists modulate neurotransmitter release in 
the CNS, this study intended to explore Ca2+ influx, [Ca2+]j changes and release of 
labelled glutamate from rat hippocampal synaptosomes, as a consequence of 




3.2.1 (-)-Nicotine-evoked [3H]-glutamate release from Percoll-purified 
hippocampal synaptosomes
3.2.1.1 Materials
Sprague-Dawley rats were obtained from the University of Bath Animal House breeding colony. 
L-[3,4-3H]-glutamic acid (L-[3H]-Glu) and D-[2,3-3H]-aspartic acid (D-[3H]-Asp) 
(specific activities 1.8 TBq / mmol (49.4 Ci / mmol) and 403.3 GBq / mmol (10.9 Ci / mmol), 
respectively) were purchased from NEN DuPont (DuPont - Stevenage, Hertfordshire UK). 
Percoll was obtained from Pharmacia Biotech (Uppsala, Sweden) and (±)-anatoxin-a 
((±)-AnTx-a) from Tocris Cookson (Bristol, UK). (-)-Nicotine, L-glutamate, D-aspartate and 
HEPES were purchased from Sigma (Poole, Dorset UK). All other chemicals used were of 
analytical grade and obtained from standard commercial sources.
3.2.1.2 Preparation of Percoll-purified hippocampal synaptosomes
Male Sprague-Dawley rats (weighing 240-250 g) were killed by cervical dislocation, decapitated, 
and brain hippocampi (200-215 mg of wet tissue weight per rat) were rapidly dissected. 
Percoll-purified synaptosomes were prepared according to the procedure of Dunkley et al. 
(1988) as previously described by Soliakov and Wonnacott (1996). Eight hippocampi 
(800-860 mg wet weight) were homogeneized (10% (w/v)) in 0.32 M sucrose 5 mM HEPES 
(pH 7.4) followed by centrifugation at 1000 g for 10 min. The resulting supernatant fraction was 
distributed between four centrifuge tubes containing discontinuous four-step Percoll gradients 
composed of 3, 10, 15 and 23% Percoll in 0.32 M sucrose (pH 7.4), respectively. 
After centrifugation at 29000 g for 5 min, five main fractions were obtained: functionally active 
synaptosomes are concentrated at the 15-23% Percoll gradient interface (Dunkley et al., 1988; 
Thome et al., 1991; Taupin et ai, 1994). This synaptosomal fraction (fraction 4) was gently 
collected by Pasteur pipette and, after dilution with 2.5 volumes Krebs bicarbonate buffer 
(118 mM NaCI, 2.4 mM KCI, 2.4 mM CaCI2l 1.2 mM MgS04> 1.2 mM K2HP04, 25 mM NaHC03, 
and 10 mM glucose, buffered to pH 7.4 with 95% 0 2 / 5% C02), was centrifuged at 20000 g 
for 20 min. The resulting pellet was washed once more, and the final synaptosomes were 
resuspended in 1.4 ml Krebs bicarbonate buffer (pH 7.4).
Synaptosomes were loaded with L-[3H]-Glu (0.2 pM, 49.4 Ci / mmol) or D-[3H]-Asp 
(0.9 pM, 10.9 Ci / mmol) at 37°C for 15 min. To increase L-[3H]-Glu or D-[3H]-Asp uptake, 
the incubations were performed in the presence of "cold" 10 pM L-glutamic acid or 
10 pM D-aspartic acid, respectively (the plasma membrane glutamate uptake carrier apparent 
Km for binding extracellular glutamate is in the range 2-50 pM - Nicholls and Atwell, 1990). 




Superfusion of synaptosomes was performed as previously described (Soliakov et al., 1995; 
Marshall et al., 1996) in a Brandel Superfusion Apparatus Model SF-12 (Brandel - Gaithersburg, 
MD USA, see Figure 3.1) using Krebs bicarbonate buffer at a flow rate of 0.5 ml/min. 
Fractions were collected every 2 min. After 30 min washing with Krebs bicarbonate buffer, 
(-)-nicotine (1, 10 or 25 pM) or (±)-AnTx-a (1 pM) in buffer was applied for 40 s, separating the 
pulse of drug from the bulk buffer flow by 10 s air bubbles. For KCI depolarisation, a 40 s pulse 
of buffer with KCI increased to 23.5 mM was applied.
Fractions were counted in a Packard TRI-CARB Liquid Scintillation Analyzer Model 1500 
(Packard Instrument Company - Downers Grove, IL USA - counting efficiency 48 %).
Figure 3.1 Schematic representation of the superfusion apparatus. Buffer and drug 
solutions (B) (maintained at 37°C by a thermostated water bath (A)) were collected using a 
stainless steel probe assembly and passed through the system by a 1 2 -channel peristaltic 
pump (C). The superfusion block (D) contained 12 open superfusion chambers in parallel. 
Superfusate was collected by a second peristaltic pump (not shown), and delivered to an 
external fraction collector (E). The direction of buffer flow is indicated by small arrows. 
Inset) Schematic representation of a superfusion chamber. The walls and sintered support 
(horizontal dotted line) were made from the base of a BioRad disposable chromatography 
poly-prep column (BioRad - Hemel Hempstead, Herts UK). Krebs bicarbonate buffer was 
pumped into the chamber via a hypodermic needle (19G - upper arrow) to ensure delivery of 
small, regular drops of buffer. Synaptosomes (filled circles) were loaded into the chambers 
using the entry pump, to ensure that the points of sample and buffer delivery were the same. 
Retention of samples in the chambers was achieved using two Whatman GF/C filter discs 
(horizontal thick lines) placed on top of the sintered support.
3.2.1.3 Superfusion data analysis
The baseline was derived by fitting the data to the following double exponential decay equation:
y = ae^  + ce^x
(Equation 3.1)
where a, b, c and d are the curve parameters and x is the fraction number.
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Evoked [3H]-Glu or [3H]-Asp release was calculated as the area under the peak after subtraction 
of the baseline. Responses are expressed as the percentage of radioactivity released from the 
total radioactivity loaded into the synaptosomes immediately before stimulation 
(Soliakov et al., 1995). For comparison between different experiments, superfusion profiles 
were normalised as percentages of the fitted baselines (Figure 3.4).
3.2.2 KCI- and (-)-nicotine-evoked Ca2+ influx in Percoll-purified 
synaptosomes from rat hippocampus
3.2.2.1 Materials
A PTI dual-excitation spectrophotofluorimeter (PTI M-series instruments / PTI software v.2.060) 
manufactured by Photon Technology International Inc. (South Brunswick, NJ USA) was 
generously facilitated by Professor J. Westwick (University of Bath, Dept, of Pharmacy and 
Pharmacology). The acetoxymethyl derivative of fura-2 (fura-2/AM see Figure 3.2 - 
1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxyl-2-(2'-amino-5'-methylphenoxy) ethane 
N,N,N',N'- tetraacetic acid) was purchased from Molecular Probes (Eugene, OR USA). 
SDS and EGTA were purchased from Sigma (Poole, Dorset UK). All other chemicals used were 
of analytical grade and obtained from standard commercial sources.
N—
COOCH2OCOCH3
Figure 3.2 Chemical structure of fura-2/AM. This fluorescent Ca2+ chelator was developed by 
Tsien and colleagues (Grynkiewicz et al., 1985) from the Ca2+ chelator BAPTA, which is the 
double aromatic analogue of EGTA. Hydrolysis of acetoxymethyl groups (underlined) by 
non-specific esterases traps the indicator in the nerve terminal cytosol.
3.2.2.2 Synaptosome loading with fura-2/AM
Percoll-purified hippocampal synaptosomes were prepared as described in 3.2.1.2. 
However, instead of normal Krebs buffer, low-Ca2+ Krebs bicarbonate buffer was used 
(118 mM NaCI, 2.4 mM KCI, 20 pM CaCI2, 1.2 mM MgS04, 1.2 mM K2HP04, 
25 mM NaHC03, and 10 mM glucose, buffered to pH 7.4 with 95 % 0 2 / 5 % C02). 
Percoll-purified hippocampal synaptosomes (fraction 4 - Percoll gradient 15-23% interface) 
were resuspended in 1 ml low-Ca2+ Krebs bicarbonate buffer before loading with fura-2/AM.
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Fura-2/AM was prepared as a 1 mM stock solution in dimethyl sulfoxide (DMSO). Highly purified 
hippocampal synaptosomes (1.7±0.3 mg protein / ml - n=9) were incubated with 5 pM fura-2/AM 
in the dark at 37°C for 40 min, while gently shaking (Fontana and Blaustein, 1993). 
This incubation enabled the internalised fura-2/AM to be hydrolised by non-specific esterases to 
the non-cell permeable Ca2+-sensitive fura-2 free acid (Figure 3.3). To remove remaining 
extrasynaptosomal fura-2/AM, the suspension was centrifuged at 500 g for 1.5 min and 
the supernatant was discarded. The pellet was then resuspended in 2 ml fresh low-Ca2+ Krebs 
bicarbonate buffer and stored on ice until use (within the following 2 h).
3.2.2.3 Calibration of [Ca24]j measurements
Ca2+ measurements rely on the change in the fluorescent properties of the indicator (fura-2) 
following Ca2+ binding. At equilibrium, the degree of Ca2+ saturation of the indicator is related to 
its free Ca2+concentration according to the mass action equation:
Ca2+ = Kd ( [CaX] I [X ])
(Equation 3.2)
where X is the fluorescent indicator which binds Ca2+ with dissociation constant Kp.
With dyes such as fura-2 (Kd = 224 nM) which give a shift in fluorescence spectrum, 
measurements can be earned out at two excitation wavelengths to obtain signals that are 
proportional to Ca2+-bound @=340 nm) and Ca2+-free indicator @.=380 nm). 
The Emission for both excitation wavelengths is 510 nm. The ratio of fluorescence at 
the two wavelengths is directly related to the ratio of the two forms of the dye and therefore can 
be used to calculate [Ca2+]j. The equation (Grynkiewicz et al., 1985) which relates the measured 
Ca2+-bound / Ca2+-free fluorescence ratio (R) to [Ca2+]i is:
[Ca2l  = Ko [ (R - R™„) / (R™x - R) ] ( S „ /S b2)
(Equation 3.3)
where Rmax and Rmjn are the fluorescence ratio values under saturating and Ca2+-free 
conditions respectively and S r  /  Sb2  is the ratio of fluorescence values for 
Ca2+-bound / Ca2+-free indicator measured at the wavelength used to monitor the Ca2+-free 
indicator. These are unitless values which depend on the chemical properties of the indicator. 
Calibration measurements at zero and saturating levels of Ca2+ are required to determine the 
constants Rmin, Rmax and S^/ Sb2.
Overall, the objective of calibration is to determine the fluorescence levels under the conditions 
of maximum and minimum Ca2+ -binding. This can be achieved by using ionophores 
(e.g. detergents) which allow extracellular Ca2+ to go inside the synaptosome and in turn
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saturate the indicator. Subsequently EGTA is added to the preparation to chelate the Ca2+ 
present in the cuvette, allowing the determination of the minimum fluorescence 
(Figure 3.7 a, c & e). [Ca2+]j values derived from (Equation 3.3) can be plotted throughout the 
experiment (Figure 3.7 b, d & f).
In this study, to determine the apparent [Ca2+]j in synaptosomes, an aliquot (200 pi) of the 
original suspension of fura-2-loaded nerve terminals, was diluted into 1.8 ml of low-Ca2+ 
Krebs bicarbonate buffer and warmed to 37°C for 5 min. The fluorescent emission of 
fura-2-loaded synaptosomes was recorded for at least 40 s before adding various reagents. 
A typical experiment involved the sequential addition of: first, 20 pi 240 mM CaCI2 
(final 2.4 mM), followed by 20 pi of either 2 M KCI (final 23.5 mM) or (-)-nicotine 
(1 mM or 5 mM (final 10 or 50 pM, respectively)). The measurements were made in a 
thenmostated cuvette (37°C) with a PTI dual wavelength spectrophotofluorimeter by alternating 
the excitation wavelengths of 340±4 nm and 380±4 nm (340 nm / 380 nm fluorescence ratio): 
fluorescent emission was monitored at 510 nm (Figure 3.3). The samples were continuously 
mixed with a magnetic stirrer.
Calibration of the fluorescent signals was performed at the end of each experiment by adding 
20 pi 20 % SDS (final concentration: 0.2% SDS) to obtain Rmax, followed by 20 pi 0.5 M EGTA 
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Figure 3.3 Determination of [C a2+]j in hippocampal synaptosomes using fura-2/AM
Percoll-purified synaptosomes from rat hippocampus are loaded with the cell-permeable 
acetoxymethyl derivative of fura-2 (fura-2/AM). During the incubation of synaptosomes with 
fura-2/AM, cytosolic non-specific esterases hydrolise the indicator to the non-cell permeable 
Ca2+-sensitive fura-2 free acid. Depolarisation of the synaptosome membrane, either by an 
increase in the external concentration of KCI or by activation of neuronal nAChR (hypothesis), 
causes the opening of Voltage Operated Calcium Channels (VOCC) and subsequently an 
increase in [Ca2+]j. Ca2+ binding to the indicator fura-2 shifts its excitation (hv£x) wavelength 
from X=380 nm to X=340 nm. Fluorescent emission (hvEM) is monitored at A=510 nm. 
Calibration is performed in each experiment by adding SDS (0.2%) and EGTA (5 mM). 
Intraterminal free Ca2+ is calculated using the Grynckiewicz equation (Equation 3.3).
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3.2.3 Graphics and statistics
Results are expressed as mean±S.D. of several Independent experiments and were analysed 
for statistical significance using Sigma Stat v.2.0 (Jandel Scientific, Germany). Graphics, plots 
and curve fittings were done using Sigma Plot for Windows v.2.0 (Jandel Scientific, Germany).
3.2.4 Protein determination
Synaptosome protein concentration was determined using a modification of the Lowry method 




3.3.1 L-[3H]-glutamate and D-[3H]-aspartate release from rat hippocampal 
synaptosomes
Preliminary superfusion experiments intended to examine nicotinic agonist-evoked 
L-[3H]-GIu and D-[3H]-Asp release from Percoll-purified rat hippocampal synaptosomes. 
To test the functional status of the preparation, a general depolarising agent (23.5 mM KCI) was 
applied to evoke neurotransmitter release (Figure 3.4).
After 20 min perfusion with Krebs bicarbonate buffer, the basal release of L-[3H]-Glu or 
D-[3H]-Asp from hippocampal synaptosomes was constant for the duration of the experiment 
(following 26 min - Figure). Depolarisation with KCI (23.5 mM 40 s) in the presence of external 
Ca2+ (2.4 mM), caused a significant increase over basal values in L-[3H]-Glu and 
D-[3H]-Asp release. KCI stimulation (23.5 mM 40 s) evoked the release of 4.18±0.76% (n=4) 
and 3.06±0.47% (n=2) of the total radioactivity present in synaptosome preparations preloaded 
with L-[3H]-GIu or D-[3H]-Asp, respectively (Figure 3.5). On return to basal medium 
(Krebs bicarbonate buffer), the level of labelled amino acid released returned to prestimulation 
values within 1-2 min (Figure 3.4).
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Figure 3.4 Representative superfusion profile for L-^HJ-Glut release from purified rat 
hippocampal synaptosomes. Hippocampal synaptosomes were prepared and superfused as 
described in Experimental Procedures (3.2.1.2). Release of L-[3H]-Glu was monitored by 
superfusion of Percoll-purified synaptosomes (fraction 4 - Percoll gradient 15-23% interface) 
with Krebs buffer, followed by stimulation (40 s) with KCI (23.5 mM), Krebs buffer or (-)-nicotine 
(10 pM). Fractions were collected every 2 min and counted for radioactivity. Superfusion profiles 
were normalised as percentages of the fitted baselines. In this particular experiment, KCI 
(23.5 mM) released 3.7% of total radioactivity present in the sample before stimulation.
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(-)-Nicotine and (±)-AnTx-a were used to assess the nicotinic agonist-evoked release of labelled 
neurotransmitter from Percoll-purified hippocampal synaptosomes. (-)-Nicotine (1,10 & 25 pM) 
and (±)-AnTx-a (1 pM) failed to elicit significant release of L-[3H]-Glu or D-[3H]-Asp from this 
preparation (Figure 3.5- type IA current EC50 values for (-)-nicotine and Antx-a are 27 pM and 
3.9 pM, respectively - Alkondon and Albuquerque, 1993). Differences between responses 
evoked by nicotinic agonists and Krebs buffer pulses were not significant 
(Figure 3.5 -  p>0.05 - one way ANOVA).
Figure 3.5 KCI- and nicotinic agonist-evoked release of (a) L-^HJ-Glu and (b) D-^HJ-Asp, 
from rat hippocampal synaptosomes. Percoll-purified hippocampal synaptosomes were 
prepared and perfused as described in 3.2.1.2. Release of L-[3H]-Glu or D-[3H]-Asp was 
monitored by superfusion of Percoll-purified synaptosomes (Percoll gradient 15-23% interface) 
with Krebs buffer followed by stimulation (40 s) with KCI (23.5 mM), Krebs buffer or 
nicotinic agonists. No significant differences were observed between the responses evoked by 
Krebs buffer and those elicited by nicotinic agonists (1, 10 & 25 pM (-)-nicotine and 
1 pM (±)-AnTx-a). However, KCI (23.5 mM) significantly increased the release of labelled 
neurotransmitter. Responses were calculated as percentage of radioactivity released from 
total label present in the sample before stimulation. Results are expressed as mean±S.D. of 
several independent experiments (n=2-4).




3.3.2 Fluorescence Ca2+studies using fura-2/AM
Hippocampal nerve terminal [C a 2+]j values were determined before and after stimulation with 
KCI or nicotinic agonists, by fura-2 fluorescence analysis ( [Ca2+]0 = 2.4 mM).
3.3.2.1 Effects of [Ca24]0and [K^o on hippocampal nerve terminals [Ca24],
The fluorescent calcium probe fura-2, have been extensively used to determine [C a 2+]j in 
synaptosomes under resting and activated conditions (e.g. Budd et al., 1996; 
Martinez Serrano et al., 1996; Larsen et al., 1998). These studies were performed with 
synaptosomes bathed in buffer containing a physiological external C a 2+ concentration of 
~1-2 mM. To evaluate the effect of [C a 2+]0 on unstimulated hippocampal synaptosomes [C a 2+]j, 
they were resuspended in buffer containing a reduced [C a 2+]0 (0.02 mM) and later challenged 
with a higher [Ca2+]0 (2.4 mM).
In unstimulated synaptosomes incubated in low C a 2+ Krebs buffer containing 0.02 mM C a C I2, 
the apparent resting [C a 2+]j was 164±17 nM (n=9). This value was only modestly affected by 
changes in [C a 2+]0. When the C a 2+ in the buffer was increased 120 fold, to 2.4 mM, 
the apparent resting [C a 2+]j increased only 27%, to 209±21 nM (n=9) (this difference was not 
statistically significant -  p>0.05 one way ANOVA). The effect of increasing [K+]0 on [C a 2+]j was 
determined in buffer containing 2.4 mM C a C I2. High [K+]0 (23.5 mM) increased [C a 2+]j by 268%, 
from 195±32 nM to 523±80 nM (n=3) (Figure a, b - difference statistically significant p<0.05 
one way ANOVA -  Bonferroni t test). When [hCjo was increased to 23.5 mM, [C a 2+]j reached a 
maximum within 1-2 s (Figure 3.6) and then remained constant, presumably because most of 
the voltage operated C a 2+ channels were then inactivated 
(Naschen and Blaustein, 1980).
500 -
_  400 -
^  300 -
“  200 -
23.5 mM KCI100 -
98 100 102 104 106 108 110
Time ( s )
Figure 3.6 Representative time-course plot of 23.5 mM KCI-evoked changes in [Ca24]i of 
hippocampal synaptosomes at [Ca2^ 0 = 2.4 mM. Percoll-purified hippocampal synaptosomes 
were prepared and loaded with fura-2/AM as described in 3.2.2. KCI-evoked depolarisation 
(arrow) of nerve terminals membrane, increased [Ca2+]j to a maximum within 1-2 s. 
In this experiment, high [K*]0 (23.5 mM) increased [Ca2+]j by 259%, from 170 nM to 441 nM. 
Raw data were fitted to an exponential function using Sigma Plot software (thin line plot).
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3.3.2.2 (-)-Nicotine induced Ca2+ influx
To date there are no published studies related to (-)-nicotine-evoked Ca2+ influx in rat 
hippocampal synaptosomes loaded with fura-2. Preliminary trials (n=6) were carried out to 
evaluate putative (-)-nicotine-evoked [Ca2+]i increases in Percoll-purified hippocampal 
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Figure 3.7  Effect of K C I and (-)-nicotine on hippocampal nerve terminals [C a 2+]j.
Representative traces showing variations in synaptosome preparations fluorescence ratio and 
[Ca2+]j in response to KCI (23.5 mM - a & b) and (-)-nicotine (10 pM (c & d) and 50 pM (e & f). 
Percoll-purified hippocampal synaptosomes were prepared and loaded with fura-2/AM as 
described in 3.2.2. Before increasing [Ca2+]p to 2.4 mM (at 50 s), the effect of a lower [Ca2+]0 
(0.02 mM) on the nerve terminal resting [Ca ]j was determined. Calibration was carried out with 
SDS (0.2%) and EGTA (5 mM) to determine maximum and minimum fluorescence, respectively 
(a, c & e). Corresponding [Ca ]j values, derived from the Grynkiewicz equation (Equation 3.3) 
are shown in b, d & f.
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Two different concentrations of (-)-nicotine were chosen to stimulate the synaptosome 
preparations: 10 pM and 50 pM (Figure 3.7, c-f). The lower concentration was previously found 
to evoke maximum [3H]-ACh release from Percoll-purified (fraction 4 - Percoll gradient 15-23% 
interface) rat hippocampal synaptosomes (E C 50 = 0.99±0.23 pM - Wilkie et al., 1996). 
The higher concentration of (-)-nicotine (50 pM) was chosen because in Ca2+ influx studies 
performed on rat E18 hippocampal neurones (monolayers) loaded with fura-2, it rendered the 
most reproducible and consistent responses (Barrantes et al., 1995). Moreover, Type IA 
currents have an EC50 value for (-)-nicotine of 27 pM (Alkondon and Albuquerque, 1993) 
so 50 pM (-)-nicotine should give a near-maximum response.
Neither 10 pM nor 50 pM (-)-nicotine evoked detectable C a 2+ influx (Figure 3.7, c-f). 
The [C a 2+]j increase after applying 10 pM and 50 pM (-)-nicotine was: from 218±3 nM to 
226±7 nM (n=3); and from 214 ± 6  nM to 219 ± 4 nM (n=3), respectively (differences non 
statistically significant p>0.05 one way ANOVA). It is important to bear in mind that under the 
same experimental conditions, 23.5 mM K C I increased [C a 2+]j by 268% above baseline 




The aim of these preliminary studies was to examine the role of a-Bgt-sensitive presynaptic 
nAChR in modulating glutamatergic neurotransmitter release in rat hippocampal preparations.
Experimental approaches other than electrophysiological techniques and Ca2+ imaging 
(Gray et al., 1996; Radcliffe and Dani, 1998), have also been applied to the study of glutamate 
release in hippocampus. For instance, in vivo studies (Toth, 1996; Fedele et al., 1998) showed 
that hippocampal microdialysis administration of (-)-nicotine specifically increased local 
extracellular levels of glutamate and aspartate, suggesting the involvement of nAChR in 
their release. On the other hand, in vitro assays using hippocampal slices (Keith et ai., 1995; 
Talke and Bickler, 1996) and nerve terminal preparations (Gannon et al., 1992; 
Terrian et al., 1993; Rodriguez et al., 1997; Breukel et al., 1997; HelmeGuizon et al., 1998) 
have been extensively used to study the effect of different drugs (e.g. VOCC blockers, 
a2-adrenergic agonists, kappa opiod agonists, phorbol esters (PDBu), histamine, 
arachidonic acid) on general depolarising agent-evoked glutamate release or on the 
intraterminal mechanisms underlying it. In vitro studies on slices have also shown 
depolarisation-evoked aspartate release in rat hippocampus (Klancnik et al., 1992; 
Keith et al., 1994, 1995). However, attempts to demonstrate directly the nicotinic presynaptic 
modulation of hippocampal glutamate/aspartate release using a neurochemical approach have 
been largely unsuccessful (e.g. Wonnacott etal., 1995).
In this study a perfusion system was used to examine labelled L-glutamate/D-aspartate release 
from synaptosomes prepared from rat hippocampi. The purity and viability of the synaptosomal 
preparation is crucial for the execution of this technique. To fulfil these criteria, hippocampal 
synaptosomes isolated by the discontinuous Percoll method were used (Dunkley et al., 1988). 
When compared with conventional sucrose density fractionation (Rapier et al., 1987), 
this procedure is faster, suitable for smaller amounts of tissue and employs an isotonic medium 
(Thome et al., 1991; Taupin et al., 1994). The use of Percoll gradients for isolating hippocampal 
"nerve terminals" yields synaptosomes in four of the five fractions from the gradient 
(Thome et al., 1991). Previous reports have shown that hippocampal fraction 4 
(Percoll gradient 15-23% interface) is enriched in intact viable synaptosomes that are relatively 
free with contamination from lysed synaptosomes and synaptic plasma membranes 
(Dunkley etal., 1988; Thorne etal., 1991). The highest uptake of [3H]-GABA and [3H]-choline in 
terms of mg of protein and the highest [3H]-(-)-nicotine binding levels were also found in this 
fraction (Thorne et al., 1991). Moreover, it has been demonstrated that hippocampal mossy 
fibre synaptosomal preparations obtained in the Percoll gradient 15-23% interface fraction, 




Although this preliminary study did not compare the Percoll gradient fractions obtained for 
L-[3H]-Glu/D-[3H]-Asp uptake, the results presented in this chapter demonstrate that 
Percoll-purified hippocampal synaptosomes from fraction 4 (15-23% interface),
are capable of releasing labelled neurotransmitter (L-[3H]-Glu or D-[3H]-Asp) upon K+ (23.5 mM) 
induced depolarisation, indicating the presence of viable glutamatergic nerve terminals in 
the preparation.
Previous studies (e.g. Verhage et al., 1989) reported a steep increase in hippocampal 
synaptosome KCI-evoked glutamate release in the range 3-30 mM [iOo (maximal release at 
[K+]0 = ~50 mM - e.g. Taupin et al., 1994; Rodriguez et al., 1997).
The effectiveness of K+ depolarisation in inducing the release of L-[3H]-Glu from preloaded 
hippocampal synaptosomes has been reported to change during rat post-natal development 
(Collard et al., 1993), between PND4 (post-natal day 4) and PND15 the response was smaller 
than that seen in adult rats, the stage at which the sensitivity of the release reached a 
maximum level. On the other hand, Gray et al. (1996) used hippocampal slices from adult rats 
(PND 20- 63) to demonstrate that a puff of nicotine (~20 pM) elevates [Ca2+]j in mossy-fibre 
presynaptic terminals (a-Bgt-sensitive response). In this study, L-[3H]-Glu/D-[3H]-Asp released 
by KCI (23.5 mM) from adult rat (PND>14) Percoll purified hippocampal synaptosomes, 
was used to test the functionality of the system (i.e. as positive control).
Moreover, the values obtained in this study for KCI-evoked L-[3H]-Glu/D-[3H]-Asp release from 
hippocampal nerve terminals (Figure 3.5) are in perfect concordance with those reported by 
Taupin et al. (1994) for KCI-evoked release of the same neurotransmitters from a 
Percoll-purified (15-23% interface) mossy fibre nerve terminal preparation.
"Slow application" (seconds to minutes) of low micromolar (-)-nicotine concentrations enabled 
the neurochemical detection of ACh (Wilkie et al., 1996), noradrenaline
(Clarke and Reuben, 1996) and GABA (Lu etal., 1998) release from hippocampal preparations, 
despite the pharmacological and kinetic properties of the nAChR involved 
(reviewed in the general introduction). Gray et al. (1996) demonstrated that the release of 
glutamate from mossy fibre nerve terminals is modulated by presynaptic a7-containing nAChR, 
equated with type IA responses in hippocampal neurones ( E C 5 0  values are 27 pM and 3.9 pM
for (-)-nicotine and AnTx-a, respectively (Alkondon and Albuquerque, 1993)).
Therefore, the (-)-nicotine (1, 10 & 25 pM) and (±)-AnTx-a (1pM) concentrations used in this 
study should have been sufficient to evoke responses. However, this study was unable to 
demonstrate nicotinic agonist-evoked L-[3H]-glutamate release from hippocampal 
synaptosomes, probably because the superfusion technique is too slow given that 
a7 nAChR-mediated neurotransmitter release has been only detected with 
fast perfusion systems (msec) in electrophysiological studies.
82
Chapter 3
Fluorescence studies using fura-2 were also carried out on the same biological preparation to 
explore changes in [Ca2+]( as a consequence of KCI- and nicotinic agonist-induced nerve 
terminal depolarisation. A number of labs have previously used the fluorescent indicator fura-2 
in hippocampal slices (Talke and Bickler, 1996) and synaptosomes 
(Bartschat and Rhodes, 1995; Martinez Serrano et al., 1996) to study the effect of 
different chemical species (e.g. a2-adrenergic agonists, phorbol esters (PMA), okadaic add, 
NO, arachidonic acid) on the apparent [Ca2+]i before and after KCI-stimulation.
Studies correlating neurotransmitter release with increase in nerve terminal [C a 2+]j have shown 
that an elevation of [C a 2+]j <330 nM is ineffedive in indudng release of transmitters and that a 
steep increase in release effectiveness is attained at a mean [C a 2+]j between 350 and 400 nM 
(Adam-Vizi and Ashley, 1987; Knight, 1987; Verhage et al., 1989). 
In this study elevation of [K+]0 to 23.5 mM, increased resting levels of [C a 2+]j to ~520 nM and, 
consistent with the results of Verhage et al. (1989), 23.5 mM KCI evoked the release of labelled 
neurotransmitter by ~400% above baseline (see Figure 3.5).
In this thesis and consistent with previous values reported for the same Percoll purified 
hippocampal preparation (e.g. Verhage et al., 1989), [Ca2+]j resting levels fell in 
the range 150-250 nM. However, factors that may contribute to explain differences between 
results reported by different labs indude the sequestration of fura-2 in intraterminal organelles 
and the presence of damaged terminals in the preparations (Fried and Blaustein, 1978). 
Fura-2 when loaded as the membrane-permeable acetoxymethyl ester, may not be confined to 
the cytosol, but may also be concentrated in intracellular organelles such as the ER 
(Goldman and Blaustein, 1990) and mitochondria (Miyata etal., 1991) altering basal [Ca2+]jlevel 
measurement. In addition, some damaged nerve terminals may be able to concentrate fura-2, 
but may nevertheless be relatively leaky to Ca2+ and have high [Ca2+]j levels. 
The observed resting potentials represent the average [Ca2+]j in the entire population of "normal" 
and damaged nerve terminals. The presence in the sample of damaged or non responding 
synaptosomes, could also affect the apparent [Ca2+]j increase evoked by high [K+]0. In addition, 
KCI-evoked [Ca2+]j increases may also have been underestimated because of the relatively slow 
time "resolution" of the recordings performed (seconds rather than milliseconds). It is possible 
that the increases in different nerve terminals within the preparation may be non-synchronous, 
so that [Ca2+]j may be still increasing in some terminals while it is already decreasing in others.
The present work has shown that, in contrast to KCI, nicotinic agonists failed to evoke the 
release of labelled amino acids from Percoll-purified hippocampal synaptosomes. 
Fluorescence studies with fura-2 (this study) allowed the detection of KCI-evoked Ca2+ influx 
because the general depolarisation affected in a sustained way, if not all, a high percentage of 
the synaptosomes present in the preparation. When using (-)-nicotine as the stimulus, 
it was initially expected to detect some signal (increase in [Ca2+]j), at least due to the activation 
of non-a7-containing nAChR present on non-glutamatergic nerve terminals. 
However, no significant (-)-nicotine-evoked increase in intratenminal Ca2+was detected.
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As early as in 1993, Sargent suggested that the extremely rapid desensitisation of the 
a7-containing nAChR was making it considerably difficult to study. Recent studies have shown 
that some nAChR can be desensitised by concentrations of agonists that are too low to activate 
the receptor directly (Grady et al., 1994; Marks et al., 1996). Moreover, Frazier et al. (1998a) 
have shown that postsynaptic a7-containing nAChR located on CA1 interneurones, cannot be 
activated by bath superfusion with agonists and can be easily desensitised by the leakage of 
small amounts of agonist from drug-containing pipettes. These experiments suggested that 
successful nAChR activation requires techniques that permit both the rapid application and 
rapid removal of agonist (Alkondon and Albuquerque, 1993; Frazier et al., 1998a; 
Radcliffe and Dani, 1998). Thus, from a functional point of view, the slow application of 
low concentrations of (-)-nicotine (100 nM -1  pM) has an antagonistic rather than an agonistic 
effect on transmission at these synapses. Frazier et al. (1998a) also showed that 
a7-containing nAChR on intemeurones can be desensitised completely by nanomolar 
concentrations of (-)-nicotine, and that this occurs under conditions in which the possibility of a 
presynaptic action of nicotine (e.g. release of neurotransmitters) is blocked. 
These results suggest an important determinant of the effects of (-)-nicotine in the brain may be 
the rate of desensitisation and that this can differ even for receptors that are thought to belong 
to the same receptor subclass. It has also been suggested e.g. Sargent, 1993; 
Anand et al., 1993) that there may be multiple populations of a7-containing receptors 
(but see Chen and Patrick, 1997), each exhibiting similar sensitivity to MLA and a-Bgt 
but having different kinetics that arise as a result of the incorporation of other receptor subunits. 
In this respect, a recent study by Cuevas and Berg (1998) reported that a a7-containing 
receptor is responsible for the slowly desensitising, a-Bgt-reversible nicotinic response 
observed in rat intracardiac ganglia. Further experiments are needed to see if the differences in 
desensitisation are due to the presence of non-a7 subunits or the result of receptor localisation 
regulation within the neurone.
At the present time, neurochemical techniques appear to lack the temporal resolution to 
demonstrate a7-mediated transmitter release (but see Turner and Dunlap, 1995 for a fast 
superfusion system that measures neurotransmitter release on a sub-second timescale). 
However, it may be possible to detect such mechanisms indirectly (see chapter 5).
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Section II: Basal ganglia: the neostriatum
A brief story of the basal ganglia
It was as early as 1664 when the first clear identification of distinct subcortical structures was 
published by the English anatomist Thomas Willis. What is now functionally known as 
the basal ganglia was then referred to as the corpus striatum. It held such a central position, 
striped with a wide range of cortical and brainstem fibres, that at the time it was thought to both 
receive all sensory modalities and initiate all motor acts. This idea appeared to be anatomically 
reinforced by its central position and clearly visible ascending and descending fibre systems.
Two subsequent events relegated the corpus striatum to an obscure and less defined position. 
The attractiveness of the histological organization of the cortex, and the possibility of localizing 
higher mental functions drew many neurologists of both the 18th and 19th centuries to 
cortical research. Amongst those that continued studying the corpus striatum, there was a 
sudden realisation that many of the functions originally assigned to it were in fact properties of 
neighbouring corticospinal paths.
At the beginning of the 20th century there were serious attempts to provide detailed comparative 
descriptions of the corpus striatum. It began to gain importance once again with the discoveries 
that lesions of these areas would often result in disorders of motor functions in humans. 
The corpus striatum came to be viewed as the major components of 
the "extrapyramidal motor system". This term loosely grouped the corpus striatum with an array 
of brain stem nuclei and reflected the assumption that this grouping constituted a complete and 
independent motor unit. The term "basal ganglia" has been generally used to refer to these 
major anatomical telencephalic subcortical nuclei at the base of the forebrain. More formally this 
definition groups the corpus striatum (neostriatum (putamen & caudate nucleus) and 
globus pallidus) with the substantia nigra and subthalamic nucleus (Figure lla).
Motor control overview
Motor control occurs in a three-level hierarchy. The spinal cord is the "most primitive", 
controlling reflex and stereotypical actions. Integration of sensory and vestibular information 
occurs in the brain stem, which controls posture, eye, and head motions. The apex of the motor 
hierarchy is the cerebral cortex, in particular the primary motor cortex, the lateral premotor area, 
and the supplementary motor area.
It appears that the supplementary motor area is concerned with programming sequences of 
movements whereas the premotor area is concerned with the selection of movement plans 
based on external cues. Motor activity is also modified by the cerebellum and basal ganglia.
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Both the cerebellum and the basal ganglia receive input from the cerebral cortex and send 
output to the cortex via the thalamus. The three major differences between the connections of 
the cerebellum and the basal ganglia are:
• the cerebellum receives input only from the sensorimotor parts of the cortex, whereas 
the basal ganglia receive input from the entire cerebral cortex.
• the cerebellum output goes only to the premotor and motor cortex, while the basal ganglia 
also project to the prefrontal association cortex.
• the cerebellum has direct ties with the spinal cord and the brain stem. The basal ganglia 
have little connection to the brainstem, and no direct connections with the spinal cord.
The cerebellum apparently modifies the output of motor systems to bring intention into line with 
performance; it acts as a "comparator". It has been suggested that the cerebellum is a very 
large associative memory. It is thought that the cerebellum regulates motion directly, whereas 
the basal ganglia have to do with the planning and execution of complicated 
motor strategies.
Basal ganglia components and pathways
The neostriatum serves as the input centre for the basal ganglia. The primary input comes 
from the cerebral cortex; there is a secondary input from the thalamus. Specific areas of 
the cortex map to specific parts of the striatum. These associations are maintained in 
projections throughout the basal ganglia.
The globus pallidus is divided into internal and external segments (Figure lib). 
The internal section is one of two main output nuclei of the basal ganglia, along with the 
substantia nigra pars reticulata. The pallidal output is passed by the thalamus primarily to the 
supplementary motor area, and possibly also to the premotor cortex. The supplementary motor 
area is also a major input to the basal ganglia; therefore there is a loop between the 
supplementary motor area and the basal ganglia. As mentioned earlier, it appears that the 
supplementary motor area is involved with planning sequences of movements. The loop 
between the supplementary motor area and the basal ganglia therefore provides a clue to the 
function of the basal ganglia. The external section of the globulus pallidus passes information 
within the basal ganglia, in particular to the subthalamic nucleus (Figure lib).
The subthalamic nucleus takes the output from the motor and premotor cortices, and from the 
external segment of the globus pallidus. The subthalamic nucleus projects to both segments of 
the globus pallidus and to the substantia nigra pars reticulata. 
The substantia nigra, along with the internal globus pallidus, is one of the two major output 
sections of the basal ganglia.
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There are two major pathways through the basal ganglia, arising from different cellular 
populations of the neostriatum. The inhibitory direct pathway projects monosynaptically from 
the putamen to the motor regions of the internal globus pallidus and the substantia nigra 
pars reticulata. The indirect pathway is inhibitory from the putamen to the external globus 
pallidus, inhibitory from there to the subthalamic nucleus, and excitatory to the external globus 
pallidus or substantia nigra pars reticulata. It appears that the net effect of the direct pathway is 
to facilitate motion by exciting the supplementary motor area; the indirect pathway has the 
opposite effect.
In addition (and crucially for Parkinsons' disease), there is a loop from the neostriatum to the 
substantia nigra pars compacta and back to the striatum (Figure lib). The return route is 
mediated by dopamine. Dopamine excites the direct pathway and inhibits the indirect pathway: 
since these two pathways have opposing effects, dopamine tends to facilitate motion. 
In effect, as it will be seen later, the dopamine terminals are in a position to influence 
information coming from cortex into the neostriatum. There are also reciprocal inhibitory 
connections between the internal and external segments of the globus pallidus.
The major output of the basal ganglia, from the internal globus pallidus and 
the substantia nigra pars reticulata, project to three nuclei in the thalamus: the ventral lateral, 
ventral anterior and mediodorsal. These thalamic nuclei in turn project to the prefrontal cortex, 
the premotor cortex, the supplementary motor area, and the motor cortex.
From an input-output analysis, therefore, the basal ganglia do not appear to generate motions 
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Figure lla A coronal section of the cerebral hemispheres shows the basal ganglia in 
















Figure lib All of the basal ganglia are interconnected by topographically organised 
projections. Cells in different parts of the caudate and putamen project to specific areas of the 
globus pallidus and substantia nigra. Thus, because the pathways are all topographically 
organised, specific areas of the cortex act through the neostriatum on specific parts of the 
globus pallidus and substantia nigra. The subthalamic nucleus receives the output of the 
external segment of the globus pallidus and projects to both segments of the globus pallidus 
and the substantia nigra pars reticulata. It also receives inputs from the primary motor and 
premotor cortices (not shown). The neostriatum receives an important dopaminergic projection 
from the substantia nigra pars compacta. The major output pathways of the basal ganglia 
(not shown) arise from the internal segment of the globus pallidus and the substantia nigra 
pars reticulata. These pathways terminate in several nuclei in the thalamus; which in turn 
project to several areas of cortex: the prefrontal cortex, the premotor cortex, the supplementary 
motor area, and the primary motor cortex. (From Kandel et al., 1995)
Diseases of the basal ganglia
As with brain research generally, much of what is known about the basal ganglia comes from 
studying diseases that affect them. This section briefly outlines the range of diseases that are 
caused by damage to the basal ganglia.
Damage to both the basal ganglia and the supplementary motor area are correlated with 
impaired performance on sequential tasks. The "theme" of diseases affecting the basal ganglia 
appears to be that the balance between the two major pathways is disturbed: the result is either 
involuntary movements or impairments to motion.
The impaired motions include: akinesia (lack of movement), bradykinesia (slowness of 
movement) and the shuffling gait of Parkinson's disease. The list of involuntary movements 
includes: tremors (rhythmic, involuntary, oscillatory movements), athetosis
(slow, writhing movements of the fingers and hands, and sometimes of the toes), chorea 
(abrupt movements of the limbs and facial muscles), ballism (violent, flailing movements) and 
dystonia (a persistent posture of a body part which can result in grotesque movements and 









Basal ganglia: the neostriatum
The major diseases of the basal ganglia are:
• Parkinsons' disease is related to a reduction of dopamine in the brain and damage to the 
dopaminergic pathway from the substantia nigra pars compacta to the neostriatum. 
The result is an increased output of the basal ganglia to the thalamus. The major symptoms 
are tremor, rigidity and akinesia.
• Huntingtons' disease is caused by a loss of specific striatal neurons. The result is 
a decreased output of the basal ganglia to the thalamus (as opposed to the increased 
output due to Parkinsons'). As one might expect from their opposing neural behaviour, 
Huntingtons' disease results in hyperkineticity, in opposite to the hypokineticity of 
Parkinsons' disease.
• Ballism is tied to damage to the subthalamic nucleus. It causes severe involuntary 
movements, which tend to slowly diminish.
• Tardive dyskinesia is related to changes in the dopaminergic receptors, 
causing hypersensitivity to dopamine. It causes abnormal involuntary movements, 
particularly of the face and tongue.
The facilitation of catecholamine release, particularly dopamine release, by nAChR is well
documented, especially at the level of the terminal projections in vitro (Wonnacott, 1997;
general introduction in this thesis). In section II, the superfusion technique was used to explore
the following aspects of the nicotinic modulation of dopamine release in rat neostriatum:
1) identification of presynaptic and/or preterminal nAChR subtypes modulating striatal 
dopamine release (this thesis chapters 4 & 5)
2) functional crosstalk between striatal nerve terminals as a consequence of nAChR 
stimulation (this thesis chapter 5), and
3) second messenger mechanisms underlying nicotinic agonist-evoked striatal dopamine 
release (this thesis chapter 6)
89
Chapter 4
4 A heterogeneous population of nAChR on dopaminergic 
nerve terminals directly modulates dopamine release 
in rat striatum
4.1 Introduction
Parkinsonism, as mentioned before, is linked to degeneration and loss of
dopaminergic neurones, particularly those in the pars compacta of the substantia nigra. 
The etiology and mechanisms underlying this pathology are not well understood.
Epidemiological evidence suggests that the incidence of Parkinsons' syndrome is lower in 
tobacco smokers than in non-smokers (Morens et al., 1995), and in animals (-)-nicotine exerts a 
neuroprotective effect on lesions of the nigrostriatal dopamine system (Janson et al., 1986). 
In vitro studies have demonstrated that (-)-nicotine can modulate dopamine (DA) release from 
striatal nerve terminals by acting on nAChR (Rapier et al., 1990; Grady et al., 1992; 
Soliakov et al., 1995). Thus, nAChR represent candidate targets for the development of 
therapeutic agents (Williams et at, 1994; Decker et at, 1994; Holladay et at, 1997).
The modulation of striatal DA release by nAChR is well documented, especially at the level of 
the terminal projections in vitro (Wonnacott, 1997). For example, nicotinic agonists evoke DA 
release from striatal synaptosomes (Rapier et at, 1988; Grady et at, 1992; 
El-Bizri and Clarke, 1994; Kaiser et at, 1998) and slices (Sacaan et at, 1995; 
Kaiser et at, 1998). Nicotine elicits Ca2+-dependent [3H]-DA release from rat striatal 
synaptosomes in a concentration dependant, mecamylamine sensitive and stereospecific
manner (Rapier etal., 1988; El-Bizri and Clarke, 1994; Soliakov et at, 1995), consistent with the
activation of presynaptic nAChR (Wonnacott, 1997). However, the nAChR subtypes responsible 
have not been identified, largely reflecting a lack of subtype-selective pharmacological tools. 
Inhibition by n-Bgt has been interpreted in favour of a3-containing nAChR (Grady et at, 1992), 
while the full (Grady et at, 1992) or reduced but substantial efficacy of cytisine 
(El-Bizri and Clarke, 1994) could implicate the (34 subunit (Luetje and Patrick, 1991). 
On the other hand, nigrostriatal lesions produced a loss of striatal high affinity agonist 
binding sites, consistent with there being a4p2 nAChR on DA terminals (Clarke etal., 1985).
Recently, a novel Conus toxin, a-conotoxin-MII (a-CTx-MII; see Figure 4.1) was described as a 
potent and selective antagonist at a nAChR subtype composed of a3 and p2 subunits 
(Cartier et at, 1996; Harvey et at, 1997). Here, this peptide was exploited to evaluate the 
contribution of the a3p2 subunit combination to the presynaptic modulation of 
striatal DA release. In this study the novel nicotinic agonist UB-165, an anatoxin-a/epibatidine 





1) the partial and differential inhibition by a-CTx-MII of the nicotinic stimulation by 
(±)-anatoxin-a of [3H]-DA release from rat striatal synaptosomes and slices. These findings, 
which corroborate and extend the recent study by Kulak et at. (1997), 
have been published (Kaiseretal., 1998).






Male Sprague-Dawley rats were obtained from the University of Bath Animal House 
breeding colony. [7,8-3H]-dopamine ([3H]-DA - specific activity, 1.78 TBq / mmol) was purchased 
from Amersham International (Amersham, Bucks UK). a-Conotoxin-MII (a-CTx-MII Figure 4.1; 
Cartier et al., 1996; Kaiser et al., 1998) and (±)-UB-165 (Wright et al., 1997) were synthesised 
as previously described. Tetrodotoxin (TTX) was obtained from Tocris Crookson (Bristol, UK). 
(±)-Epibatidine and methyllycaconitine (MI_A) were purchased from RBI 
(Nateck, MA USA). (-)-Cytisine, mecamylamine, pargyline and nomifensine were purchased 
from Sigma (Poole, Dorset UK). All other chemicals used were of analytical grade and obtained 
from standard commercial sources.
4.2.2 a-CTx-MII synthesis
a-CTx-MII was synthesised at the University of Bath with correct disulphide bond formation 
exactly as described by Cartier et al. (1996). The linear peptide was produced using a 
Miligen 9050 peptide synthesiser. Because the peptide has two disulphide bonds (Figure ), 
these were subsequently formed sequentially under controlled conditions, by incorporating 
acid-labile S-trityl cysteine in positions 3 and 16, and acid-stable S-acetamidomethyl cysteine in 
positions 2 and 8, as described (Cartier et al., 1996). The peptide was isolated by solid phase 
extraction (recovery 68%) followed by reverse phase HPLC. The peak corresponding to the 
bicyclic peptide was confirmed by mass spectrometry. The concentration of a-CTx-MII in our 
stock solution was determined by quantitative amino acid analysis.
NH2-GCCSNPVCHLEHSNLC-carboxyamide
Figure 4.1 Amino acid sequence of a-conotoxin-MII. a-CTx-MII is a 16-amino acid peptide 
isolated from the venom of the marine snail Conus magus which potently antagonise 
a3p2-containing nAChR (Cartier et al., 1996; Harvey etal., 1997). The disulfide bond pattern of 
a-CTx-MII is also represented: C3C16 and C2C8. This peptide was synthesised as previously 
described (Cartier et al., 1996) by Sue Phillips and Richard Kinsman (University of Bath). 




4.2.3 Two electrode voltage clamp
The electrophysiological studies in this chapter were performed by Dr S.C. Harvey and 
Dr C.W. Luetje (Department of Molecular and Cellular Pharmacology, University of Miami, 
Miami, FL USA). See Kaiser et al. (1998) for details.
4.2.4 Superfusion experiments
Superfusion experiments involving the use of a-CTx-MII were performed in conjunction with 
Dr Lev Soliakov.
4.2.4.1 Superfusion of P2 striatal synaptosomes and striatal slices for ^HJ-DA release
Male Sprague-Dawley rats (240-250 g) were killed by cervical dislocation, decapitated and 
brain striata (180-240 mg of wet tissue weight / rat) rapidly dissected for the preparation of 
synaptosomes and / or slices. P2 synaptosomes were prepared by differential centrifugation as 
previously described (Soliakov et al., 1995). Synaptosomes were loaded with [3H]-DA 
(0.1 pM, 0.132 MBq / ml) for 15 min at 37°C and superfused in open chambers 
(Soliakov etal., 1995). All superfusion experiments were performed in Krebs bicarbonate buffer 
of the following composition: 118 mM NaCI, 2.4 mM KCI, 2.4 mM CaCI2, 1.2 mM MgS04,
1.2 mM KH2P04, 25 mM NaHC03 and 10 mM glucose, buffered to pH 7.4 with 
95% 0 2 / 5% C02 and supplemented with 1mM ascorbic acid, 8 pM pargyline and 0.5 pM 
nomifensine to prevent DA degradation and DA re-uptake.
Striatal slices (0.25 mm) were prepared as previously described (Marshall et al., 1996) using a 
Mcllwain tissue chopper. In brief, striatal tissue prisms from two rats were washed twice with 
Krebs buffer (same composition as indicated above) and loaded with [3H]-DA 
(0.1 pM, 0.132 MBq / ml) for 15 min at 37°C. After two washes, slices were resuspended in 
Krebs buffer and approximately 45 - 50 mg of slices / chamber were loaded into six closed 
superfusion chambers.
Superfusion of synaptosomes (open chambers) or slices (closed chambers) was performed as 
previously described (Soliakov et al., 1995; Marshall et al., 1996) in a Brandel apparatus using 
Krebs bicarbonate buffer at a flow rate of 0.5 ml / min; 2-min fractions were collected. 
After 30 min washing (20 min with normal buffer and a subsequent 10 min with buffer containing 
a-CTx-MII (1.1-112.0 nM) or 10 pM mecamylamine or no antagonist), (±)-AnTx-a (0.2-25.0 pM), 
(-)-nicotine (0.1-50.0 pM), cytisine (0.005-50.000 pM), UB-165 (0.01-1.00 pM) or 
(±)-epibatidine (0.1 pM) in buffer with or without antagonist was applied for 40 s. 
The pulse of drug was separated from the bulk buffer flow by 10s air bubbles. 
For KCI depolarisation, a 40 s pulse of buffer with KCI increased to 23.5 mM was applied.
Fractions were counted in a TRI-CARB 1500 liquid scintillation counter 
(counting efficiency 48%). Evoked tritium release above baseline was calculated as a 
percentage of the total radioactivity present in the synaptosomes immediately before stimulation 
(Soliakov et al., 1995). To estimate the radioactivity remaining in slices at the end of the
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experiment, superfusion was continued for 30 min with 10 mM HCI, to lyse the slices 
(Marshall et al., 1996). Aliquots (1ml) of the lysates were counted for radioactivity. 
Total radioactivity in slices at the time of stimulation was calculated as the sum of subsequently 
released [3H]-DA plus lysate.
4.2.4.2 Superfusion Data Analysis
The baseline was derived by fitting the following double exponential decay equation to the data, 
using Sigma Plot version 2.0 for Windows:
y = ae^* + ce^
(Equation 4.1)
where a, b, c and d are the curve parameters and x is the fraction number.
Evoked [3H]-DA release was calculated as the area under the peak after subtraction of the 
baseline. Data are represented as percentages of the corresponding controls, assayed in 
parallel in the absence of antagonist, and are mean±S.E.M. of several independent 
experiments, each consisting of two to three replicate chambers for each condition. One way 
ANOVA test was used to determine the significance of differences from control (Sigma Stat - 
Jandel Scientific, Germany).
For comparison between different experiments (Figure 4.3), superfusion profiles were 
normalised as percentages of the fitted baselines.
For analysis of agonist or antagonist dose-dependent relationships, the data 
(after subtraction of non-specific release determined in the presence of 10 pM mecamylamine) 
were fitted to the 4 parameter logistic equation:
y = (a - d) / [ 1 + (x / k)n] + d
(Equation 4.2)
where a is the asymptotic maximum; d is the asymptotic minimum; k is the value at the 




a-CTx-MII was synthesised as previously described (Cartier et al., 1996). Its biological activity 
and specificity were examined by Harvey and Luetje by testing the ability of this synthetic 
peptide to antagonise nicotinic responses of defined rat nAChR subunit combinations 
expressed in Xenopus oocytes (Figure 4.2). ACh concentrations below the EC50 value for each 
of the subunit combinations were used to elicit responses (see Figure 4.2). Brief incubation 
(5 min) of the oocytes with a-CTx-MII inhibited ACh-evoked responses from the a3p2 subunit 
combination with an I C 5 0  of 8.0±1.1nM. The a-CTx-MII concentration that produced complete 
inhibition (112 nM) showed no antagonism of ACh-elicited responses from a4p2, a2p2, and 
a3(34 nAChR subunit combinations (Figure 4.2). Therefore this synthetic peptide has the nAChR 















i°g [ a-Conotoxin-MII] (nM)
Figure 4.2 a-CTx-MII is selective for the rat a3p2 nAChR subunit combination.
a-CTx-MII inhibition of a3p2 (•), a4p2 (■), a2p2 (□) and a3p4 (O) neuronal nicotinic receptors 
expressed in Xenopus oocytes is shown. The response to an ACh concentration below the 
EC50 for each receptor after 5 min incubation with various concentrations of 
a-CTx-MII is presented as a percentage of the pre-incubation ACh response 
(mean±S.D. of 3-4 oocytes). The a3p2 data are fitted to a Hill equation 
(see (Equation 4.1), yielding an I C 5 0  = 8.0±1.1nM; n=1.29.
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To investigate the putative nAChR subtypes involved in the nicotinic modulation of DA release 
in rat striatum, the ability of a-CTx-MII to block this effect was examined. Using superfusion, 
the nicotinic stimulation of [3H]-DA release from striatal synaptosomes and slices were 
compared, as models of presynaptic nAChR on dopamine terminals and of nAChR present in a 
more intact preparation, respectively. (±)-AnTx-a was the agonist of choice based on previous 
studies in the Wonnacott lab (Soliakov et al., 1995; Soliakov and Wonnacott, 1996) in which 
(±)-AnTx-a evoked [3H]-DA release from striatal synaptosomes was characterised and showed it 
to be a potent and efficacious agonist ( E C 5 0  = 0.11 pM Soliakov et al., 1995). 
(±)-AnTx-a (1 pM) evoked a discrete peak of [3H]-DA release over basal release, and this was 
higher in slices than in synaptosomes (Figure). The non-selective nicotinic antagonist 
mecamylamine (10 pM) inhibited (±)-AnTx-a evoked release by 77.9+3.7% (n=12) 
in synaptosomes and 88.0±2.1% (n=5) in slices, respectively. In contrast 112 nM a-CTx-MII 
produced a partial but significant decrease in the mecamylamine-sensitive (±)-AnTx-a evoked 
release: 56.0+5.5% (n=8) inhibition in synaptosomes and 28.4+4.1% (n=8) inhibition in slices, 
respectively (Figure 4.3). a-CTx-MII (112 nM) had no effect on basal release. 
In the presence of a-CTx-MII (112 nM), [3H]-DA release elicited from striatal slices by 
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Figure 4.3 Superfusion profiles of fHJ-DA release from (a) synaptosomes and (b) slices. 
Rat striatal synaptosomes (a) or slices (b) were prepared and superfused as described in Error! 
Unknown switch argument.. Antagonist (112 nM a-CTx-MII, □; 10 pM mecamylamine, ▼) 
was added to the perfusing buffer 10 min prior to stimulation with 1 pM (±)-AnTx-a for 40 s. 
Control responses (• )  were determined in parallel in samples not exposed to antagonist. 
Release is calculated as
a % of mean basal release. Vertical bars indicate the S.E.M. from 5 (slices) or 
6 (synaptosomes) independent experiments, each consisting of two or more replicates. 
(** p<0.01 significantly different from control, one way ANOVA -  Bonferroni t test)
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To examine the inhibition by a-CTx-MII in more detail, dose-response curves were constructed 
for the inhibition of 1^M (±)-AnTx-a evoked [3H]-DA release over a range of a-CTx-MII 
concentrations from 1 nM to 112 nM. The results are expressed as a percentage of 
mecamylamine-sensitive responses determined in parallel (Figure 4.4). The inhibition was 
dose-dependent; synaptosomes and slices gave similar IC50 values (24.3±2.9nM and 
17.3±0.1nM, respectively). In both cases the inhibition was partial and was maximum at 
112 nM aCTx-MII. (±)-AnTx:a-evoked [3H]-DA release from synaptosomes was blocked to a 
greater extent than that from slices.
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Figure 4.4 Dose-dependent inhibition of [*H]-DA release by a-CTx-MII.
Striatal synaptosomes (A) or slices (T) were superfused in the presence or absence of 
increasing concentrations of a-CTx-MII prior to stimulation with 1 p.M (±)-AnTx-a (control) 
for 40 s as described in 4.2.4.1. Evoked [3H]-DA release in the presence of toxin is calculated as 
a % of the mecamylamine-sensitive fraction of the control response in the absence of 
a-CTx-MII. Vertical bars indicate the S.E.M. from 5 (slices) or 6  (synaptosomes) independent 
experiments each consisting of two or more replicates (** p<0 . 0 1  significantly different from 
control, one way ANOVA -  Bonferroni t test). The data are fitted to a 4 parameter logistic 
equation (see 4.2.4.2 (Equation 4.2)), yielding IC50 = 24.3±2.9nM (synaptosomes) and 
IC50 = 17.3±0.1nM (slices).
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The effect of increasing concentrations of peptide (1 nM - 112nM a-CTx-MII) was studied at 
different agonist concentrations (0.2, 1.0 and 25.0 jaM (±)-AnTx-a) in synaptosome preparations 
(Figure 4.5). This experiment was conducted by Dr L.Soliakov in parallel with the other work in 
this chapter and is presented here to provide a more complete picture. 
As the agonist concentration was increased, the dose-response relationship of inhibition by 
a-CTx-MII was shifted to the right (ICso values for a-CTx-MII were: 5.4+0.1nM, 24.3±2.9nM and 
51.5±5.9nM at 0.2, 1.0 and 25.0 ^M (±)-AnTx-a, respectively). However, at each agonist 
concentration the maximum inhibition of mecamylamine-sensitive responses achieved by 
a-CTx-MII was similar (48.2±4.9% (n=3) at 0.2 fiM (±)-AnTx-a, 57.6±5.4% (n=8) at 
1.0 |^ M (±)-AnTx-a, 46.4+3.5% (n=6) at 25.0 i^M (±)-AnTx-a), confirming the partial inhibition 
described above.
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Figure 4.5 Dose-dependent inhibition of ^HJ-DA release from striatal synaptosomes by 
a-CTx-MII with increasing concentrations of (±)-AnTx-a. Striatal synaptosomes were 
superfused in the presence or absence of increasing concentrations of a-CTx-MII ((1) 1.0 nM, 
(2) 5.5 nM, (3) 11.0 nM, (4) 28.0 nM, (5) 56.0 nM, (6) 112.0 nM) prior to stimulation for 40 s with 
(a) 0.2 p.M (±)-AnTx-a; (b) 1.0 fiM (±)-AnTx-a; and (c) 25.0 pM (±)-AnTx-a. Under control 
conditions (C), these concentrations of agonist resulted in the release of 109.3±6.2 fmoles 
[3H]-DA / mg synaptosomal protein, 160.7+9.8 fmoles [3H]-DA / mg synaptosomal protein and 
168.9+7.6 fmoles [3H]-DA / mg synaptosomal protein respectively. Release in the presence of 
a-CTx-MII is presented as a % of control (mecamylamine-sensitive response) at each agonist 
concentration. Vertical bars indicate the S.E.M. from 3 to 8 synaptosome preparations. 
(* p < 0.05, ** p < 0.01 and *** p < 0.001 significantly different from control, 
one way ANOVA -  Bonferroni t test)
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The effect of TTX (1.5 pM) on the a-CTx-MII-sensitive response was also tested. As previously 
reported (Marshall et al., 1996), 1.5 pM TTX partially (~50%) inhibited nicotinic evoked striatal 
DA release from synaptosomes. In this study, when a maximally effective concentration of 
a-CTx-MII (112 nM - see Figure 4.2 and Figure 4.4) was coapplied wit 1.5 pM TTX, 
the inhibition was not significantly different from that produced by each toxin applied alone 
(Figure 4.6).
+ + T T X &  
a-CTx-MII a-CTx-MII
AnTx-a + TTX
Figure 4.6 Effect of TTX on (±)-AnTx-a-evoked ^HJ-DA release from striatal 
synaptosomes. Results are expressed as percentage±S.D. of a control response 
([ H]-DA release evoked by 1 pM (±)-AnTx-a). In the presence of TTX (1.5 pM) 
or a-CTx-MII (112 nM) the response was inhibited by 44.4±5.7% and 44.4±3.0%, respectively 
(n=3). When both toxins were coapplied, the effects were not additive (50.4±11.4% inhibition - 
n=3).
(* p<0.05 significantly different from control, one way ANOVA -  Bonferroni t test).
During the course of this work, the novel agonist UB-165 (Figure 4.7), an anatoxin-a/epibatidine 
hybrid was developed by our collaborator, Professor Gallagher (Wright et al., 1997) and it was 
of interest to examine its agonist properties in the DA release assay. UB-165 was compared 
with (±)-AnTx-a, (-)-cytisine and (-)-nicotine (Figure 4.7) for their abilities to promote [3H]-DA 
release from rat striatal synaptosomes (Figure 4.8). Of these four compounds, (-)-nicotine was 
the most efficacious and least potent, whereas (-)-cytisine and (±)-AnTx-a were similarly potent 
and equiefficacious, generating about 70% of the maximum response achieved by (-)-nicotine. 
Although UB-165 was slightly more potent than (±)-AnTx-a, it was much less efficacious then 







Figure 4.7 Molecular structures of (+)-AnTx-a, (-)-epibatidine, the enantiomer of 
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Figure 4.8 Dose-responses curves for the release of ^HJ-DA evoked by increasing 
concentrations of (-)-nicotine, (±)-AnTx-a, cytisine and UB-165. Each agonist concentration 
was tested in the presence and absence of mecamylamine (10 pM) to determine specific 
nAChR-mediated release. Responses were normalised to the response to 1 pM (±)-AnTx-a 
determined in parallel, and are percentage±S.E.M. (n^3). The rank order of potencies ( E C 5 0 S )  is 





nAChR mediating the presynaptic nicotinic stimulation of [3H]-DA release from striatal terminals 
appear to be heterogeneous, based on the partial inhibition by the a3J32-selective toxin 
a-CTx-MII (Figure 4.4 - Kulak et al., 1997). A maximally effective concentration of this toxin 
(112 nM) was compared with mecamylamine (10 pM) for their abilities to inhibit [3H]-DA release 
evoked by the four agonists above and by (±)-epibatidine (Figure 4.9). Concentrations of the 
agonists giving maximum [3H]-DA release were compared: the results demonstrate the 
differences in efficacy noted above, and show that (±)-epibatidine is the most efficacious, 
eliciting a response that is 200% of that of (±)-AnTx-a. Whereas mecamylamine inhibited 
agonist-evoked [3H]-DA release to the same extent in each case (the residual release being the 
non-specific component that is elicited by a buffer pulse without agonist), a-CTx-MII produced 
different degrees of inhibition. The mecamylamine-sensitive response to (±)-AnTx-a was 
reduced by 56.0% by the toxin, in agreement with the results showed in Figure 4.4, whereas the 
mecamylamine-sensitive [3H]-DA release evoked by (±)-epibatidine, (-)-cytisine and (-)-nicotine 
was inhibited by 47.9%, 45.0% and 32.4%, respectively. However, the response to UB-165 was 
almost completely blocked by a-CTx-MII (87.8% inhibition).











H H  agonist
■hhi + 112 nM a-conotoxin-Mli 
mrnm + 10 pM mecamylamine
epi nicotine AnTx-a cytisine UB-165
Figure 4.9 Comparison of the inhibition by a-conotoxin-MII (112 nM) and mecamylamine 
(10 pM) of ^HJ-DA release-evoked by maximally effective concentrations of agonists.
Striatal synaptosomes were perfused with antagonist for 10 min before stimulation with 
(±)-epibatidine (0.1 pM), (-)-nicotine (10 pM), (±)-AnTx-a (1 pM), (-)-cytisine (50 pM) or 
UB-165 (1 pM). Responses were normalised to the response evoked by 1 pM (±)-AnTx-a 
determined in parallel. Values are expressed as percentage±S.D. of the control response (n=3).
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In this study, the effect of a-CTx-MII on a7-containing nAChR expressed in Xenopus oocytes 
was not tested by Harvey and Luetje. In order to explore a putative contribution of 
MLA-sensitive nAChR to the response evoked by UB-165 in striatal synaptosomes, the effect of 
MLA on UB-165-evoked [3H]-DA release was examined. MLA (50 nM) did not have any effect 
on 1 pM UB-165-evoked [3H]-DA release from striatal synaptosomes (Figure 4.10). 
This result rules out a7-containing nAChR for the UB-165 component of the response.
UB-165 + MLA + a-CTx-M II
Figure 4.10 Effect of MLA (50 nM) on 1 pM UB-165-evoked ^HJ-DA release from striatal 
synaptosomes. Responses are expressed as percentage±S.D. of the 1 pM UB-165-evoked 
response (control - n=3-6). MLA (50 nM) had no significant effect on the response elicited by 
1 pM UB-165 whereas a-CTx-MII (112 nM) inhibited it by 87.8±6.7%.




The ability of nicotinic agonists to stimulate DA release from rat striatal preparations in vitro is 
well documented (Rapier et al., 1988; El-Bizri and Clarke, 1994; Sacaan et al., 1995) but the 
particular nAChR subtypes mediating this effect have not been conclusively identified 
(Wonnacott, 1997; Kulak et al., 1997). Involvement of nAChR comprising a3 nAChR subunits 
was suggested on the basis of sensitivity to n-Bgt in slices (Schulz and Zigmond, 1989) and 
synaptosomes (Grady etal., 1992). In addition receptors that correlate with high affinity agonist 
binding sites comprising a4 and (32 subunits have been implicated by lesion studies 
(Clarke and Pert, 1985).
In this study, a-CTx-MII was exploited as an antagonist selective for the a3p2-interface of rat 
nAChR (Cartier et al., 1996; Harvey et al., 1997) to examine the subtype responsible for the 
nicotinic modulation of striatal [3H]-DA release. To achieve this, the peptide was synthesised 
according to the previously documented method (Cartier et al., 1996). Assessment of 
aCTx-MII on different putative nAChR expressed in Xenopus oocytes showed it to have 
specificity for the a3p2 subunit combination reported previously (Cartier et al., 1996a; 
Harvey et al., 1997). The IC50 (8.0±1.1nM) is approximately 2 fold less potent than found 
previously using the same static bath applied system (IC50 = 3.5 nM; Harvey et al., 1997). 
These values are higher than the IC50 of 0.5 nM reported by Cartier et al. (1996) for rat a3p2 
expressed in Xenopus oocytes, but this probably reflects a difference in the drug application 
technique, namely application of a-CTx-MII by continuous perfusion 
(see Harvey et al., 1997). Despite these discrepancies it is clear that a-CTx-MII specifically 
antagonises responses of nAChR composed of a3 and p2 subunits at concentrations that have 
no effect on other nAChR subunit combinations tested (a4p2, a2p2, a3p4). Therefore this toxin 
could be used to distinguish a3p2-like nAChR from these combinations of nicotinic subunits.
In superfusion experiments (±)-AnTx-a-evoked DA release was sensitive to a-CTx-MII, 
consistent with the participation of a3p2-like nAChR. The IC50 values of 17.3 nM and 24.3 nM 
for slices and synaptosomes respectively (Error! Unknown switch argument.) are higher than 
the IC50 (8.0±1.1nM) found for the a3p2 combination of nAChR subunits expressed in Xenopus 
oocytes. Differences in experimental protocol and agonist concentration (relative to their 
respective EC50 values) provide a likely explanation of these differences in IC5 0 . The EC50 for 
(±)-AnTx-a evoked [3 H]-DA release from striatal synaptosomes was previously determined to be
0.11 pM
(Soliakov et al., 1995), with 1 pM (±)-AnTx-a giving almost maximum responses. 
Using an (±)-AnTx-a concentration closer to the EC50 (0.2 pM), the IC50 (5.4±0.1nM) 
for inhibition by a-CTx-MII in synaptosomes compares very well with the potency of a-CTx-MII 
determined in Xenopus oocytes. The shift of the IC50 values to the right with increasing
103
Chapter 4
concentrations of (±)-AnTx-a indicates that antagonism by a-CTx-MII is surmountable, 
consistent with the competitive mode of action of a-CTx-MII proposed by Cartier et al. (1996b).
Despite the clear antagonism by a-CTx-MII, maximally effective concentrations failed to fully 
inhibit (±)-AnTx-a evoked DA release in synaptosomes and slices compared with the inhibition 
by mecamylamine. This partial blockade of mecamylamine sensitive responses shows that 
more than one nAChR must be involved in nicotinic evoked rat striatal DA release. 
This finding agrees with the recent study of Kulak et al. (1997) who used a more efficacious 
agonist, (-)-nicotine (Figure 4.8), to stimulate [3H]-DA release from striatal synaptosomes. 
In the present study, a-CTx-MII inhibited by 56% the mecamylamine-sensitive 
(±)-AnTx-a-evoked [3H]-DA release from synaptosomes. Although Kulak et al. (1997) found a 
slightly lower inhibition (34%-49%) of (-)-nicotine stimulated [3H]-DA release by a-CTx-MII, 
their results match those reported in this chapter using (±)-AnTx-a. Because synaptosomes 
represent isolated nerve terminals, they provide a model for studying presynaptic receptors. 
Under the conditions of superfusion it can be assumed that only nAChR associated with 
DA terminals can promote [3H]-DA release in the experiments described here. 
The present results indicate that these nAChR are heterogeneous but cannot distinguish 
between multiple receptor subtypes on a single nerve ending (Figure 4.11a1) or segregation of 
nAChR subtypes to different subpopulations of DA terminals (Figure 4.11a2). 
This finding of heterogeneity of presynaptic nAChR subtypes mediating striatal DA release 





Figure 4.11 Schematic representation of nicotinic modulation of DA release based on (a) 
synaptosome studies and (b) slice experiments. In synaptosomes (a) (±)-AnTx-a can directly 
stimulate DA release, acting at presynaptic nAChR. a3p2-like nAChR (x) and aCTx-MII- 




terminals (a2). In more Intact preparations, represented by slices (b), (±)-AnTx-a may indirectly 
enhance DA release via presynaptic nAChR (z: a-CTx-MII-insensitive nAChR) located on 
non-DA terminals, in addition to presynaptic nAChR on DA terminals.
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The tetrodotoxin (TTX) insensitivity of nicotinic agonist-elicited responses has been taken to 
define presynaptic nAChR in integrated preparations, such as brain slices and 
neuronal cultures. TTX sensitivity of nicotinic responses in the absence of nerve conduction has 
been interpreted in favour of a “preterminar location, i.e. on the axon rather than the terminal 
bouton (Lena et al., 1993). However, synaptosome preparations, in which nerve terminals 
should constitute the only functional elements, have given controversial results with various 
degrees of TTX sensitivity of nicotinic agonist-stimulated 86Rb+ efflux or dopamine release 
(e.g. Marks et al., 1995; Soliakov et al., 1995). In accordance with a previous report from 
this lab (Marshall et al., 1996), this study suggest that at least two populations of presynaptic 
nAChR (TTX-sensitive and TTX-insensitive) participate in nicotinic-evoked DA release from 
rat striatal synaptosomes (Figure ). The nAChR that elicit TTX-insensitive release may be 
located close to the exocytotic machinery such that their activation produces sufficient 
Na+ and / or Ca2+ influx to trigger release directly. Alternatively, the partial TTX-sensitivity 
observed in several studies (including this thesis) could suggest that nAChR segregate onto 
e.g. two types of nerve terminals, one expressing fewer voltage operated Na+ channels 
(TTX-insensitive component of the response) than the other (TTX-sensitive component). 
In this chapter, it has been shown that the effects of maximally effective concentrations of TTX 
and a-CTx-MII on (±)-AnTx-a-evoked DA release from synaptosomes, were similar and not 
additive (Figure 4.6). This provokes the speculation that:
1. a-CTX-MII-sensitive nAChR may occur at some distance from the release sites, requiring 
the intervention of voltage operated Na+ channels in order to elicit release, whereas 
the a-CTx-MII-insensitive nAChR may reside close to the release sites; or
2. a-CTX-MII-sensitive and a-CTx-MII-insensitive nAChR are segregated onto two different 
populations of nerve terminals (Figure 4.11a2) expressing different densities of 
voltage operated Na+ channels.
However, the TTX-sensitivity of the response to activation of these nAChR may also depend 
upon various factors (such as the resting potential of the nerve terminals) which may contribute 
to the reports of variable TTX sensitivity.
Nicotinic agonists evoke dopamine release with different potencies and efficacies 
(Figure 4.8 - see Holladay et al., 1997). In this study the natural and stereoselective alkaloid 
AnTx-a was used as the nicotinic agonist of reference. (±)-AnTx-a evokes DA release from rat 
striatal synaptosomes in a dose dependent-manner with an EC50 of 134 nM (Figure 4.8) 
in agreement with previous observations ( E C 5 0  = 110 nM - Soliakov et al., 1995). 
As the nicotinic agonist activity resides mainly in the (+) enantiomer of AnTx-a, the true E C 5 0  
may be overestimated by a factor of 2. In this respect, Wonnacott et al. (1995) and 
Clarke and Reuben (1996) reported an E C 5 0  value of 0.05 pM for (+)-AnTx-a-evoked [3H]-DA 
release from rat striatal synaptosomes. (±)-AnTx-a is more potent than (-)-nicotine in evoking 
[3H]-DA release from rat striatal synaptosomes: E C 5 0  values for (-)-nicotine range from 3.8 pM 
(Rapier et al., 1988) to 0.16 pM (Clarke and Reuben, 1996). Grady et al., (1992) reported an 
EC50 value of 0.48 pM for nicotine-evoked [3H]-DA release from mouse striatal synaptosomes.
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The EC50 obtained in the present study for (-)-nicotine-evoked DA release from rat 
synaptosomes (1.60±0.38pM) is in good agreement with these previously published data. 
In this work (±)-AnTx-a and (-)-cytisine have been shown to be equipotent and equiefficacious 
(Figure 4.8), but the efficacies of (±)-AnTx-a and (-)-cytisine are clearly lower than that of 
(-)-nicotine (~70%). A previous study by Wonnacott et al. (1995) showed that (+)-AnTx-a 
attained only 54% of the maximum [3H]-DA release from rat striatal synaptosomes elicited by 
(-)-nicotine (EC50 =1. 1 pM), whereas Clarke and Reuben (1996) reported for the same 
preparation that (+)-AnTx-a maximal effects were similar to those of (-)-nicotine. 
(±)-Epibatidine has been shown to potently (EC50 *  0.4 nM - Sullivan et al., 1994) evoke 
DA release from rat striatal slices (also Sacaan et al., 1996). Consistent with Sullivan et al. 
(1994), it has been demonstrated in this chapter that (±)-epibatidine is the most efficacious of 
the nicotinic agonists used (Error! Unknown switch argument.) in eliciting DA release from rat 
striatal synaptosomes.
In this study the novel nicotinic agonist UB-165 (Error! Unknown switch argument. - Wright et 
al., 1997) was also characterised for [3H]-DA release from rat striatal synaptosomes. It only 
elicited ~40% of the maximum release evoked by 1 pM (±)-AnTx-a. This partial agonism of UB- 
165 was almost completely blocked by a-CTx-MII (112 nM) but unaffected by MLA (50 nM), 
suggesting that
UB-165 only activates a3|32-containing nAChR on striatal DAergic nerve terminals 
(Figure 4.10).
Insight into the possible subunit composition of nAChR can be sought from pharmacological 
studies on the one hand and from approaches such as In situ hybridisation and 
immunoprecipitation on the other. Although a-CTx-MII sensitivity implicates a3p2-like nAChR, 
there is little pharmacological information on other subtypes that might also participate because 
of the lack of tools to discriminate nAChR subtypes. The a4p2 nAChR is a candidate for the 
a-CTx-MII insensitive presynaptic nAChR, based on evidence for [3H]-nicotine binding sites on 
dopaminergic terminals from lesion studies (Clarke and Pert, 1985). The partial agonism of 
(-)-cytisine at rat p2-containing nAChR expressed in Xenopus oocytes 
(Luetje and Patrick, 1991) has been used to attempt to define native a4p2 nAChR, although 
partial versus full agonism by (-)-cytisine only distinguishes p2 from p4 subunits. 
The ability of (-)-cytisine to release [3H]-DA from striatal synaptosomes has been inconsistent. 
(-)-Cytisine has been reported to be a full agonist with respect to [3H]-DA release from 
mouse striatum (EC50 = 483 nM - Grady et al., 1992) but was less efficacious than (-)-nicotine in 
rat studies (El-Bizri and Clarke, 1994 EC50 » 0.1 pM; Wonnacott et al., 1995 EC50 « 0.1 pM; 
this study EC50 « 0.08 pM), so species differences in nAChR properties or composition may be 
important. The almost total lack of response to (-)-cytisine predicted for p2-containing nAChR 
from oocyte experiments (Luetje and Patrick, 1991) has not been observed, although 
heterogeneity of nAChR subtypes mediating [3H]-DA release could mask such differences.
107
Chapter 4
However, p4 mRNA has not been detected in these DA neurones (see LeNovere et al., 1996; 
Wonnacott, 1997).
For in situ hybridisation results pertinent to presynaptic nAChR on striatal dopamine terminals it 
is necessary to examine mRNA expression in the brain region containing the cell bodies, 
namely the substantia nigra pars compacta. In the rat this region expresses a3, a4, a5, a6, |32 
and (33 mRNAs, but a2 and p4 mRNAs were not detected (see LeNovere et al., 1996; 
Wonnacott, 1997). This pattern is compatible with a3p2 and a4p2 nAChR subunit combinations 
but clearly additional subunits could also contribute to form native receptors 
(and could influence the efficacy of (-)-cytisine, discussed above). In particular, high expression 
of a6 and p3 mRNA in catecholaminergic nuclei, including substantia nigra, has been noted 
(LeNovere et al., 1996). Recent immunohistochemical studies (Goeldner et al., 1997) 
demonstrated that the a6 nAChR protein is present on dopaminergic neurones of the midbrain 
(i.e. substantia nigra and ventral tegmental area).
Although a-CTx-MII specifically inhibits the a3p2 subunit combination expressed in Xenopus 
oocytes it should only be assumed to recognise the interface between a3 and p2 subunits 
(Harvey et al., 1997; Kulak et al., 1997). Indeed only one a3p2 pair of subunits may be sufficient 
for a-CTx-MII sensitivity (Kulak et al., 1997). Therefore the presence of additional subunits in 
the pentamer cannot be excluded. There is precedent for neuronal nAChR composed of three 
or even four different types of subunits, including a5 (e.g. Conroy and Berg, 1995; see 2.1.1.1 
and 2 .1 .1 .2 ).
Striatal slices showed lower inhibition by a- CTx-MII of (±)-AnTx-a evoked [3H]-DA. 
The IC50 value for a-CTx-MII (17.3±0.1nM) in striatal slices is very similar to that found in 
synaptosomes (24.3 ± 2.9 nM) at the same agonist concentration, suggesting that a-CTx-MII is 
interacting with the same class of nAChR in both preparations. As slices are more intact striatal 
preparations, the lower inhibition by a-CTx-MII might reflect additional nAChR 
(which are a-CTx-MII insensitive) on non-dopaminergic terminals, whose activation may 
indirectly enhance DA release (Figure 4.11b). For example local application of (-)-nicotine 
in vivo has been shown to release L-glutamate in the rat striatum (Toth et al., 1993) and 
L-glutamate can stimulate DA release from striatal slices (Roberts and Anderson, 1979) and 
synaptosomes (Ch6 ramy et al., 1996). In chapter 5, the putative indirect nicotinic stimulation of 
striatal DA release via an increase in glutamate efflux will be examined.
This study has shown a) that a-CTx-MII partially and differentially blocks (±)-AnTx-a evoked 
[3H]-DA release from striatal synaptosomes and slices, and b) that UB-165 selectively activates 
a-CTx-MII-sensitive nAChR on DAergic nerve terminals. From these results it can be 
concluded: 1) at least two populations of presynaptic nAChR (a-CTx-MII sensitive and 
a-CTx-MII insensitive) are involved in the direct modulation of DA release from rat striatal 
dopaminergic terminals; 2) the presynaptic a-CTx-MII sensitive nAChR comprises
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ot3 and (32 nAChR subunits but additional subunits cannot be excluded; 
3) in slices, nAChR on non-dopaminergic terminals may enhance DA release by releasing other 
neurotransmitters that in turn act on DAergic terminals; and 4) a-CTx-MII sensitive nAChR are 
not involved, or play a minimum role, in this indirect effect.
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5 Indirect nicotinic modulation of dopamine release in 
rat striatum by (±)-anatoxin-a-evoked glutamate release
5.1 Introduction
The interaction between brain neurotransmitters has been the focus of recent research 
(e.g. Di Chiara et al. 1994; Cheramy et al., 1996; Garcia-Munoz et a/., 1996). In particular, 
the cross-talk between glutamatatergic (Glu) and cholinergic (ACh) with dopaminergic (DA) 
brain pathways have received much attention because of their implication in aging 
(Exposito et al., 1995; Porras and Mora; 1995), in neurodegenerative disorders such as 
Parkinsons' disease and schizophrenia (Carlsson and Carlsson; 1990), as well as in 
drug addiction (tobacco consumption - Dani and Heinemann; 1996).
One of the most studied brain regions, in relation to neurotransmitter interactions, is the 
neostriatum (Carlsson and Carlsson, 1990; Di Chiara et al., 1994; Lannes and Micheletti, 1994; 
Porras and Mora, 1994); due, in part at least, to the present knowledge of its connectivity and 




Figure 5.1 Diagram of the major afferent and efferent pathways and cholinergic 
interneurones in the striatum (St). Glutamatergic inputs from cortex (Cx) and thalamus (Th), 
dopaminergic inputs from the substantia nigra pars compacta (SNc), and 5-HT inputs from the 
dorsal raphe nuclei (DR), synapse with the major efferent neurones, the GABAergic 
medium-sized spiny cells that project to the external segment of the globus pallidus 
(GPe - globus pallidus in non-primates), internal segment of the globus pallidus 
(GPi-entopeduncular nucleus in non-primates) and substantia nigra pars reticulata (SNr).
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5.1.1 Anatomy of striatal DA-Glu interactions
The striatum regulates the activity of the GABAergic projection neurones of the substantia nigra 
pars reticulata (SNr) via two main functional opposing pathways, the direct and the indirect 
pathways (Figure 5.2 - Albin et al., 1989; Alexander and Crutcher; 1990; Smith et al., 1998). 
The former is represented by the striatonigral GABAergic projection and monosynaptically 
inhibits the nigrothalamic GABA pathway, leading to a thalamic disinhibition of the glutamatergic 
drive to the cortex and therefore leading to movement initiation, whereas the latter 
encompasses a trisynaptic link including 1) a GABAergic projection from the striatum to the 
external segment of the globus pallidus (GPe), 2) a GABAergic projection from the GPe to the 
subthalamic nucleus (STN), and 3) a glutamatergic projection from the STN to the SNr, which 
also innervates the GPe. Activation of the striatopallidal "link" in the indirect pathway is 
associated with an increase in STN glutamatergic input to the SNr and GP, and this results in 
changes in both thalamic activity and locomotor behaviour opposite to those elicited by 
activation of the direct pathway (Albin et al., 1989; Alexander and Crutcher, 1990; 
Smith etal., 1998).
The striatum receives dopaminergic input from the SNc (Figure 5.1 and Figure 5.2) and the 
main neostriatal targets of these projections are the GABAergic medium-sized spiny neurones 
(Freund et al., 1984; Yung et al., 1996) that innervate the SNr and the GP (Figure 5.2). 
It has been proposed that degeneration of the nigrostriatal dopaminergic pathway 
(e.g. in Parkinsons' disease) may differentially affect the two striatal GABAergic projections 
described above (Ingham et al., 1998). Such a potential imbalance of activity in these two 
pathways is thought to be critical in generating the hyperkinesias or hypokinesias observed in 
basal ganglia disorders (Albin et al., 1989; Alexander and Crutcher, 1990; De Long, 1990). 
Another main source of synaptic input to dendritic spines in the neostriatum is excitatory and is 
derived from cortex and thalamus (Figure 5.1 and Figure 5.2). In contrast to dopaminergic 
axons that form predominantly symmetric synapses on the necks of dendritic spines 
(Freund et al., 1984; Groves et al., 1994), the glutamatergic synaptic contacts are on the heads 
of spines, and exhibit asymmetric membrane specialisations (Somogyi et al., 1981; 
Meshul and Casey, 1989; Chen and Hillman, 1990). Moreover, a proportion of cortical and 
nigral inputs converge on the same spines of medium spiny neurones (Bouyer et al., 1984; 
Freund etal., 1984; Smith etal., 1994; Groves etal., 1994; Kung etal., 1998), suggesting that a 
major function of dopaminergic inputs to the striatum is the regulation of the glutamatergic 
corticostriatal pathway, or viceversa. Although the dopaminergic and glutamatergic striatal 
afferents form synapses in close proximity onto the dendritic spine, no direct synaptic 
connections between them have been shown (Bouyer et al., 1984). Thus, endogenous 
neurotransmitters released into the extracellular space may diffuse short distances to reach 
appropriate presynaptic receptors and establish nonsynaptic (volumetric) interactions 
(Fuxe and Agnati, 1991; Lannes and Micheletti, 1994). A recent report by Scanziani et al. 
(1997), indicating that Glu released from synapses diffuses to perisynaptic zones to act on Glu 









Figure 5.2 Simplified schematic representation of the basal ganglia-thalamocortical 
neuronal circuitry. Inhibitory projections are shown as black arrows, excitatory projections as 
blue arrows. According to this model, cortical information that reaches the striatum is conveyed 
to the basal output structures (GPi / SNr) via two pathways: a direct inhibitory projection from 
the striatum to the GPi / SNr and an indirect pathway, which involves an inhibitory projection 
from the striatum to the GPe, an inhibitory projection from the GPe to the STN and an excitatory 
projection from the STN to the GPi / SNr. The information is then transmitted back to the cortex 
via a relay in the thalamus or conveyed to various brain stem structures. 
The direct and indirect pathways largely arise from different populations of striatal medium-sized 
spiny neurones that contain different peptides and preferentially express different subclasses of 
dopamine receptors. The dopaminergic neurones of the substantia nigra pars compacts exert a 
net excitatory effect on spiny neurones giving rise to the direct pathway by the activation of 
Di receptors, whereas they exert a net inhibitory effect on spiny neurones giving rise to the 
indirect pathway by activation of D2 receptors. GPe, external segment of the globus pallidus; 
GPi, internal segment of the globus pallidus; SNr, substantia nigra pars reticulata; 
SNc, substantia nigra pars compacts', STN, subthalamic nucleus; St, striatum; Th, thalamus; 
Cx, motor cortex. It should be noted that the diagram is a simplification, as many connections 
have not been indicated (Modified from Smith et al., 1998).
5.1.2 Functional striatal DA-Glu cross-talk and nAChR
In striatum, in vivo infusion via a microdialysis probe of either NMDA (Keefe et al., 1992; 
Morari et al., 1993; Kendrick et al., 1996) or AMPA (Kendrick et al., 1996; 
Smolders et al., 1996), increases the release of DA in this brain area. Using the same in vivo 
approach, local application of NMDA antagonists to the terminal regions of the mesolimbic 
(Museo and Pert, 1994) and nigrostriatal (Toth et al., 1992) pathways markedly decreased the 
ability of locally applied nicotine to elicit DA release in vivo. Furthermore, locally applied
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(-)-nicotine has been shown to increase levels of excitatory amino acids in the striatum and 
frontal cortex, predominantly glutamate (Toth et al., 1993), and this effect was
t
mecamylamine-sensitive. Thus, it has been proposed that (-)-nicotine can act at presynaptic 
nAChR on glutamatergic nerve terminals to release glutamate, which in turn stimulates the 
release of dopamine via presynaptic glutamate receptors on DA neurones, a conclusion 
consistent with recent electrophysiological recordings from striatum in situ 
(Garcia-Munoz et al., 1996). A similar interaction between glutamate and dopamine is 
suggested in the frontal cortex (Jedema and Moghaddam, 1996).
In vitro, as long ago as 1979, glutamate was reported to stimulate [3H]-DA release from 
rat striatal slices (Roberts and Anderson, 1979), interpreted as a reflection of presynaptic 
glutamate receptors on DAergic nerve terminals. This notion has been reinforced in subsequent 
studies, with evidence for the presence of both AMPA/kainate and NMDA receptors 
(e.g. Wang etal., 1991; Desce etal., 1992). Activation of AMPA/kainate receptors could relieve 
the physiological Mg2* block of the NMDA receptors. In striatal synaptosomes, it has recently 
been proposed that ACh or (-)-nicotine, acting at presynaptic nAChR on DA terminals, can also 
relieve the Mg2+ block of the NMDA receptors, having a synergistic effect with NMDA itself 
(Cheramy et al., 1996). The potential importance of presynaptic nAChR in modulating glutamate 
release was recently highlighted in electrophysiological studies (see chapter 2 : 
e.g. McGehee et al., 1995; Gray et al., 1996). These studies are of considerable importance 
because it has been reported (Hunter et al., 1994) that the highly Ca2+ permeable a7 nAChR 
may function in synapse formation and stabilisation i.e. a phenomena akin to LTP 
(long term potentiation) which could be pertinent to learnt behaviours underlying 
the addiction process. Clearly, a thorough examination of nicotine-evoked glutamate release in 
the striatum is timely and pertinent.
In the previous chapter it has been demonstrated that nAChR on DAergic nerve terminals are 
heterogeneous and those containing a302 subunits have been identified (Kulak et al., 1997; 
Kaiser et al., 1998). Although the IC50 value for a-CTx-MII in striatal slices was very similar to 
that found in synaptosomes at the same agonist concentration, striatal slices showed lower 
inhibition by a-CTx-MII of (±)-AnTx-a evoked [3H]-DA (Error! Unknown switch argument.). As 
slices are more intact striatal preparations, the lower inhibition by a-CTx-MII might reflect 
additional nAChR (which are
a-CTx-MII- insensitive) on non-dopaminergic terminals, whose activation may indirectly 
enhance DA release. The main objectives of the present study were:
1 ) to investigate in the striatum a possible indirect enhancement of nicotinic agonist-evoked 
DA release, via activation of nAChR on glutamatergic nerve terminals; and
2) to pharmacologically characterise the nAChR subtype/s involved.
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Using the superfusion technique, the effects of nicotinic- and glutamate-related compounds on 
evoked striatal DA release, were addressed. Synaptosome preparations allow the study of 
ligand gated ion channels on dopaminergic nerve terminals and their functional cross-talk. 
However, studies performed on slices, a more intact preparation, provide evidence for functional 
interactions between striatal dopaminergic and glutamatergic nerve terminals as a consequence 





The following drugs were used in this study: 6,7-dinitroquinoxaline-2,3-dione (DNQX), 
kynurenic acid (KYNA - Tocris Crookson - Bristol, UK), a-conotoxin-lml (a-CTx-lml - 
Calbiochem - San Diego, CA USA), 4-amino pyridine (4-AP - RBI Natick, MA USA), L-glycine, 
N-methyl-D-aspartate (NMDA), strychnine (Sigma - Poole, Dorset U.K). All other chemicals 
used were of analytical grade and obtained from standard commercial sources.
5.2.2 Superfusion technique
P2 synaptosomes and slices (0.25 mm) were prepared from the striata of male Sprague-Dawley 
rats (250-280 g - University of Bath Animal House breeding colony), loaded with [3 H]-DA and 
perfused as previously described (Marshall et al., 1996 - see 4.2.4.1) with
Krebs bicarbonate buffer.
In brief, samples (synaptosomes or slices) were washed for 20 min with Krebs bicarbonate 
buffer and a further 10 min with nonmal buffer or buffer containing antagonist (112 nM a-Ctx-MII, 
1 pM a-Ctx-lml, 50 nM MI_A, 10 pM mecamylamine, 500 pM KYNA, 100 pM DNQX). 
The pre-incubation time for a-Bgt (40 nM) was 1 h at 37°C. Then, the nicotinic agonists: 
(-)-nicotine or (±)-AnTx-a; or a non-specific chemical stimulus (KCI or 4-AP) was applied for 40s. 
Two min (0.5 ml / min) fractions were collected and counted for radioactivity.
Superfusion data analysis (see also 4.2.4.2)
The baseline was derived by fitting a double exponential decay equation (equation 4.1) 
to the data using Sigma Plot for Windows (Jandel Scientific, Germany). Evoked [3H]-DA release 
was calculated as the area under the peak after subtraction of the baseline. 
Data are represented as percentages of the corresponding controls, assayed in parallel in the 
absence of antagonist, and are mean±S.D. of several independent experiments, each 
consisting of two to three replicate chambers for each condition. The one way ANOVA test was 
used to determine the significance of differences from control (Sigma Stat - Jandel Scientific).
For analysis of the (±)-AnTx-a dose-response curve in striatal slices, the data were fitted to the 
2 -sites model equation:
y = {a / [1 + (k1 / x) n1]> + (b / [1 + ( k2 / x)"2 ]}
(Equation 5.1)
where a & b are the asymptotic maximums; k1 & k2 are the values at the inflection points 




5.3.1 Permissive effect of (-)-nicotine for the NMDA-evoked release of 
[*H]-DA from striatal slices
To evaluate the possible cross-talk between iGluR and nAChR on striatal dopaminergic nerve 
terminals, studies involving the application of NMDA and (-)-nicotine (applied alone or together) 
were performed. [3H]-DA release from striatal slices was monitored using the superfusion 
technique. Initial studies were carried out in the presence and absence of the NMDA-R 
coagonist L-glycine (Gly, 1pM). Slices were perfused with Krebs buffer containing 
1 pM strychnine to avoid any effect of glycine on glycine receptors (Gly-R). (-)-Nicotine (10 pM) 
stimulated the release of [3H]-DA from rat striatal slices (Figure 5.3). Basal release was defined 
as the non-specific 10 pM (-)-nicotine-evoked response in the presence of
10 pM mecamylamine, a non-competitive nAChR blocker (Figure 5.3). In the absence of added 
L-glycine (Figure 5.3 left panel), 1 mM NMDA had no significant effect (17.9±3.2% - n=4) on 
basal (27.3±15.1% - n=4) or 10 pM (-)-nicotine-evoked [3H]-DA release (106.9±17.9% - n=4). 
However, [3H]-DA release from slices was significantly increased by 52.3±7.4% (n=4) following 
application of (-)-nicotine (10 pM) and NMDA (1 mM) in the presence of 1 pM L-glycine 
(Figure 5.3 right panel). NMDA (1 mM) plus L-glycine (1 pM) in the absence of (-)-nicotine 
(16.1 ±3.0% - n=4) still had no significant effect on basal release (25.4±8.0% - n=4).
In summary, presumably because of the Mg2+-blockade of NMDA-receptors, NMDA alone 
(either in the presence or absence of added L-glycine) was without effect on [3H]-DA release. 
However, (-)-nicotine exerted a "permissive effect" on the NMDA-evoked [3H]-DA release, 
only in the presence of L-glycine. These results confirm previous observations by Desce et al. 
(1992) and Ch§ramy etal. (1996).
To correctly interpret the results it is necessary to consider the effect L-glycine and Mg2+ on the 
evoked responses. Ch6ramy et al. (1996) reported that NMDA-evoked release 
(in the absence of Mg2+) was progressively reduced in the presence of increasing 
concentrations of Mg2+, complete blockade being observed with 0.28 mM Mg2+. In contrast, 
the marked stimulation of [3H]-DA release induced by the combined application of NMDA and 
ACh (in the presence of L-glycine and absence of Mg2+) was almost insensitive to increasing 
concentrations of Mg2+. The response was not affected by the physiological concentration of 
Mg2+ (0.83 mM) and was only slightly reduced at a much higher concentration (7.48 mM) 
(Cheramy et al., 1996). In this study, bearing in mind these previous data, a concentration of 
Mg2+ (1.2 mM) in the physiological range was used.
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The system was also tested for a possible antagonistic effect of strychnine (1 pM) on nAChR. 
The effect of the Gly-R antagonist on 10 pM (-)-nicotine-evoked [3H]-DA release was assessed 
in slices. In Krebs buffer without strychnine, [3H]-DA-evoked by 10 pM (-)-nicotine represented 
105.3%±7.4% (n=4) of control (10 pM (-)-nicotine-evoked response in buffer containing 
1 pM strychnine). The difference was not significant (p>0.05 - one way ANOVA). 
In the following experiments, neither L-glycine nor strychnine was added to the 
Krebs bicarbonate buffer.
without glycine with glycine
8 100 -
Nic Nic NMDA NMDA 
+ mec + Nic
Nic Nic NMDA NMDA 
+ mec + Nic
Figure 5.3 NMDA evokes ^HJ-DA release from rat striatal slices when coapplied with 
(-)-nicotine and L-glycine. Tissue prisms were continuously perfused with Krebs buffer 
containing strychnine (1 pM) to block striatal Gly-R. Basal release was defined as the 
non-specific 10 pM (-)-nicotine-evoked response in the presence of 10 jjM mecamylamine. 
Responses are expressed as mean percentages±S.D. of control ([ H]-DA-released by 
10 pM (-)-nicotine). In the absence of added L-glycine (left panel), 1 mM NMDA had no 
significant effect on basal or 10 pM (-)-nicotine-evoked [ H]-DA release. However, [3H]-DA 
release from slices was significantly increased (~53%) following application of (-)-nicotine 
(10 pM) and NMDA (1 mM) in the presence of 1 pM L-glycine (right panel). NMDA (1 mM) plus 
L-glycine (1 pM) in the absence of (-)-nicotine still had no significant effect on basal release.
(* p<0.05 significantly different from control, one way ANOVA -  Bonferroni t test)
5.3.2 lonotropic glutam ate receptor antagonists inh ib it DA release from  
rat striatal slices
Further experiments were designed to establish the possible involvement of endogenous 
glutamate in the modulation of striatal DA release by presynaptic nAChR. Initially, the effect of 
the non-specific iGluR antagonist kynurenic acid (KYNA) on evoked striatal [3H]-DA release 
from slices was examined. Addition of KYNA (500 pM and 800 pM) to the superfusion buffer 
caused a small but significant reduction of the [3H]-DA released by KCI and 4-AP
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(Figure 5.4 a & b). KYNA (500pM) inhibited 23.5 mM KCI- and 1 mM 4-AP-evoked DA release 
(controls) by 21.0±3.1% and 23.0±6.0% (n=3), respectively. A higher KYNA concentration 
(800 pM) did not increase the inhibition (18.0±5.0% and 21.0±4.0% (n=3) of the responses 
evoked by 23.5 mM KCI and 1 mM 4-AP, respectively. These results would suggest that 
L-glutamate, released by general depolarising agents, indirectly enhances DA release from 
striatal dopaminergic nerve terminals.
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Figure 5.4 Effect of KYNA (500 pM and 800 pM) on (a) KCI-(23.5 mM) and (b) 4-AP-(1 mM) 
evoked ^HJ-DA release from rat striatal slices. Responses are expressed as 
mean percentages±S.D. of either 23.5 mM KCI- or 1 mM 4-AP-evoked [3H]-DA-release 
(controls). KYNA (500pM) significantly inhibited 23.5 mM KCI- and 1 mM 4-AP-evoked 
DA release. A higher KYNA concentration (800 pM) did not increase the inhibition observed in 
the presence of 500 pM KYNA.
(* p<0.05 significantly different from control, one way ANOVA -  Bonfenroni t test)
In slices, KYNA (500 pM and 800 pM) also decreased the evoked response when, 
instead of depolarising agents, the nAChR agonist (±)-AnTx-a (1 pM) was used to elicit [3H]-DA 
release (Figure 5.5 left panel). In slices, 500 and 800 pM KYNA inhibited 1 pM (±)-AnTx-a- 
evoked [3H]-DA release (control) by 18.0±5.0% (n=4) and 18.0±2.0% (n=4), respectively. 
The effect of KYNA (500 pM and 800 pM) on 1 pM (±)-AnTx-a-evoked DA release was also 
studied in striatal synaptosomes (Figure 5.5 right panel). This set of experiments was designed 
to detect any possible non-specific effect of KYNA on nAChR. In synaptosomes, 
1 pM (±)-AnTx-a-evoked DA release in the presence of 500 pM and 800 pM KYNA represented 
98.0±2.0% (n=4) and 96.0±7.0% (n=4) of control (1 pM (±)-AnTx-a-evoked response in 
the absence of KYNA), respectively. Neither KYNA concentration (500 pM and 800 pM) had any 
significant effect on (±)-AnTx-a-evoked [3H]-DA release from the nerve terminal preparation. 
These results would suggest that (±)-AnTx-a evokes DA release in striatum directly by acting on 
DA nerve terminals and indirectly by evoking the release of glutamate, than in turn acts on 
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Figure 5.5 Effect of KYNA (500 pM and 800 pM) on 1 pM (±)-AnTx-a-evoked 
^HJ-DA release from rat striatal slices and synaptosomes. Responses are expressed as 
mean percentages±S.D. of 1 pM (±)-AnTx-a-evoked [ H]-DA-release. In slices, 500 and 800 pM 
KYNA inhibited (±)-AnTx-a-evoked [3H]-DA release. However, at these concentrations, KYNA 
had no significant non-specific effects on nAChR when tested in synaptosomes.
(* p<0.05 significantly different from control, one way ANOVA -  Bonferroni t test)
The (±)-AnTx-a concentration (1 pM) used in the above experiments was chosen bearing in 
mind the dose-response curve for (±)-AnTx-a-evoked DA release in striatal synaptosomes 
(EC50 = 134±26nM -  Figure 4.8). To compare the potency of (±)-AnTx-a in evoking [3H]-DA 
release from striatal slices, a dose-response curve was constructed. Unexpectedly, it had a 
reproducible and distinct biphasic overall shape with apparent EC50 values of 241.8±36.1nM 
and 5.1±0.3pM (n=8-26 -  Figure 5.6).
As already stated, 500 pM KYNA had a small but significant effect on [3H]-DA release from 
slices evoked by 1 pM (±)-AnTx-a (Figure 5.5 left panel). Testing 500 pM KYNA against higher 
concentrations of (±)-AnTx-a showed that the second phase of the dose-response curve was 
almost completely abolished in the presence of this antagonist (Figure 5.6), whereas 
mecamylamine (10 pM) decreased evoked release to -20% of control across the entire 
dose-response curve. KYNA (500 pM) inhibited mecamylamine-sensitive responses to 






8 f  150 
8 125
5? 1 0 0
* *




log [ (±)-AnTx-a ] (pM)
Figure 5.6 Dose-response curve for (l)-AnTx-a-evoked ^HJ-DA release from rat striatal 
slices. In slices, the dose-response curve for (±)-AnTx-a-evoked [3H]-DA release was biphasic 
with apparent EC50 values of 241.8±36.1nM and 5.1±0.3pM (n=8-26). All the responses are 
expressed as mean percentages ± S.D. of the response evoked by 1 pM (±)-AnTx-a (control). 
KYNA (500 pM) almost abolished the second phase of the dose-response curve, whereas 
mecamylamine (10 pM) decreased evoked release to ~20% of control across the entire 
dose-response curve. Data were fitted to a 2-sites model using equation 5.1.
(** p<0.01 significantly different from 1 pM, 10 pM and 25 pM (±)-AnTx-a-evoked responses in 
the absence of KYNA, one way ANOVA -  Dunnett test)
5.3.3 iGluR involved in [3H]-DA release from striatal slices
In addition to KYNA, the non-NMDA-R antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX), 
was also examined on responses elicited by 25 pM (±)-AnTx-a. In slices, DNQX (100 pM) 
inhibited 25 pM (±)-AnTx-a-evoked [3H]-DA release by 42.6±8.0% (n=5 -  Figure 5.7 right panel). 
The magnitude of this inhibition was similar to that seen, under the same experimental 
conditions, with 500 pM KYNA (Figure 5.7 right panel). However, when KYNA (500 pM) and 
DNQX (100pM) were coapplied, they decreased mecamylamine-sensitive 25 pM (±)-AnTx-a- 
evoked response by 42.5±10.0% (n=4 -  Figure 5.7 right panel). The fact that no additive effect 
was observed, would indicate that both antagonists were acting predominantly on the same 
iGluR On nominally glycine-free conditions and in the presence of 1.2 mM Mg2+). 
As previously described (see Figure 4.8), 1 pM and 25 pM (±)-AnTx-a evoked maximum
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dopamine release from striatal synaptosomes (Figure 5.7 left panel). In the same preparation, 
neither 500 pM KYNA (88.1 ±12.0% - n=4) nor 100 pM DNQX (88.0±10.5% - n=4) had 
significant effect on 25 pM (±)-AnTx-a-evoked [3H]-DA release (105.2±13.3% n=4 -  Figure 5.7 
left panel). This result suggests that neither KYNA nor DNQX (at the concentrations used) 
exert non-specific effects on nAChR present on dopaminergic nerve terminals.
<J> SYNAPTO SO M ES SLICES
♦ KYNA ♦ DNQX ♦ KYNA & 
DNQX
♦ KYNA ♦ DNQX
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1pM 25 pM 1pM 25 pM
(±)-AnTx-a (±)-AnTx-a (±)-AnTx-a (±)-AnTx-a
Figure 5.7 Comparison of the effects of DNQX and KYNA on 25 pM (i)-AnTx-a-evoked 
^HJ-DA release from rat striatal synaptosomes and slices. Results are expressed as mean 
percentages±S.D. of mecamylamine-sensitive 1 pM (±)-AnTx-a-evoked responses (control). 
In slices, DNQX (100 pM) significantly inhibited 25 pM (±)-AnTx-a-evoked [3H]-DA release. 
However, when KYNA (500 pM) and DNQX (100pM) were coapplied, no additive effect was 
observed (right panel). In synaptosomes, 1 pM and 25 pM (±)-AnTx-a evoked maximum 
dopamine release, whereas neither 500 pM KYNA nor 100 pM DNQX had significant effect on 
25 pM (±)-AnTx-a-evoked [3H]-DA release (left panel).
(** p<0.01 significantly different from 25 pM (±)-AnTx-a-evoked response, one way ANOVA -  
Bonferroni t test)
5.3.4 Pharmacology of nAChR modulating DA release in striatal slices
To characterise the nAChR modulating striatal DA release, several nAChR antagonists were 
assayed on the responses evoked by 1pM and 25 pM (±)-AnTx-a in synaptosomes and slices. 
MLA (50 nM) and ot-CTx-lml (1 pM) were applied as selective antagonists of a7-containing 
nAChR whereas a-CTx-MII (112 nM) was used to competitively antagonise nAChR containing 
a3p2 interfaces. Figure 5.8 summarises the results obtained for (±)-AnTx-a-evoked DA release 
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Figure 5.8 Pharmacology of (±)-AnTx-a-evoked fHJ-DA release in rat striatal 
synaptosomes and slices. Results are expressed as mean percentages±S.D. of 
mecamylamine-sensitive 1 pM (±)-AnTx-a-evoked responses (control). In synaptosomes, 
1 pM and 25 pM (±)-AnTx-a elicited maximum dopamine release. a-CTx-MII (112 nM) 
significantly diminished 1 pM and 25 pM (±)-AnTx-a-evoked DA release. Although MLA (50 nM) 
significantly inhibited the 1 pM (±)-AnTx-a-evoked response, it had no significant effect on the 
25 pM (±)-AnTx-a-evoked response. a-Ctx-lml (1 pM) had no significant effect on the response 
evoked by 25 pM (±)-AnTx-a. In slices, the response elicited by 25 pM (±)-AnTx-a was 
significantly higher than control. MLA (50 nM) and a-CTx-MII (112 nM) significantly diminished 
1 pM and 25 pM (±)-AnTx-a-evoked DA release. a-CTx-lml also had significant effect on 
25 pM (±)-AnTx-a-evoked DA release.
(* p<0.05 significantly different from control; ** p<0.01 significantly different from 
25 pM (±)-AnTx-a-evoked response, one way ANOVA -  Bonferroni t test)
In synaptosomes, the response elicited by 25 pM (±)-AnTx-a (111.3±13.9% - n=9) was not 
significantly different from control (1 pM (±)-AnTx-a-evoked mecamylamine-sensitive response). 
MLA (50 nM) and a-CTx-MII (112 nM) decreased 1 pM (±)-AnTx-a-evoked DA release by 
39.1 ±10.2% (n=5) and 57.6±5.4% (n=8), respectively. a-CTx-MII (112nM) diminished 
25 pM (±)-AnTx-a-evoked DA release by 46.4%±5.4% (n=6). However, MLA (50 nM) and 
a-Ctx-lml (1 pM) had no significant effect on the response evoked by 25 pM (±)-AnTx-a in 
synaptosomes. Responses in the presence of MLA and a-CTx-lml were 88.8±10.2% (n=6) and 
89.4±9.7% (n=3) of the 25 pM (±)-AnTx-a-evoked response, respectively.
In slices, the response elicited by 25 pM (±)-AnTx-a was significantly higher (178.2±23.23% - 
n=26) than control (1 pM (±)-AnTx-a-evoked mecamylamine-sensitive response). 
MLA (50 nM) and a-CTx-MII (112 nM) reduced 1 pM (±)-AnTx-a-evoked DA release by 
31,3±9.0% (n=7) and 29.1±4.8% (n=4), respectively. Moreover, MLA (50 nM), a-CTx-MII 
(112 nM) and a-CTx-lml (1 pM) decreased the 25 pM (±)-AnTx-a-evoked response by 
42.7±6.2% (n=4), 36.8±10.5% (n=4) and 31.9±10.4% (n=5), respectively.
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As previously described in chapter 4, 112 nM a-CTx-MII partially inhibited the (±)-AnTx-a- 
evoked response in slices and synaptosomes (Figure 5.8 and Figure 4.4). Interestingly, 
the slice preparation also showed partial sensitivity to a7-containing nAChR antagonists 
(MLA and a-CTx-lml -  Figure 5.8 right panel). As will be discussed in section 5.4, 
striatal dopaminergic nerve terminals are not thought to possess a7-containing nAChR. 
However, in this study, MLA (50 nM) unexpectedly inhibited (±)-AnTx-a-evoked DA release from 
synaptosomes. In an attempt to shed some light on this result, the effects of a lower (10 nM) 
and a higher (500 nM) MLA. concentration were also tested (Figure 5.9). The results obtained 
showed that 10 nM and 50 nM MLA inhibited mecamylamine-sensitive 1 pM (±)-AnTx-a-evoked 
DA release from synaptosomes by 37.1 ±9.9% (n=6) and 39.1 ±10.2% (n=5), and are not 
significantly different (p>0.01, one way ANOVA). However, 500 nM MLA produced significantly 
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Figure 5.9 Effect of MLA on (±)-AnTx-a-evoked ^HJ-DA release from rat striatal 
synaptosomes. Results are expressed as mean percentages±S.D. of the
mecamylamine-sensitive 1 pM (±)-AnTx-a-evoked response (control). Low nanomolar 
concentrations of MLA, 10 nM and 50 nM, inhibited 1 pM (±)-AnTx-a-evoked responses. 
The effects of 10 nM and 50 nM MLA were not statistically different. However, 500 nM MLA 
produced significantly more inhibition than 10 or 50 nM MLA.
(* p<0.05 significantly different from control, one way ANOVA -  Bonferroni t test)
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5.3.5 a-Bgt-sensitive nAChR modulate glutamate release in 
rat striatal slices
The sensitivity of (±)-AnTx-a-evoked [3H]-DA release from slices to MLA and a-CTx-lml hinted 
at the possible participation in the response of a7-containing nAChR. In order to test this 
hypothesis, another a7-selective antagonist, a-Bgt, was examined. Striatal slices were 
preincubated in 40 nM a-Bgt for 1 h at 37°C, before stimulation with 25 pM (±)-AnTx-a. 
This treatment decreased the response by 39.8±15.6% (n= 8  Figure 5.11), i.e. to the same 
extent as 50 nM MLA and 1 pM a-CTx-lml (Figure 9 and Figure 5.10). The similar sensitivity of 
the response evoked in slices by (±)-AnTx-a to maximally effective concentrations of three 
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Figure 5.11 Combined effect of a7-selective antagonists and DNQX or a-CTx-MII on 25 pM 
(±)-AnTx-a evoked ^HJ-DA release in rat striatal slices. Results are expressed as mean 
percentages±S.D. of mecamylamine sensitive 25 pM (±)-AnTx-a-evoked responses (control). 
In slices, a-Bgt (40 nM) significantly decreased DA release. This inhibition was not significantly 
different from that achieved during coapplication of DNQX (100 pM) with either a-Bgt (40 M) or 
MLA (50 nM). When a-CTx-MII (112 nM) was coapplied with either a-Bgt (40 nM) or 
MLA (50 nM) the effects were additive.
( * * 1 p<0.01 significantly different from response in the presence of a-Bgt and DNQX; 
* * 2 p<0.01 significantly different from response in the presence of MLA and DNQX, 
one way ANOVA -  Bonferroni t test)
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Additional experiments were carried out to elucidate if the a-Bgt-sensitive nAChR were 
responsible for the indirect glutamate enhancement of DA release. The inhibition achieved with 
a-Bgt alone (39.8±15.6% n=8) was not significantly different from that observed during 
coapplication of DNQX (100 pM) with either 40 nM a-Bgt (38.9±9.6% - n=5) or 
50 nM MLA (32.7±11.9% - n=3). However, when a-CTx-MII (112 nM) was coapplied with either 
a-Bgt (40 nM) or MLA (50 nM) the inhibition increased to 72.6±18.0% (n=5) and 71.3±2.5% 




In this study, the superfusion technique was used to investigate possible striatal interactions 
that could lead to DA release enhancement as a consequence of presynaptic nAChR activation 
on non-dopaminergic nerve terminals. In particular, assays were designed and performed in an 
attempt to describe a putative involvement of presynaptic nAChR in striatal glutamate release.
5.4.1 "Permissive effect" of nAChR-activation on NMDA-evoked DA 
striatal release
It is well known that neostriatal neurones receive direct excitatory innervation from cortex and 
thalamus (review: see Di Chiara, 1994). Presynaptic modulation of DA release in striatum by 
excitatory afferents occurs at different levels. Released glutamate, e.g. from corticostriatal nerve 
terminals, would be expected to interact with postsynaptic NMDA- and / or non-NMDA- 
(AMPA/kainate) receptors. Moreover, both glutamate release and the excitability of 
glutamate-containing corticostriatal terminals are increased by activation of glutamate 
autoreceptors (Biziere and Coyle, 1978; Greenamyre and Young, 1989; 
Garcia-Munoz et al., 1991). Indirect modulation of the excitatory input may also occur as a 
consequence of local changes in the extracellular concentration of endogenous compounds 
capable of altering the performance of ionotropic excitatory amino acid receptors. 
L-Glycine, the coagonist of NMDA-receptors, is known to exert such a modulatory effect on 
NMDA-R (Johnson and Asher, 1987). Then, subtle changes in extracelullar concentrations of 
L-glycine or endogenous antagonists of strychnine insensitive-glycine sites (e.g. D-serine) may 
indirectly regulate the excitatory effects of NMDA-activated ion conductances. Local generation 
in astrocytes of kynurenic add (KYNA) may also indirectly modify the effects of glutamatergic 
agonists. KYNA is a “broad spectrum” excitatory amino acid receptor antagonist that 
competitively antagonises NMDA- and AMPA/kainate- receptors.
It is important to highlight at this point two features of the NMDA-R. First, in the absence of 
L-glydne, NMDA completely fails to activate the NMDA-receptor 
(Kleckner and Dingledine, 1988; Vyklicky et al., 1990). Second, although the potentiating effect 
of L-glycine is seen even at low concentrations of this amino add, it has been reported that the 
NMDA response desensitises at low L-glydne concentrations (i.e. 0.1 pM). Only an increase of 
the glydne concentration in the medium (e.g. to 3 pM), suppresses the NMDA-R desensitisation 
(Vyklicky etal., 1990; Benveniste etal., 1990).
Under physiological conditions, the Mg2+-induced blockade of the NMDA ionophore is suffident 
to hide the L-glycine potentiation of NMDA exdtation. However, this study shows that, 
in the presence of magnesium (1.2 mM) and L-glydne (1 pM), NMDA stimulated DA release 
when coapplied with (-)-nicotine. On the other hand, the absence of response when slices were 
stimulated with NMDA alone, revealed the permissive effect of (-)-nicotine on the NMDA-evoked 
DA release, an effect previously reported in striatal synaptosomes by Ch6ramy et al. (1996).
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The same permissive role observed for nAChR, was also reported by Desce et al. (1992) for the 
AMPA-R. The synergism between NMDA-R and nAChR presumably results from removal of the 
magnesium block of NMDA receptors after nicotinic depolarisation of the nerve terminal 
membrane (Ch6ramy et al., 1996). These results would suggest that nAChR and NMDA-R are 
located relatively close to each other on DAergic nerve terminals.
In this chapter, it has been also demonstrated that L-glycine, under standard experimental 
conditions (Krebs buffer as extracelullar medium), is not present at saturating concentrations. 
This observation is evident since addition of exogenous L-glycine potentiated 
[3H]-DA release from striatal slices evoked by (-)-nicotine and NMDA applied together. 
When L-glycine was not added to the buffer (nominally L-glycine-free conditions), the synergism 
was not observed.
5.4.2 (±)-AnTx-a-evoked striatal glutamate release
Although axoaxonic synapses between dopaminergic and cortical afferents are not present, 
these inputs to the striatum form synapses in close proximity to each other onto the dendrites 
and dendritic spines of medium-sized spiny neurones. Thus, endogenous neurotransmitter 
released from one nerve terminal may diffuse short distances to stimulate heteroreceptors and 
thereby indirectly affect the release in another neurotransmitter pathway. It appears that 
neurotransmitter release can be modulated not only by changes in the frequency of incoming 
action potentials, but also by changes in transmitter levels in the local presynaptic environment. 
Modification of the local concentration of one neurotransmitter can produce subsequent 
changes in stimulation of presynaptic heteroreceptors on the axons or nerve terminals of 
another transmitter system. Most D1 dopaminergic receptors are located on striatal dendrites 
outside symmetric synapses formed by dopaminergic terminal fibres (Levey et al., 1993; 
Gonon, 1998). As mentioned in the introduction, these receptors are often located in the 
proximity of asymmetric synapses formed by glutamatergic terminals on the head of dendritic 
spines (Levey etal. 1993; Ingham etal., 1998). Recent studies (Ingham etal., 1998) have made 
evident the complexity of these synaptic interactions. Unilateral lesion of the nigrostriatal 
pathway using 6-OHDA, showed that loss of dendritic spines on striatal medium-sized spiny 
neurones is accompanied by a loss of asymmetric synapses, rather than by the movement of 
excitatory synapses from spines to other postsynaptic targets.
When striatal slices are stimulated with general depolarising agents such as 4-aminopyridine 
(4-AP) or KCI, a major percentage of the transmitters present in the sample are probably 
released. These compounds exert their effect through different mechanisms. The former by 
blocking a particular type of \C channels, and the latter by perturbing the electrochemical 
equilibrium across the nerve terminal membrane. In 1994, Jin and Fredholm showed that, 
in the presence of 4-AP, endogenous glutamate contributes to dopamine release from 
striatal slices. Later, in 1997, the same lab reported that glutamate, by acting on NMDA -R in 
the absence of Mg2+, regulates electrically-evoked DA release from the same brain preparation.
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In the present study, DA release from striatal slices was initially evoked, in the presence 
of Mg2+, by acute application of 4-AP or KCI (see Figure 5.4). The broad spectrum iGluR 
antagonist KYNA (500 pM), reduced striatal 4-AP- and KCI-evoked DA release by 
23.0% and 21.0%, respectively. A higher KYNA concentration (800 pM) did not increase the 
inhibition: 21.0% and 18.0% for 4-AP and KCI, respectively. Therefore, these results suggested 
that part of the 4-AP- and KCI-evoked DA release was mediated by glutamate. 
Although Jin and Fredholm (1997), using similar KYNA concentrations (400 pM), reported a 
higher degree of inhibition (>50%), the present results qualitatively reproduce theirs. 
Quantitative mismatch between this study and their observations probably reflects differences in 
experimental design, such as the addition of Mg2+ to the buffer and the nature 
(chemical vs. electrical) and the duration (40 s vs. 3 min) of the evoking-stimulus.
In striatal slices, 1 pM (±)-AnTx-a-evoked [3 H]-DA release was also partially blocked by 
500 pM (18.0%) and 800 pM (18.0%) KYNA (see Figure 5.6). However, in striatal 
synaptosomes and in the presence of Mg2+, KYNA (500 pM and 800 pM) had no significant 
effect on the response elicited by 1 pM (±)-AnTx-a. Therefore, KYNA (at the concentrations 
used) had not non-specific effects on DAergic nerve terminal nAChR. It is important to consider 
that (±)-AnTx-a probably releases only a small percentage of the neurotransmitters released by 
general depolarising agents (e.g. 1 pM (±)-AnTx-a gives a response that is 46% of the [3H]-DA 
released by 25 mM KCI in striatal synaptosomes - Soliakov et al., 1995). In absolute numbers 
(±)-AnTx-a (1pM) and KCI/4-AP (at the concentrations used in this study) evoked 
1.5-2.0% and 5.0-6.0% of the total [3H]-DA loaded into the striatal slices, respectively. 
Thus, although in relative terms the degree of inhibition found for the nicotinic agonist is close to 
that found for 4-AP/KCI (~2 0 % of controls), in absolute numbers it was significantly lower 
(~0.35% vs. ~1.10% of total slice cpm). These results have also indicated that (±)-AnTx-a can 
evoke at least the release of one neurotransmitter, glutamate, that in turn modifies (±)-AnTx-a- 
evoked DA release.
(±)-AnTx-a dose-dependently evokes striatal DA release from synaptosomes 
(Soliakov et al., 1995 - Figure 4.8) and slices (see Figure 5.7). In striatal synaptosomes, the 
dose-response curve was monophasic with an apparent EC50 of 134 nM. This observation and 
the nAChR heterogeneity on DAergic nerve terminals previously reported (Kaiser et al., 1998), 
suggest that (±)-AnTx-a has similar potencies at a-Ctx-MII-sensitive and a-Ctx-MII-insensitive 
nAChR. In slices, (±)-AnTx-a-evoked DA release was biphasic with apparent EC50 values of 
241.8±36.1nM and 5.1±0.3pM suggesting the contribution of additional nAChR with low affinity 
for (-)-AnTx-a and absent from DA-containing synaptosomes. As seen in Figure 5.7, 
the fact that the second phase of the dose-response curve was almost completely abolished in 
the presence of KYNA (500 pM) suggests that the low affinity nAChR mediates [3H]-DA release 
via the mediation of glutamate release. Thus, in addition to its direct effect on dopaminergic 
nerve terminals, striatal administration of a nicotinic agonist generate other striatal interactions 
(as reported above) that indirectly modify nigrostriatal neurotransmission.
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The overall shape of the dose-response curve obtained in this study for 
(±)-AnTx-a-evoked DA release from striatal slices, could be described as the apparent 
summation of at least two curves (equation 5.1) corresponding to nAChR with different 
sensitivities to (±)-AnTx-a. Similarities between the EC50S defined in this lab for (±)-AnTx-a- 
evoked DA release from synaptosomes ( E C 5 0  = 110 nM Soliakov et al., 1995; E C 5 0  = 134 nM 
Figure 4.8) and slices ( E C 5 0  = 241 nM - first phase of the dose-response curve Figure 5.7) 
support this view. The suppression of the second phase in the presence of KYNA is consistent 
with the presence of nAChR on striatal glutamatergic terminals. An apparent E C 5 0  for the 
second phase in the low micromolar range could reflect that nAChR on the glutamatergic 
terminal have lower affinity for (±)-AnTx-a than those nAChR present on the DAergic terminal. 
Consistent with the pharmacological profile (Figure 5.9 - also see below) and the apparent low 
micromolar E C 5 0  ( E C 5 0  = 5.1 pM - second phase of the dose-response curve Figure 5.7) 
observed in this study for nAChR on glutamatergic terminals, Alkondon and Albuquerque (1993) 
reported an AnTx-a E C 5 0  of 3.9±0.6pM for Type IA currents (a-Bgt-sensitive) recorded from rat 
foetal hippocampal neurones. In this chapter, it has been demonstrated in vitro that 
(±)-AnTx-a-evoked glutamate release indirectly enhances DA release in rat striatum. However, 
it can not be excluded the possibility that additional modulation of striatal DA release by nicotinic 
agonists could involve the release of neurotransmitters other than glutamate. For example, 
previous studies have reported nicotine-evoked 5-hydroxytryptamine (5-HT) release 
(Westfall et ai., 1983; Takahashi et ai.t 1998), and 5-HT-evoked DA release in striatum 
(Blandina etal., 1989; De Deurwaerdere etal., 1997).
As mentioned before in this chapter, it is well established that non-NMDA- and NMDA-receptors 
are present on DAergic nerve terminals (Desce et al., 1992; Ch6 ramy et al., 1996). 
However, although DNQX (100 pM) blocked the 25 pM (±)-AnTx-a response to the same extent 
as KYNA (500 pM), both iGluR antagonists when applied together did not show an additive 
effect in slices (see Figure 5.7 right panel). Probably, under the experimental conditions chosen 
(nominally glycine-free conditions) and despite of the permissive effect of nAChR and 
non-NMDA-R activation on DAergic terminals, NMDA-R were not activated or at least rapidly 
desensitised.
To summarise, these results suggest that the second phase of the dose-response curve is, at 
least partially and under this studys' experimental conditions, a consequence of (±)-AnTx-a- 
evoked glutamate release that in turn enhances DA release via activation of non-NMDA-R on 
the DAergic nerve terminal.
Before analysing the pharmacology of (±)-AnTx-a-evoked DA release from striatal slices, 
it is necessary to discuss the non-significant, but observable, effect of KYNA and DNQX on the 
25 pM (±)-AnTx-a-evoked response in striatal synaptosomes (see Figure 5.7 left panel). 
A "mild" and non-specific effect of commonly used KYNA and DNQX concentrations 
(Jin and Fredholm, 1997; Sulzer et al., 1998) on nAChR could explain this observation. 
These compounds act as competitive antagonists of iGluR. To my best knowledge,
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there are no studies reporting non-specific effects of KYNA or DNQX on nAChR. 
These antagonists undoubtedly had not significant effect on the 
1 pM (±)-AnTx-a-evoked response in synaptosomes (not shown). Although having different 
chemical structures, KYNA (500 pM) and DNQX (100 pM) inhibited 
25 pM (±)-AnTx-a-evoked DA release to the same extent (~12% Figure 5.8 left panel). 
Assuming that they could act in a competitive way on nAChR, the opposite trend should have 
been observed.
To test whether (±)-AnTx-a-evoked glutamate release might affect DA release from DAergic 
terminals in perfused synaptosome preparation, the following experiment was designed. 
Striatal synaptosomes and a 1:4 dilution, were assayed for [3H]-DA release evoked by 25 pM 
(±)-AnTx-a in the absence (control) and presence of KYNA (500 pM). When compared with 
controls, the low-density synaptosome sample showed the same decrease of DA release as the 
undiluted preparation (~15%). This result suggests that the observed effect of KYNA on 
25 pM (±)-AnTx-a-evoked DA release from striatal synaptosomes could not be merely explained 
by the proximity of DAergic and glutamatergic terminals, as a consequence of the sample 
synaptosome density.
On the other hand, several lines of evidence have suggested that the ventral midbrain 
dopamine neurones that give rise to the major CNS dopaminergic projections may also be 
glutamatergic (Hattori et al., 1991; Plenz and Kitai, 1996). Recently (1998), Sulzer et al. 
reported that most DA neurones in the intact brain, as well as postnatal ventral tegmental area 
(VTA) cell cultures, immunostain for Glu (neurotransmitter, neither GABA precursor nor 
metabolic Glu). Moreover, ultrastructural studies have shown that single DA neurones are 
capable of forming synapses with both DAergic symmetric and glutamatergic asymmetric 
synaptic specialisations. Therefore, the observed effects of KYNA in synaptosomes could be a 
consequence of this iGluR antagonist acting on DAergic nerve terminal 
iGlu-autoreceptors. However, similar KYNA effects might be obtained if, during the preparation 
of synaptosomes, the mechanical disruption (homogenisation procedure) of the striatum does 
not yield totally independent nerve terminals. Then, nigrostriatal DAergic and corticostriatal 
glutamatergic nerve terminals would remain closely attached to postsynaptic membranes 
(spines), preserving the original structural and functional relationship.
5.4.3 Striatal nAChR subtypes
Although the pre-synaptic nicotinic modulation of dopamine release from striatal nerve terminals 
is well established, the nAChR subtypes underlying this response are far from being completely 
identified (Wonnacott et al., 1990; Wonnacott, 1997; Kaiser and Wonnacott, 1998). 
In striatal synaptosomes, the nicotinic stimulation of DA release is blocked by mecamylamine, 
DHpE and n-Bgt and is insensitive to a-Bgt (Rapier et al., 1990) and a-CTx-lml 
(Kulak et al., 1997). The sensitivity of (-)-nicotine-evoked [3H]-DA release to n-Bgt has been 
interpreted in favour of a3-type nAChR (Schulz and Zigmond, 1989; Grady et al., 1992).
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However, loss of [3H]-(-)-nicotine binding sites following lesion of the nigrostriatal tract 
(Clarke and Pert, 1985) favours presynaptic nAChR composed of a4 and p2 subunits on striatal 
DAergic nerve terminals.
In the present study, the effects of MLA (Alkondon et al., 1992), a-CTx-lml 
(Johnson et al., 1995; Pereira et al., 1996) and a-CTx-MII (Cartier et al., 1996; 
Harvey et al., 1997) on striatal (±)-AnTx-a-evoked DA release from both synaptosomes and 
slices, were compared (see Figure 5.8). Previous studies have excluded the presence of 
the a7 subunit on DAergic terminals, as (-)-nicotine-evoked [3H]-DA release was found to be 
insensitive to a-Bgt (Rapier et al., 1990; Grady et al., 1992; Wonnacott et al., 1995) 
and a-CTx-lml (Kulak et al., 1997). However, [125l]-a-Bgt binding sites (Clarke et al., 1985; 
Rapier et al., 1990; Davies et al., 1999) as well as [3H]-MLA binding sites 
(Davies et al., 1999) are present in rat striatum.
In slices (this study), MLA (50 nM), a-CTx-lm! (1 pM), a-Bgt (40 nM) and a-CTx-MII (112 nM) 
decreased the 25 pM (±)-AnTx-a-evoked response by 42.7%, 31.9%, 39.8% and 36.8%, 
respectively (see Figure 5.8 and Figure 5.10). In striatal synaptosomes, (±)-AnTx-a-evoked DA 
release was partially sensitive to a-CTx-MII (Figure 4.4 and Figure 5.8; Kulak et al., 1997; 
Kaiser et al., 1998) but clearly insensitive to a-CTx-lml (this study Figure 5.8; 
Kulak et al., 1997). The observed sensitivity to a-Bgt, a-CTx-lml and MLA of the (±)-AnTx-a- 
evoked response in slices, together with the insensitivity to these antagonists reported in striatal 
synaptosomes for nicotinic agonist-evoked responses, support the presence of 
a7-containing nAChR on striatal non-DAergic nerve terminals. Moreover, when a-Bgt (40 nM) 
and MLA (50 nM) where applied together with a-CTx-MII (112 nM), the effects were additive 
(Figure 5.11). These results suggest that aCtx-MII- and a-Bgt-sensitive nAChR are segregated 
onto different striatal nerve terminals. Interestingly, iGlu-R and a7-nAChR antagonists inhibited 
the second phase of release in a non-additive manner (Figure 5.11), observations consistent 
with a7-containing nAChR modulating the release of glutamate that in turn enhances 
striatal DA release (Figure 5.12).
The nicotinic facilitation of glutamate release from habenular, olfactory bulb and hippocampal 
neurones involves a presynaptic nAChR that contains the a7 subunit, based on sensitivity of 
evoked currents to a-Bgt and MLA (McGehee et al., 1995; Alkondon et al., 1996; 
Gray et al., 1996; Radcliffe and Dani, 1998) and antisense knockout experiments 
(McGehee et al., 1995). This study has demonstrated using a neurochemical approach, 
the involvement of presynaptic a-Bgt-sensitive nAChR in striatal glutamate release.
131
Chapter 5
Glu DA a 7 nAChR
f
iGluR
^  a302 nAChR
a402 nAChR ?
Figure 5.12 Possible physiological relationship between DA and Glu terminals in the 
striatum. Left panel ) Synapses onto the dendritic spine of a medium-sized spiny neurone. 
Glutamatergic and dopaminergic terminals make synapses onto the head and neck of a 
medium-sized spiny GABAergic neurone, respectively. Right panel) Schematic representation 
of the proposed segregation of particular nAChR subtypes on different afferent nerve terminals.
MLA is known to be a potent and selective antagonist of a7-containing nAChR 
(Alkondon et al., 1992). Unexpectedly, 10 nM, 50 nM and 500 nM MLA inhibited 
1 pM (±)-AnTx-a-evoked DA release from synaptosomes by 37.1%, 39.1% and 60.6%, 
respectively (see Figure 5.9). There are few published data supporting a low nanomolar MLA 
(10-50 nM) inhibition of striatal DA release evoked by nicotinic agonists. In 1996, 
Clarke and Reuben reported that MLA blocks DA release evoked from striatal synaptosomes by 
(-)-nicotine with an IC50 of 38±1nM. The observed low nanomolar MLA-sensitivity for (±)-AnTx-a 
evoked DA release in synaptosomes, together with the results presented for the novel 
nicotinic agonist UB-165 (see Figure 4.10), could suggest that striatal a-Bgt-insensitive MLA 
binding sites on DAergic nerve terminals, at least do not contain either a3p2 interfaces 
or a7 nAChR subunits. In the rat, the substantia nigra expresses a3, a4, a5, a6, p2 and p3 
mRNAs, but a2 and p4 mRNAs were not detected (see LeNovere et al., 1996; 
Wonnacott, 1997). This pattern is compatible with a3p2 and a4p2 nAChR subunit combinations 
but clearly additional subunits could also contribute to form native receptors (and could explain 
the MLA-sensitivity observed above). In particular, high expression of a6 and p3 mRNA in 
catecholaminergic nuclei, including substantia nigra, has been noted (LeNovere et al., 1996) but 
the pharmacology conferred by these subunits is unknown.
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This chapter, using the superfusion technique and a more holistic preparation (tissue slices), 
presented evidence for the involvement of further subtypes of nAChR in striatal DA release. 
This may be the first neurochemical demonstration of a-Bgt-sensitive nAChR 
(a7-containing nAChR) mediating glutamate release in the rat striatum. 
The diversity of nAChR involved in striatal DA release reported in this thesis, increases the 
range of potential presynaptic nicotinic modulatory effects on neurotransmitter release in this 
brain area. Second-messenger-mediated mechanisms underlying this modulation are briefly 
considered in the next chapter.
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6 Second messenger-mediated mechanisms involved in 
(±)-anatoxin-a-evoked dopamine release in rat striatum: 
phosphorylation of synapsin I
6.1 Introduction
Presynaptic nAChR probably have more subtle modulatory functions than simply triggering 
transmitter release: e.g. nAChR are proposed to increase the probability of release 
(Gray et a/., 1996), to modulate the frequency of EPSP (Frazier et a/., 1998) and to sustain 
release through the mobilisation of a reserve pool of neurotransmitter (Bowman et al., 1990). 
Such actions are likely to be mediated by second messengers, and phosphorylation / 
dephosphorylation events offer a plausible regulatory mechanism. The high relative permeability 
to Ca2+ of neuronal nAChR advocates the potential involvement of Ca2+-dependent kinases 
(such as Ca2+-calmodulin dependent kinase II (Ca2+/CaM kinase II) and 
protein kinase C (PKC)), as well as Ca2+-activatable phosphatases.
Synapsin I, composed of 86 kDa synapsin la and 80 kDa synapsin lb, is a basic phosphoprotein 
expressed specifically in neurones and located preferentially in presynaptic nerve terminals 
(De Camilli et al., 1990; Hilfiker et al., 1998). Previous studies indicated that synapsin I binds to 
actin, tubulin, neurofilaments, and is associated with synaptic vesicles 
(Benfenati et al., 1992). Quick freeze-deep etch electron microscopy analysis strongly 
suggested that synapsin I forms cross-bridges among synaptic vesicles and the nerve terminal 
cytoskeleton, mainly with actin filaments (Hirokawa et al., 1989).
The binding of synapsin I and cytoskeletal elements or membranes has been reported to be 
regulated by phosphorylation of synapsin I via Ca27calmodulin kinase II (Ca2+'CaM kinase II - 
Benfenati et al., 1992). In addition, physiological studies have also proposed that 
phosphorylation of synapsin I could regulate the release of neurotransmitter by making the 
vesicles readily available for release (Llin£s et al., 1991; Greengard et al., 1993). 
A recent link between presynaptic nAChR stimulation, protein kinase activation and transmitter 
release, relevant to the mobilisation of a reserve pool of neurotransmitter, comes from the study 
of Ochoa and O’Shea (1994). These authors reported that the nicotinic stimulation of ACh 
release from cortical synaptosomes was accompanied by a Ca2+-dependent increase in the 
phosphorylation of a 80 kDa band, proposed to correspond to synapsin I. Further analysis 
indicated that nicotine (50 pM) resulted in phosphorylation of site 3 on the synapsin I molecule 
(Ochoa and O'Shea, 1994). This site is known to be phosphorylated by vesicle-associated 
Ca2+/CaM kinase II (Benfenati et al., 1992), and Ca2+ entry accompanying nAChR activation 
might provide the stimulus. Recently, an increase in the level of site 3-phospho-synapsin I, 
together with an increase in Ca2+/CaM kinase II activity, has been proposed to play a role in the 




PKC has been also implicated in the modulation of exocytosis and PKC activators such as 
phorbol esters enhance neurotransmitter release evoked by electrical stimulation or KCI 
depolarisation (Dekker et al., 1991). Evidence for a PKC enhancement of the nicotinic 
stimulation of transmitter release comes from studies on chromaffin cells (Terbush et al., 1988; 
Cox and Parsons, 1997). Here, the nicotine-induced secretion of catecholamines is associated 
with entry of extracellular Ca2+ (Wakade et al., 1986), rapid translocation of PKC from cytosol to 
membrane (Terbush etal., 1988) and concomitant activation of PKC (Brocklehurst etal., 1985). 
There has been little work published on any interaction between nAChR and PKC in neurones. 
Cheramy al. (1996) reported that the synergism between (-)-nicotine and NMDA in stimulating 
[3H]-DA release from striatal synaptosomes (attributed to the nicotinic depolarisation relieving 
the Mg2+ block of NMDA receptors - see 5.3.1) was sensitive to blockade by the PKC inhibitors 
staurosporine and chelerythrine. Recently, Soliakov and Wonnacott (in preparation) found that 
(±)-AnTx-a activation of presynaptic nAChR on striatal DAergic nerve terminals elicits a 
contribution from PKC in promoting [3H]-DA release, and that independent activation of PKC 
can greatly enhance the response to nicotinic stimulation. It has also been proposed that PKC 
can influence transmitter release by phosphorylating ion channels (Smart, 1997) or acting on 
proteins that participate in vesicle docking and fusion events (Gillis et al., 1996). 
The presynaptic nAChR may itself be a target for PKC: phosphorylation of the a4 subunit by 
PKC has been hypothesised to be necessary for maintaining the a4(32 nAChR in an activatable 
state (Eilers etal., 1997), although phosphorylation of muscle and ganglionic nAChR has been 
found to enhance desensitisation (Hoffmann et al., 1994). 
Transmitter release or 86Rb* efflux stimulated by presynaptic nAChR is subject to short term 
(desensitisation) and long term (functional inactivation) reduction, in response to sub-stimulating 
and stimulatory agonist concentrations, respectively (Rowell and Hillebrand, 1994; 
Marks et al., 1996). Any contribution of kinase or phosphatase activities in mediating these 
responses is not known, but such mechanisms are very plausible.
This brief chapter presents preliminary functional (superfusion experiments) 
and biochemical (immunoblots) evidence for the involvement of Ca2+/CaM kinase II and PKC in 





The following reagents were used in this study: monoclonal mouse antibody
anti-synapsin I (mAb 355 concentration: 1 pg/pl - Chemicon International, Temecula, CA USA), 
Ro-31-8220, KN-62 (Calbiochem, Nottingham, UK - Figure 6.1), KN-04
(Seikagaku Corporation, Tokyo, Japan - Figure 6.1) pepstatin, leupeptin, aprotinin, antipain and 
chimostatin (Sigma, Pooie, Dorset UK). Enhanced chemiluminescence (ECL) immunoblotting 
reagents and Hyperfilm-ECL were purchased from Amersham International 
(Amersham International, Bucks UK). Immobilon-P polyvinylidine difluoride (PVDF) membranes 
and Centricon-50 membrane concentrators were obtained from Millipore (Watford, Herts UK). 






Figure 6.1 Molecular structures of the Ca2+/CaM-kinase II inhibitor KN-62, its inactive 
analogue KN-04 and the PKC inhibitor Ro-31-8220 (the arrow indicates the chemical group 
that converts KN-04 in the active compound KN-62).
6.2.2 Superfusion technique
P2 synaptosomes were prepared from the striata of male Sprague-Dawley rats (250-280 g - 
University of Bath Animal House breeding colony), loaded with [3H]-DA and perfused as 
previously described (see 4.2.4.1 - Soliakov et al., 1995) with Krebs bicarbonate buffer.
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In brief, synaptosomes were washed for 20 min with Krebs bicarbonate buffer and a further 
10 min with normal buffer or buffer containing antagonist (5 pM KN-62, 5 pM KN-04, 
1 pM Ro-31-8220 or 10 pM mecamylamine). Then, (±)-AnTx-a (1 pM) was applied for 40s. 
Two min (0.5 ml / min) fractions were collected and counted for radioactivity. 
Data were analysed (see 4.2.4.2) using Sigma Plot for Windows version 2.0 (Jandel Scientific - 
Germany), and responses were compared using the one way ANOVA test (Sigma Stat - 
Jandel Scientific).
6.2.3 Preparation of cytosolic and membrane fractions from Percoll 
gradient purified synaptosomes for western blotting
Percoll purified synaptosomes were prepared from striata dissected from 4 male Sprague 
Dawley rats as described previously (see section 3.2; Dunkley et al., 1988; Thome et al., 1991). 
Functionally active synaptosomes were collected from the 15-23% Percoll gradient interface 
and washed once with Krebs-bicarbonate buffer. Then, they were resuspended in the same 
buffer to a final volume of 0.5 ml (protein concentration 3.6-4.2 mg/ml). Aliquots (90pl) were 
preincubated for 10 min at 37°C in the presence or absence of antagonists (KN-62, KN-04, 
mecamylamine); then (±)-AnTx (1pM) or buffer (in control and antagonist/s-exposed 
preparations) was applied (5s-40s). The stimulation was stopped by adding 
20 volumes of ice-cold hypotonic lysis buffer composed of 20mM Tris-HCI, pH 7.4, 1mM EGTA, 
1mM EDTA, 100pM PMSF and supplemented with 1pg/ml pepstatin, 2.5pg/ml leupeptin, 
2.5pg/ml aprotinin, 2.5pg/ml antipain and 1pg/ml chimostatin. After 15 min on ice, samples were 
homogenised in a glass-teflon homogeniser by 10 up and down strokes at maximum speed. 
After another 20 min on ice, the homogenisation procedure was repeated. Following an 
additional 10 min on ice, the samples were centrifuged for 45 min at 100,000g, and pellets 
containing the membrane fraction, were separated from the cytosolic supernatant fraction. 
Pellets were resuspended in Laemmli SDS sample buffer (Laemmli, 1970) by shaking for 
40 min in a total volume of 90 pi. Supernatant fractions were concentrated on a Centricon 50 
membrane concentrator to about 45 pi and mixed with an equal volume of 2x Laemmli SDS 
sample buffer, to give a final volume of 90 pi. All samples were heated for 5 min at 95°C and run 
using 7.5% SDS PAGE. Blotting onto PDVF (Millipore) membranes was earned out in a semi­
dry apparatus. Monoclonal mouse anti-synapsin I antibodies (mAb 355 diluted 1:2000) were 
used as first antibodies and HRP-conjugated monoclonal anti-mouse immunoglobulins 
(diluted 1:3000) were used as secondary antibodies. ECL western blotting reagents were used 
for detection of synapsin I according to the manufacturer’s instructions. Protein bands were 
quantified using an AGFA Arcus II scanner and Scanalytics Zero-Dscan v.1.0 software. 




6.3.1 Effect of Ca2+/calmodulin-dependent protein kinase II and PKC 
inhibitors on (±)-AnTx-evoked striatal [3H]-DA release
To start studying the cytoplasmic mechanisms underlying nicotinic modulation of 
striatal [3H]-DA release from synaptosomes, the system was stimulated with the nicotinic 
agonist (±)-AnTx-a (this study; Soliakov et al., 1995; Soliakov and Wonnacott, 1996) 
in the presence and absence of Ca2+/calmodulin-dependent protein kinase II and PKC 
inhibitors. Application of (±)-AnTx-a (1 pM) for 40 s evoked a clear response over basal efflux in 
striatal synaptosomes (see Figure 4.3).
Figure 6.2 Effect of KN-62, KN-04 and Ro-31-8220 on (t)-AnTx-a-evoked ^HJ-DA release 
from striatal synaptosomes. Responses are expressed as percentage±S.D. of control 
(1 pM (±)-AnTx-a-evoked response). The Ca27CaM-kinase II inhibitor KN-62 (5 pM) and 
the PKC inhibitor Ro-31-8220 (1 pM) significantly decreased the control response. 
When KN-62 and Ro-31-8220 were applied together, no additive effect was observed. 
The control response was not significantly affected by 5 pM KN04, the KN-62 inactive analogue. 
KN-62 (5pM) did not evoke a response significantly different from that elicited by 
1 pM (±)-AnTx-a in the presence of 10 pM mecamylamine.
(* p<0.05 significantly different from control, one way ANOVA -  Bonferroni t test)
To define the residual nonspecific release of [3H]-DA from striatal synaptosomes, 
1 pM (±)-AnTx-a was applied in the presence of 10 pM mecamylamine 
(22.1 ±3.7% of control n=3 Figure 6.2). To determine if Ca2+/calmodulin-dependent 
protein kinase II (Ca2+/CaM kinase II) is involved in nAChR-mediated [3H]-DA release from 
striatal synaptosomes the effect of KN-62, an inhibitor of Ca2+/CaM kinase II
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(Tokumitsu et al., 1990 - Figure 6.1), was examined (Figure 6.2). KN-62 (5pM) alone 
did not evoke a response significantly different from that elicited by 1 pM (±)-AnTx-a in the 
presence of 10 pM mecamylamine (31.5±4.9% of control n=3 - Figure 6.2). 
Synaptosomes were also exposed to KN-62 (5 pM) for 10 min prior to stimulation with 
(±)-AnTx-a (1 pM). KN-62 (5 pM) significantly decreased 1 pM (±)-AnTx-a-evoked [3H]-DA 
release by 30.8±11.7% (n=8 - Figure 6.2). This concentration of KN-62 should be maximally 
effective (Ki = 0.9 pM; Tokumitsu et al., 1990), while retaining specificity for Ca2+/CaM kinase II. 
In contrast KN-04 (5pM - Figure 6.1), the inactive structural analogue of KN-62, had no 
significant effect on (±)-AnTx-evoked [3H]-DA release (101.9±4.4% of control n=3 - Figure 6.2). 
Taken together, these results suggest that nAChR-evoked [3H]-DA release from rat striatal 
synaptosomes involves, at least partially, the activation of Ca2+/CaM kinase II.
Having determined that a Ca2+/CaM kinase II inhibitor (5 pM KN-62) can attenuate 
(±)-AnTx-a-evoked [3H]-DA release, the effect of a PKC inhibitor (Ro-31-8220 Figure 6.1) on 
(±)-AnTx-a-evoked [3H]-DA release from striatal synaptosomes was examined. Synaptosome 
pretreatment with 1 pM Ro-31-8220 (10 min) decreased the 1 pM (±)-AnTx-a-evoked response 
by 36.7±7.6% (n=4 - Figure 6.2). This concentration of Ro-31-8220 should be maximally 
effective ( I C 5 0  =10 nM; Davis et al., 1992), while retaining specificity for PKC. This observation 
agrees well with previous studies in this lab which also showed that the maximum effect by 
Ro-31-8220 was achieved after 7 min preincubation with 1 pM Ro-31-8220 
(Soliakov and Wonnacott, 1998). Interestingly, when KN-62 and Ro-31-8220 were coapplied, 
their individual effects were not additive (38.5±7.8% inhibition n=3 - Figure 6.2). 
This observation suggests that both second messenger cascades are related at some point.
6.3.2 Translocation of synapsin I in response to (±)-AnTx-a stimulation of 
isolated nerve terminals
Experiments were performed to examine the distribution of the Ca2+/CaM kinase II substrate 
synapsin I, in cytosolic (soluble) and particulate fractions of synaptosomes after stimulation with 
(±)-AnTx-a (1 pM) for varying times (5-40s). Phosphorylation of synapsin I results in 
its translocation from the particulate to the cytosolic fraction (Sihra et al., 1989). The subcellular 
localisation of synapsin I was determined by using hypotonic lysis to disrupt the highly purified 
striatal synaptosomes after stimulation with (±)-AnTx-a. The separated fractions were then 
subjected to SDS/PAGE, electrotransferred onto PVDF membranes, and probed with a mouse 
monoclonal antibody anti-synapsin I (mAb 355). Initial results showed that (±)-AnTx-a 
stimulation of synaptosomes causes a rapid (within 2-5 s) increase of synapsin I in 
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Figure 6.3 Time course of translocation of synapsin I into the cytosolic (soluble) fraction 
following 1 pM (±)-AnTx-a stimulation. Striatal Percoll purified synaptosomes were stimulated 
for the indicated times, hypotonically lysed, and fractioned as described in Error! Unknown 
switch argument.. Synapsin I bands were identified by Western blot analysis using mouse anti- 
sinapsin I mAb 355 and the ECL technique (insets). Curve values are expressed as percentage 
above control:





Figure 6.4 Effect of KN-62, KN-04 and mecamylamine on 1 pM (±)-AnTx-a evoked 
synapsin I translocation in striatal synaptosome preparations. Percoll purified 
synaptosomes were pretreated for 10 min with KN-62 (5 pM), KN-04 (5 pM) or mecamylamine 
(10 pM) before stimulation with (±)-AnTx-a (1pM, 20 s). After hypotonic lysis and separation of 
soluble and particulate factions, synapsin I bands were identified by Western blot analysis using 
mAb 355 and the ECL technique. A control response was obtained by stimulating the 
synaptosomes just with Krebs buffer for 20 s.
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Further experiments were designed to study the effect of the Ca2+/CaM-kinase II inhibitor KN-62 
on the (±)-AnTx-a-evoked translocation of synapsin I in striatal synaptomes (Figure 6.4). 
The subcellular distribution of synapsin I was studied under experimental conditions (see 6.2.3) 
closely resembling those used for superfusion experiments (see 6.2.2). Six experiments were 
performed. However, only one of them showed results "compatible" with those obtained using 
the superfusion technique (Figure 6.2).
The preliminary immunoblot in Figure 6.4 illustrates the effect of 5 pM KN-62 on 
(±)-AnTx-a-evoked synapsin I transiocation in striatal synaptosomes. The translocation was 
maximum when the nicotinic agonist was applied alone; and minimum when, 
instead of 1 pM (±)-AnTx-a, Krebs buffer (20 s) or 1 pM (±)-AnTx-a in the presence of 
10 pM mecamylamine was used to elicit the response. Consistent with the superfusion data 
presented in 6.3.1, KN-62 (5 pM) partially decreased the (±)-AnTx-a-evoked movement of 
synapsin I from particulate to cytosolic synaptosome fractions whereas its inactive analogue 




Brain nAChR may serve a predominantly modulatory role, exemplified by the facilitation of 
neurotransmitter release by presynaptic nAChR (Wonnacott, 1997). The interaction between a 
nicotinic agonist and nAChR may be the first step in a series of events that culminate in 
exocytosis of e.g. DA-filled vesicles. (-)-Nicotine, by acting on presynaptic nAChR, depolarises 
the nerve terminal membrane and promotes the influx of Ca2+ into synaptosomes 
(Grady etal., 1992; Soliakov et al., 1995; Marshall et al., 1996; Soliakov and Wonnacott, 1996). 
This ionic influx may trigger many intracellular mechanisms that depend on this divalent cation, 
among them the phosphorylation of specific proteins such as synapsin I 
(Greengard et al., 1993) and calpacitins such as GAP-43 and MARCKS. Both, 
Ca2+/CaM kinase ll-mediated phosphorylation of synapsin I (Llin£s et al., 1991; 
Greengard et al., 1993) and PKC-mediated phosphorylation of GAP-43 and MARCKS, have 
been postulated to enhance Ca2+-dependent neurotransmitter release (Dekker et al., 1989; 
Hens et al., 1995). However, whether these phosphorylated proteins contribute to the nicotinic 
agonist-mediated DA release from striatal synaptosomes has been scarcely studied. 
The fact that striatal DA release evoked by nicotinic agonists is highly dependant on 
extracelullar Ca2+ suggests that these proteins could potentially participate in 
the nicotinic-evoked response.
In vitro, synapsin I binds reversibly to synaptic vesicles, promotes G-actin nucleation and 
polymerisation and induces the formation of thick bundles of actin filaments 
(Valtorta et al., 1992; Greengard et al., 1993). Phosphorylation (i.e. by Ca2+/CaM kinase II) 
at sites 2 and 3 abolishes the interactions of synapsin I with synaptic vesicles and actin 
filaments (Pieribone at al., 1995; Rosahl et al., 1995), therefore increasing the cytoplasmic and 
vesicular pool of neurotransmitter available for release. Superfusion and immunoblot 
preliminary data, obtained in this study using the Ca27CaM kinase II selective inhibitor KN-62 
(Tokumitsu etal., 1989) and its inactive analogue KN-04, support synapsin I phosphorylation by 
Ca27CaM kinase II in response to (±)-AnTx-a stimulation of striatal synaptosomes 
(Figure 6.2 and Figure 6.4). Moreover, as previously reported for KCI depolarisation of striatal 
synaptosomes (Sihra et al., 1989), synapsin I translocation after stimulation with 
1 pM (±)-AnTx-a showed a critical time dependence, reaching a maximum when the system 
was stimulated for ~20s (Figure 6.3).
On the other hand and according to previous studies performed by Soliakov and Wonnacott
(1998), the PKC inhibitor Ro-31-8220 (1pM) significantly inhibited the release of [3H]-DA evoked 
by (±)-AnTx-a (Figure 6.2). Although, an involvement of PKC in striatal 
(±)-AnTx-a-evoked DA release is evident, the source of diacylglycerol following nAChR 
stimulation is not clear. There is considerable documentation that depolarising conditions elicit 
the generation of inositol phosphates (presumably in concert with the fonmation of 
diacylglycerol; see Dekker et al., 1991), and nicotinic stimulation may fall into this category. 
Indeed, in chromaffin cells, KCI depolarisation or nAChR stimulation by DMPP increased the
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accumulation of inositol phosphates (Eberhand and Holz, 1987), and a mechanism based on 
the activation of PLC by the increase in intracellular Ca2+ was advocated. That PKC activation 
contributes to the release of neurotransmitters from nerve terminals is clear, 
but the mechanisms by which it do so remain obscure. As mentioned before, 
a correlation between PKC-mediated phosphorylation of GAP-43 and neurotransmitter release 
has been reported (Dekker et al., 1989; 1991). Although it is unclear which property of GAP-43 
is essential for transmitter release, the phosphorylation state of GAP-43 rather than PKC activity 
per se may be important for Ca2+-dependant release (Hens et al., 1995). 
Because PKC-mediated phosphorylation of GAP-43 leads to dissociation of calmodulin (CaM), 
there could be more CaM available in the synaptosomal cytosol to contribute to 
Ca2+ -dependent processes (e.g. activation of Ca2+/CaM kinase II). However, an understanding 
of how kinases (e.g Ca2+/CaM kinase II and PKC) modulate exocytosis will not be complete until 
the physiological substrates are identified and functionally characterised. Recently, it has been 
reported that PKC also acts on proteins that participate in vesicle docking and fusion events 
(Gillis et al., 1996). This observation could help to explain the lack of additive effects on 
(±)-AnTx-a evoked DA release observed in this study when KN-62 and Ro-31-8220 were 
coapplied (Figure 6.2). This outcome suggests that both kinases act on the same exocytotic 
pathway, with PKC controlling at least one of its later steps. These results would also propose:
1. the existence of other, undetermined mechanisms/pathways not related with the activation 
of Ca2+/CaM kinase II or PKC, involved in striatal (±)-AnTx-a evoked [3H]-DA release; or
2. the inhibition by KN-62/Ro-31-8220 of the intraterminal cascades activated by 
one population of nAChR mediating DA release.
Both synapsin I and calpacitins (e.g. GAP-43) are widely distributed in the brain, and virtually all 
nerve terminals have both protein types (Walaas et al., 1988; Skene, 1989). 
However, functional superfusion experiments performed in synaptosomes (this study; 
Sokiakov and Wonnacott, 1998) have linked for the very first time stimulation of presynaptic 
nAChR with activation of Ca2*/CaM kinase II / PKC and subsequent release of DA from rat 
striatal nerve terminals.
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7 Conclusions: unanswered questions and future prospects
This thesis has considered the evidence for presynaptic nAChR in the mammalian CNS and 
discussed the possible mechanisms and physiological relevance of these receptors. 
It is evident from the information presented in section 1.2 that presynaptic nAChR are 
widespread in the brain, and are associated with many different transmitters. 
The pharmacological characteristics of nAChR in different preparations vary, consistent with 
several different nAChR subtypes fulfilling a presynaptic role. Despite this wealth of 
documentation, we are still far from understanding their contribution to normal synaptic 
transmission and brain function. Some of the questions that have already been alluded to in 
this thesis are:
• What is the subunit composition of presynaptic nAChR associated with particular 
transmitters? Incomplete pharmacological profiles and, more importantly, the dearth of 
definitive subtype-selective tools have obstructed the identification of subtypes. 
Elucidation of the full complement of constituent subunits is even more challenging, and 
this task has not been accomplished for any particular nAChR yet. Antisense strategies 
(McGehee etal., 1995) or metabolic labelling / immunoisolation of nAChR in synaptosome 
preparations are plausible approaches.
• Where on nerve terminals are nAChR localised with respect to (i) release sites; 
(ii) cholinergic innervation to provide the endogenous agonist for activation? Does a single 
nerve terminal have more than one subtype of nAChR, and if so are they spatially 
segregated? These are crucial questions that can only be addressed by microscopic 
techniques such as immunogold labelling of nAChR subunits and colabelling of transmitter 
markers for visualisation at the electron microscope level. This approach has proved very 
illuminating in the case of GABAa and glutamate receptors (Nusser et al., 1996). In addition 
to establishing the proximity to release sites, electron microscopy can also demonstrate 
the co-localisation of different receptor subunits. However, microscopy does not necessarily 
reflect functional receptors.
• What is the purpose of presynaptic nAChR? At the neuronal level, electrophysiological 
studies are perhaps the best means of assessing receptor function in a physiological 
context (e.g. Gray etal., 1996). However, such experiments are technically demanding and 
measurements are indirect because terminals are too small to impale. Recourse to cultured 
neurones for this purpose imposes the limitation that the culture system may provide a 
developmental snapshot, the cultured neurones generally being of perinatal origin. 
Biochemical studies are also needed, to investigate the down stream events that follow 
nAChR activation. It will be important to elucidate changes produced in the nerve terminal 
(e.g. phosphorylation events, intraterminal Ca2+ dynamics, vesicle recruitment), 
in addition to the release of transmitter. To evaluate the contribution of presynaptic nAChR 
on a broader scale, i.e. in terms of brain function, in vivo antisense or transgenic knockout
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strategies but neither of these approaches is selective for presynaptic nAChR: subunit 
deletion will affect nAChR on soma and dendrites as well as terminals. If it emerges that 
certain subtypes are only localised to terminals, the deletion approaches would have 
considerable merit, although interpretation of results can be confounded by compensatory 
or plastic adaptations (McGehee et al., 1995).
• Are presynaptic nAChR valid therapeutic targets? Given our poverty of understanding of 
the significance of these receptors in normal brain function, this question is difficult to 
answer. Putative presynaptic nAChR are lost in Alzheimers' and Parkinsons' disease and 
offer a rational site of drug action to boost residual activity, especially in the earlier stages of 
degeneration. Indeed presynaptic nAChR may become more effective under sub-optimal 
conditions (Marchi et al., 1996). Moreover, the modulatory actions of presynaptic nAChR 
make them attractive therapeutic targets, as modulation is preferable to direct manipulation 
of on/off signals.
There is much more still to be learnt about nAChR in the brain and this, I am sure, will be a 
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